This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

THIS PAGE BLANK (USPTO).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

A1

(11) International Publication Number:

WO 92/06176

C12N 1/24, 15/00, C07H 21/00

(43) International Publication Date:

16 April 1992 (16.04.92)

(21) International Application Number:

PCT/US91/07141

(22) International Filing Date:

27 September 1991 (27.09.91)

(30) Priority data: 590,664

28 September 1990 (28.09.90) US

(71) Applicant: IXSYS, INC. [US/US]; 3550 General Atomics Court, Suite L103, San Diego, CA 92121 (US).

(72) Inventor: HUSE, William, D.; 471 Avenida Primavera, Del Mar, CA 92014 (US).

(74) Agents: CAMPBELL, Cathryn et al.; Pretty, Schroeder, Brueggemann & Clark, 444 South Flower Street, Suite 2000, Los Angeles, CA 90071 (US).

(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI pateut), CM (OAPI patent), CS, DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU+,TD (OAPI patent), TG (OAPI patent).

Published

With international search report.

(54) Title: SURFACE EXPRESSION LIBRARIES OF RANDOMIZED PEPTIDES

(57) Abstract

A composition of matter comprising a plurality of procaryotic cells containing a diverse population of expressible oligonucleotides operationally linked to expression elements, said expressible oligonucleotides having a desirable bias of random codon sequences.

+ DESIGNATIONS OF "SU"

Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

• •					
AT AU BB BE BF BG BJ BR CA CF CG CH CI CM CS	Austria Australia Barbados Belgium Burkina Faso Bulgaria Benin Brazil Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon Czechoslovakia	ES PI PR GA GB GN GR HU IT JP KP KR LI LU	Spain Finland France Gabon United Kingdom Guinea Grosse Hungary Italy Japan Democratic People's Republic of Korea Republic of Korea Liechtenstein Sri Lanka Luxembourg	MG ML MN MR NW NL NO FL NO NO FL NO NO NO NO NO NO NO NO NO NO NO NO NO	Madagascar Mali Mongolia Mauritania Malawi Netherlands Norway Poland Romania Sudan Sweden Senegal Soviet Union Chad Togo United States of America
-	Czorbosłovakia Germany Denmark	-	-		

5

10

SURFACE EXPRESSION LIBRARIES OF RANDOMIZED PEPTIDES

٩

BACKGROUND OF THE INVENTION

This invention relates generally to methods for synthesizing and expressing oligonucleotides and, more particularly, to methods for expressing oligonucleotides having random codon sequences.

Oligonucleotide synthesis proceeds via linear coupling of individual monomers in a stepwise reaction. reactions are generally performed on a solid phase support by first coupling the 3' end of the first monomer to the support. The second monomer is added to the 5' end of the 15 first monomer in a condensation reaction to yield a dinucleotide coupled to the solid support. At the end of each coupling reaction, the by-products and unreacted, free monomers are washed away so that the starting material for the next round of synthesis is the pure oligonucleotide In this reaction scheme, the 20 attached to the support. stepwise addition of individual monomers to a single, growing end of a oligonucleotide ensures accurate synthesis of the desired sequence. Moreover, unwanted side reactions condensation are eliminated, such as the 25 oligonucleotides, resulting in high product yields.

In some instances, it is desired that synthetic oligonucleotides have random nucleotide sequences. result can be accomplished by adding equal proportions of all four nucleotides in the monomer coupling reactions, 30 leading to the random incorporation of all nucleotides and yielding a population of oligonucleotides with random sequences. Since all possible combinations of nucleotide sequences are represented within the population, all possible codon triplets will also be represented. If the objective is ultimately to generate random peptide products, this approach has a severe limitation because the random codons synthesized will bias the amino acids incorporated during translation of the DNA by the cell into polypeptides.

The bias is due to the redundancy of the genetic code.

There are four nucleotide monomers which leads to sixtyfour possible triplet codons. With only twenty amino acids
to specify, many of the amino acids are encoded by multiple
codons. Therefore, a population of oligonucleotides
synthesized by sequential addition of monomers from a
random population will not encode peptides whose amino acid
sequence represents all possible combinations of the twenty
different amino acids in equal proportions. That is, the
frequency of amino acids incorporated into polypeptides
will be biased toward those amino acids which are specified
by multiple codons.

the genetic code, the oligonucleotides can be synthesized from nucleotide triplets. Here, a triplet coding for each of the twenty amino acids is synthesized from individual monomers. Once synthesized, the triplets are used in the coupling reactions instead of individual monomers. By mixing equal proportions of the triplets, synthesis of oligonucleotides with random codons can be accomplished. However, the cost of synthesis from such triplets far exceeds that of synthesis from individual monomers because triplets are not commercially available.

Amino acid bias can be reduced, however, by synthesizing the degenerate codon sequence NNK where N is a mixture of all four nucleotides and K is a mixture guanine and thymine nucleotides. Each position within an oligonucleotide having this codon sequence will contain a total of 32 codons (12 encoding amino acids being

20

represented once, 5 represented twice, 3 represented three times and one codon being a stop codon). Oligonucleotides expressed with such degenerate codon sequences will produce peptide products whose sequences are biased toward those amino acids being represented more than once. Thus, populations of peptides whose sequences are completely random cannot be obtained from oligonucleotides synthesized from degenerate sequences.

There thus exists a need for a method to express oligonucleotides having a fully random or desirably biased sequence which alleviates genetic redundancy. The present invention satisfies these needs and provides additional advantages as well.

SUMMARY OF THE INVENTION

The invention provides a plurality of procaryotic cells containing a diverse population of expressible oligonucleotides operationally linked to expression elements, the expressible oligonucleotides having a desirable bias of random codon sequences.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic drawing for synthesizing oligonucleotides from nucleotide monomers with random tuplets at each position using twenty reaction vessels.

Figure 2 is a schematic drawing for synthesizing oligonucleotides from nucleotide monomers with random tuplets at each position using ten reaction vessels.

Figure 3 is a schematic diagram of the two vectors used for sublibrary and library production from precursor oligonucleotide portions. M13IX22 (Figure 3A) is the vector used to clone the anti-sense precursor portions

(hatched box). The single-headed arrow represents the Lac p/o expression sequences and the double-headed arrow represents the portion of M13IX22 which is to be combined The amber stop codon for biological with M13IX42. 5 selection and relevant restriction sites are also shown. M13IX42 (Figure 3B) is the vector used to clone the sense precursor portions (open box). Thick lines represent the pseudo-wild type (Ψ gVIII) and wild type (gVIII) gene VIII sequences. The double-headed arrow represents the portion 10 of M13IX42 which is to be combined with M13IX22. amber stop codons and relevant restriction sites are also shown. Figure 3C shows the joining of vector population from sublibraries to form the functional surface expression vector M13IX. Figure 3D shows the generation of a surface 15 expression library in a non-suppressor strain and the production of phage. The phage are used to infect a suppressor strain (Figure 3E) for surface expression and screening of the library.

Figure 4 is a schematic diagram of the vector used for generation of surface expression libraries from random oligonucleotide populations (M13IX30). The symbols are as described for Figure 3.

Figure 5 is the nucleotide sequence of M13IX42 (SEQ ID NO: 1).

Figure 6 is the nucleotide sequence of M13IX22 (SEQ ID NO: 2).

Figure 7 is the nucleotide sequence of M13IX30 (SEQ ID NO: 3).

Figure 8 is the nucleotide sequence of M13ED03 (SEQ ID 30 NO: 4).

Figure 9 is the nucleotide sequence of M13IX421 (SEQ

5

ID NO: 5).

Figure 10 is the nucleotide sequence of M13ED04 (SEQ ID NO: 6).

DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to a simple and inexpensive 5 method for synthesizing and expressing oligonucleotides having a desirable bias of random codons using individual The method is advantageous in that individual monomers are used instead of triplets and by synthesizing 10 only a non-degenerate subset of all triplets, codon redundancy is alleviated. Thus, the oligonucleotides synthesized represent a large proportion of possible random obtained. can be which triplet sequences oligonucleotides can be expressed, for example, on the 15 surface of filamentous bacteriophage in a form which does not alter phage viability or impose biological selections against certain peptide sequences. The oligonucleotides produced are therefore useful for generating an unlimited number of pharmacological and research products.

entails the invention embodiment, the one 20 sequential coupling of monomers to produce oligonucleotides The coupling with a desirable bias of random codons. reactions for the randomization of twenty codons which specify the amino acids of the genetic code are performed Each reaction vessel in ten different reaction vessels. contains a support on which the monomers for two different codons are coupled in three sequential reactions. One of the reactions couples an equal mixture of two monomers such that the final product has two different codon sequences. The codons are randomized by removing the supports from the 30 reaction vessels and mixing them to produce a single batch of supports containing all twenty codons at a particular position. Synthesis at the next codon position proceeds by equally dividing the mixed batch of supports into ten reaction vessels as before and sequentially coupling the monomers for each pair of codons. The support: are again mixed to randomize the codons at the position just synthesized. The cycle of coupling, mixing and dividing continues until the desired number of codon positions have been randomized. After the last position has been randomized, the oligonucleotides with random codons are cleaved from the support. The random oligonucleotides can then be expressed, for example, on the surface of filamentous bacteriophage as gene VIII-peptide fusion proteins. Alternative genes can be used as well.

In its broadest form, the invention provides a diverse population of synthetic oligonucleotides contained in vectors so as to be expressible in cells. Such populations of diverse oligonucleotides can be fully random at one or more codon sites or can be fully defined at one or more site, so long as at least one site the codons are randomly variable. The populations of oligonucleotides can be expressed as fusion products in combination with surface proteins of filamentous bacteriophage, such as M13, as with gene VIII. The vectors can be transfected into a plurality of cells, such as the procaryote E. coli.

The diverse population of oligonucleotides can be formed by randomly combining first and second precursor populations, each precursor population having a desirable bias of random codon sequences. Methods of synthesizing and expressing the diverse population of expressible oligonucleotides are also provided.

In a preferred embodiment, two populations of random oligonucleotides are synthesized. The oligonucleotides within each population encode a portion of the final oligonucleotide which is to be expressed. Oligonucleotides within one population encode the carboxy terminal portion

of the expressed oligonucleotides. These oligonucleotides are cloned in frame with a gene VIII (gVIII) sequence so . that translation of the sequence produces peptide fusion proteins. The second population of oligonucleotides are 5 cloned into a separate vector. Fach oligonucleotide within this population encodes the anti-sense of the amino terminal portion of the expressed oligonucleotides. vector also contains the elements necessary for expression. The two vectors containing the random oligonucleotides are 10 combined such that the two precursor oligonucleotide portions are joined together at random to form a population larger oligonucleotides derived from two smaller portions. The vectors contain selectable markers to ensure joining together maximum efficiency in 15 oligonucleotide populations. A mechanism also exists to control the expression of gVIII-peptide fusion proteins during library construction and screening.

As used herein, the term "monomer" or "nucleotide monomer" refers to individual nucleotides used in the 20 chemical synthesis of oligonucleotides. Monomers that can be used include both the ribo- and deoxyribo- forms of each of the five standard nucleotides (derived from the bases adenine (A or dA, respectively), guanine (G or dG), cytosine (C or dC), thymine (T) and uracil 25 Derivatives and precursors of bases such as inosine which are capable of supporting polypeptide biosynthesis are also Also included are chemically included as monomers. modified nucleotides, for example, one having a reversible blocking agent attached to any of the positions on the 30 purine or pyrimidine bases, the ribose or deoxyribose sugar or the phosphate or hydroxyl moieties of the monomer. Such blocking groups include, for example, dimethoxytrityl, benzoyl, isobutyryl, beta-cyanoethyl and diisopropylamine groups, and are used to protect hydroxyls, exocyclic amines 35 and phosphate moieties. Other blocking agents can also be used and are known to one skilled in the art.

10

As used herein, the term "tuplet" refers to a group of elements of a definable size. The elements of a tuplet as used herein are nucleotide monomers. For example, a tuplet can be a dinucleotide, a trinucleotide or can also be four or more nucleotides.

As used herein, the term "codon" or "triplet" refers to a tuplet consisting of three adjacent nucleotide monomers which specify one of the twenty naturally occurring amino acids found in polypeptide biosynthesis. The term also includes nonsense, or stop, codons which do not specify any amino acid.

"Random codons" or "randomized codons," as used herein, refers to more than one codon at a position within a collection of oligonucleotides. The number of different 15 codons can be from two to twenty at any particular position. "Randomized oligonucleotides," as used herein, refers to a collection of oligonucleotides with random codons at one or more positions. "Random codon sequences" as used herein means that more than one codon position 20 within a randomized oligonucleotide contains random codons. For example, if randomized oligonucleotides are six nucleotides in length (i.e., two codons) and both the first and second codon positions are randomized to encode all twenty amino acids, then a population of oligonucleotides random codon sequences with every possible combination of the twenty triplets in the first and second position makes up the above population of randomized possible number of oligonucleotides. The randomized if Likewise, 20². combinations is 30 oligonucleotides of fifteen nucleotides in length are synthesized which have random codon sequences at all positions encoding all twenty amino acids, then all triplets coding for each of the twenty amino acids will be found in equal proportions at every position. 35 population constituting the randomized oligonucleotides WO 92/06176 PCT/US91/07141

9

will contain 20¹⁵ different possible species of oligonucleotides. "Random tuplets," or "randomized tuplets" are defined analogously.

As used herein, the term "bias" refers to a preference. It is understood that there can be degrees of preference or bias toward codon sequences which encode particular amino acids. For example, an oligonucleotide whose codon sequences do not preferably encode particular amino acids is unbiased and therefore completely random.

The oligonucleotide codon sequences can also be biased toward predetermined codon sequences or codon frequencies and while still diverse and random, will exhibit codon sequences biased toward a defined, or preferred, sequence.

"A desirable bias of random codon sequences" as used herein, refers to the predetermined degree of bias which can be selected from totally random to essentially, but not totally, defined (or preferred). There must be at least one codon position which is variable, however.

As used herein, the term "support" refers to a solid phase material for attaching monomers for chemical synthesis. Such support is usually composed of materials such as beads of control pore glass but can be other materials known to one skilled in the art. The term is also meant to include one or more monomers coupled to the support for additional oligonucleotide synthesis reactions.

As used herein, the terms "coupling" or "condensing" refers to the chemical reactions for attaching one monomer to a second monomer or to a solid support. Such reactions are known to one skilled in the art and are typically performed on an automated DNA synthesizer such as a MilliGen/Biosearch Cyclone Plus Synthesizer using procedures recommended by the manufacturer. "Sequentially coupling" as used herein, refers to the stepwise addition of monomers.

A method of synthesizing oligonucleotides having random tuplets using individual monomers is described. The method consists of several steps, the first being synthesis of a nucleotide tuplet for each tuplet to be randomized.

5 As described here and below, a nucleotide triplet (i.e., a codon) will be used as a specific example of a tuplet. Any size tuplet will work using the methods disclosed herein, and one skilled in the art would know how to use the methods to randomize tuplets of any size.

If the randomization of codons specifying all twenty 10 amino acids is desired at a position, then twenty different codons are synthesized. Likewise, if randomization of only ten codons at a particular position is desired then those ten codons are synthesized. Randomization of codons from 15 two to sixty-four can be accomplished by synthesizing each desired triplet. Preferably, randomization of from two to twenty codons is used for any one position because of the redundancy of the genetic code. The codons selected at one position do not have to be the same codons selected at the Additionally, the sense or anti-sense 20 next position. sequence oligonucleotide can be synthesized. The process therefore provides for randomization of any desired codon position with any number of codons.

25 by coupling the first monomer of each codon to separate supports. The supports for the synthesis of each codon can, for example, be contained in different reaction vessels such that one reaction vessel corresponds to the monomer coupling reactions for one codon. As will be used here and below, if twenty codons are to be randomized, then twenty reaction vessels can be used in independent coupling reactions for the first twenty monomers of each codon. Synthesis proceeds by sequentially coupling the second monomer of each codon to the first monomer to produce a dimer, followed by coupling the third monomer for each

codon to each of the above-synthesized dimers to produce a trimer (Figure 1, step 1, where M_1 , M_2 and M_3 represent the first, second and third monomer, respectively, for each codon to be randomized).

Following synthesis of the first codons from individual monomers, the randomization is achieved by mixing the supports from all twenty reaction vessels which contain the individual codons to be randomized. The solid phase support can be removed from its vessel and mixed to achieve a random distribution of all codon species within the population (Figure 1, step 2). The mixed population of supports, constituting all codon species, are then redistributed into twenty independent reaction vessels (Figure 1, step 3). The resultant vessels are all identical and contain equal portions of all twenty codons coupled to a solid phase support.

For randomization of the second position codon, synthesis of twenty additional codons is performed in each of the twenty reaction vessels produced in step 3 as the 20 condensing substrates of step 1 (Figure 1, step 4). Steps 1 and 4 are therefore equivalent except that step 4 uses the supports produced by the previous synthesis cycle (steps 1 through 3) for codon synthesis whereas step 1 is initial synthesis of the first codon in the The supports resulting from step 4 will 25 oligonucleotide. codons attached to them each have two hexanucleotide) with the codon at the first position being any one of twenty possible codons (i.e., random) and the codon at the second position being one of the twenty 30 possible codons.

For randomization of the codon at the second position and synthesis of the third position codon, steps 2 through 4 are again repeated. This process yields in each vessel a three codon oligonucleotide (i.e., 9 nucleotides) with

codon positions 1 and 2 randomized and position three containing one of the twenty possible codons. Steps 2 through 4 are repeated to randomize the third position codon and synthesize the codon at the next position. The process is continued until an oligonucleotide of the desired length is achieved. After the final randomization step, the oligonucleotide can be cleaved from the supports and isolated by methods known to one skilled in the art. Alternatively, the oligonucleotides can remain on the supports for use in methods employing probe hybridization.

The diversity of codon sequences, i.e., the number of different possible oligonucleotides, which can be obtained using the methods of the present invention, is extremely large and only limited by the physical characteristics of available materials. For example, a support composed of beads of about 100 $\mu\mathrm{m}$ in diameter will be limited to about 10,000 beads/reaction vessel using a 1 μM reaction vessel containing 25 mg of beads. This size bead can support about 1 x 107 oligonucleotides per bead. Synthesis using separate reaction vessels for each of the twenty amino acids will produce beads in which all the oligonucleotides attached to an individual bead are identical. diversity which can be obtained under these conditions is approximately 107 copies of 10,000 x 20 or 200,000 different random oligonucleotides. The diversity can be increased, however, in several ways without departing from the basic methods disclosed herein. For example, the number of possible sequences can be increased by decreasing the size of the individual beads which make up the support. A bead 30 of about 30 μm in diameter will increase the number of beads per reaction vessel and therefore the number of oligonucleotides synthesized. Another way to increase the diversity of oligonucleotides with random codons is to increase the volume of the reaction vessel. For example, 35 using the same size bead, a larger volume can contain a greater number of beads than a smaller vessel and therefore

greater number of a synthesis the support oligonucleotides. Increasing the number of codons coupled . to a support in a single reaction vessel also increases the diversity of the random oligonucleotides. 5 diversity will be the number of codons coupled per vessel raised to the number of codon positions synthesized. For example, using ten reaction vessels, each synthesizing two codons to randomize a total of twenty codons, the number of different oligonucleotides of ten codons in length per 100 $10~\mu\mathrm{m}$ bead can be increased where each bead will contain about 2^{10} or 1 x 10^3 different sequences instead of one. skilled in the art will know how to modify such parameters to increase the diversity of oligonucleotides with random codons.

A method of synthesizing oligonucleotides having 15 random codons at each position using individual monomers wherein the number of reaction vessels is less than the number of codons to be randomized is also described. example, if twenty codons are to be randomized at each 20 position within an oligonucleotide population, then ten reaction vessels can be used. The use of a smaller number of reaction vessels than the number of codons to be randomized at each position is preferred because the smaller number of reaction vessels is easier to manipulate possible greater number а in results 25 and oligonucleotides synthesized.

The use of a smaller number of reaction vessels for random synthesis of twenty codons at a desired position within an oligonucleotide is similar to that described above using twenty reaction vessels except that each reaction vessel can contain the synthesis products of more than one codon. For example, step one synthesis using ten reaction vessels proceeds by coupling about two different codons on supports contained in each of ten reaction vessels. This is shown in Figure 2 where each of the two

.

codons coupled to a different support can consist of the following sequences: (1) (T/G)TT for Phe and Val; (2) (T/C)CT for Ser and Pro; (3) (T/C)AT for Tyr and His; (4) (T/C)GT for Cys and Arg; (5) (C/A)TG for Leu and Met; (6) (C/G)AG for Gln and Glu; (7) (A/G)CT for Thr and Ala; (8) (A/G)AT for Asn and Asp; (9) (T/G)GG for Trp and Gly and (10) A(T/A)A for Ile and Cys. The slash (/) signifies that a mixture of the monomers indicated on each side of the slash are used as if they were a single monomer in the indicated coupling step. The antisense sequence for each of the above codons can be generated by synthesizing the complementary sequence. For example, the antisense for Phe and Val can be AA(C/A). The amino acids encoded by each of the above pairs of sequences are given as the standard three letter nomenclature.

Coupling of the monomers in this fashion will yield codons specifying all twenty of the naturally occurring amino acids attached to supports in ten reaction vessels. However, the number of individual reaction vessels to be used will depend on the number of codons to be randomized at the desired position and can be determined by one skilled in the art. For example, if ten codons are to be randomized, then five reaction vessels can be used for coupling. The codon sequences given above can be used for this synthesis as well. The sequences of the codons can also be changed to incorporate or be replaced by any of the additional forty-four codons which constitutes the genetic code.

The remaining steps of synthesis of oligonucleotides
with random codons using a smaller number of reaction
vessels are as outlined above for synthesis with twenty
reaction vessels except that the mixing and dividing steps
are performed with supports from about half the number of
reaction vessels. These remaining steps are shown in
Figure 2 (steps 2 through 4).

Oligonucleotides having at least one specified tuplet at a predetermined position and the remaining positions . having random tuplets can also be synthesized using the methods described herein. The synthesis steps are similar 5 to those outlined above using twenty or less reaction vessels except that prior to synthesis of the specified codon position, the dividing of the supports into separate reaction vessels for synthesis of different codons is omitted. For example, if the codon at the second position 10 of the oligonucleotide is to be specified, then following synthesis of random codons at the first position and mixing of the supports, the mixed supports are not divided into new reaction vessels but, instead, can be contained in a single reaction vessel to synthesize the specified codon. 15 The specified codon is synthesized sequentially from individual monomers as described above. Thus, the number of reaction vessels can be increased or decreased at each step to allow for the synthesis of a specified codon or a desired number of random codons.

20 Following codon synthesis, the mixed supports are divided into individual reaction vessels for synthesis of the next codon to be randomized (Figure 1, step 3) or can be used without separation for synthesis of a consecutive specified codon. The rounds of synthesis can be repeated for each codon to be added until the desired number of positions with predetermined or randomized codons are obtained.

Synthesis of oligonucleotides with the first position codon being specified can also be synthesized using the above method. In this case, the first position codon is synthesized from the appropriate monomers. The supports are divided into the required number of reaction vessels needed for synthesis of random codons at the second position and the rounds of synthesis, mixing and dividing are performed as described above.

A method of synthesizing oligonucleotides having tuplets which are diverse but biased toward a predetermined sequence is also described herein. This method employs two reaction vessels, one vessel for the synthesis of a 5 predetermined sequence and the second vessel for the This method random sequence. synthesis of a advantageous to use when a significant number of codon positions, for example, are to be of a specified sequence since it alleviates the use of multiple reaction vessels. Instead, a mixture of four different monomers such as adenine, guanine, cytosine and thymine nucleotides are used for the first and second monomers in the codon. The codon is completed by coupling a mixture of a pair of monomers of either guanine and thymine or cytosine and adenine nucleotides at the third monomer position. In the second 15 vessel, nucleotide monomers are coupled sequentially to yield the predetermined codon sequence. Mixing of the two supports yields a population of oligonucleotides containing both the predetermined codon and the random codons at the 20 desired position. Synthesis can proceed by using this mixture of supports in a single reaction vessel, for example, for coupling additional predetermined codons or, further dividing the mixture into two reaction vessels for synthesis of additional random codons.

25 The two reaction vessel method can be used for codon synthesis within an oligonucleotide with a predetermined tuplet sequence by dividing the support mixture into two portions at the desired codon position to be randomized. Additionally, this method allows for the extent of randomization to be adjusted. For example, unequal mixing or dividing of the two supports will change the fraction of codons with predetermined sequences compared to those with random codons at the desired position. Unequal mixing and dividing of supports can be useful when there is a need to synthesize random codons at a significant number of positions within an oligonucleotide of a longer or shorter

length.

The extent of randomization can also be adjusted by using unequal mixtures of monomers in the first, second and third monomer coupling steps of the random codon position.

The unequal mixtures can be in any or all of the coupling steps to yield a population of codons enriched in sequences reflective of the monomer proportions.

Synthesis of randomized oligonucleotides is performed using methods well known to one skilled in the art. Linear coupling of monomers can, for example, be accomplished using phosphoramidite chemistry with a MilliGen/Biosearch Cyclone Plus automated synthesizer as described by the manufacturer (Millipore, Burlington, MA). Other chemistries and automated synthesizers can be employed as well and are known to one skilled in the art.

Synthesis of multiple codons can be performed without modification to the synthesizer by separately synthesizing the codons in individual sets of reactions. Alternatively, modification of an automated DNA synthesizer can be performed for the simultaneous synthesis of codons in multiple reaction vessels.

In one embodiment, the invention provides a plurality of procaryotic cells containing a diverse population of expressible oligonucleotides operationally linked to expression elements, the expressible oligonucleotides having a desirable bias of random codon sequences produced from diverse combinations of first and second oligonucleotides having a desirable bias of random sequences. The invention provides for a method for constructing such a plurality of procaryotic cells as well.

The oligonucleotides synthesized by the above methods can be used to express a plurality of random peptides which

are unbiased, diverse but biased toward a predetermined sequence or which contain at least one specified codon at a predetermined position. The need will determine which type of oligonucleotide is to be expressed to give the 5 resultant population of random peptides and is known to one skilled in the art. Expression can be performed in any compatible vector/host system. Such systems include, for example, plasmids or phagemids in procaryotes such as \underline{E} . coli, yeast systems, and other eucaryotic systems such as 10 mammalian cells, but will be described herein in context with its presently preferred embodiment, i.e. expression on the surface of filamentous bacteriophage. Filamentous bacteriophage can be, for example, M13, fl and fd. phage have circular single-stranded genomes and double 15 strand replicative DNA forms. Additionally, the peptides can also be expressed in soluble or secreted form depending on the need and the vector/host system employed.

Expression of random peptides on the surface of M13 can be accomplished, for example, using the vector system shown in Figure 3. Construction of the vectors enabling 20 one of ordinary skill to make them are explicitly set out in Examples I and II. The complete nucleotide sequences are given in Figures 5, 6 and 7 (SEQ ID NOS: 1, 2 and 3, produces system This respectively). 25 oligonucleotides functionally linked to expression elements and to gVIII by combining two smaller oligonucleotide portions contained in separate vectors into a single vector. The diversity of oligonucleotide species obtained by this system or others described herein can be 5 \times 10 7 or Diversity of less than 5×10^7 can also be 30 greater. obtained and will be determined by the need and type of random peptides to be expressed. The random combination of two precursor portions into a larger oligonucleotide increases the diversity of the population several fold and has the added advantage of producing oligonucleotides larger than what can be synthesized by standard methods. Additionally, although the correlation is not known, when the number of possible paths an cligonucleotide can take during synthesis such as described herein is greater than the number of beads, then there will be a correlation between the synthesis path and the sequences obtained. By combining oligonucleotide populations which are synthesized separately, this correlation will be destroyed. Therefore, any bias which may be inherent in the synthesis procedures will be alleviated by joining two precursor portions into a contiguous random oligonucleotide.

Populations of precursor oligonucleotides to be combined into an expressible form are each cloned into separate vectors. The two precursor portions which make up the combined oligonucleotide corresponds to the carboxy and 15 amino terminal portions of the expressed peptide. precursor oligonucleotide can encode either the sense or anti-sense and will depend on the orientation of the expression elements and the gene encoding the fusion portion of the protein as well as the mechanism used to 20 join the two precursor oligonucleotides. For the vectors shown in Figure 3, precursor oligonucleotides corresponding to the carboxy terminal portion of the peptide encode the Those corresponding to the amino terminal sense strand. Oligonucleotide portion encode the anti-sense strand. 25 populations are inserted between the Eco RI and Sac I restriction enzyme sites in M13IX22 and M13IX42 (Figure 3A M13IX42 (SEQ ID NO: 1) is the vector used for sense strand precursor oligonucleotide portions and M13IX22 (SEQ ID NO: 2) is used for anti-sense precursor portions.

The populations of randomized oligonucleotides inserted into the vectors are synthesized with Eco RI and Sac I recognition sequences flanking opposite ends of the random codon sequences. The sites allow annealing and ligation of these single strand oligonucleotides into a double stranded vector restricted with Eco RI and Sac I.

Alternatively, the oligonucleotides can be inserted into the vector by standard mutagenesis methods. In this latter method, single stranded vector DNA is isolated from the phage and annealed with random oligonucleotides having known sequences complementary to vector sequences. The oligonucleotides are extended with DNA polymerase to produce double stranded vectors containing the randomized oligonucleotides.

The vector used for sense strand oligonucleotide 10 portions, M13IX42 (Figure 3B) contains down-stream and in frame with the Eco RI and Sac I restriction sites a sequence encoding the pseudo-wild type gVIII product. This gene encodes the wild type M13 gVIII amino acid sequence but has been changed at the nucleotide level to reduce 15 homologous recombination with the wild type gVIII contained The wild type gVIII is present to on the same vector. ensure that at least some functional, non-fusion coat protein will be produced. The inclusion of a wild type gVIII therefore reduces the possibility of non-viable phage 20 production and biological selection against certain peptide fusion proteins. Differential regulation of the two genes can also be used to control the relative ratio of the pseudo and wild type proteins.

Also contained downstream and in frame with the Eco RI
and Sac I restriction sites is an amber stop codon. The
mutation is located six codons downstream from Sac I and
therefore lies between the inserted oligonucleotides and
the gVIII sequence. As was the function of the wild type
gVIII, the amber stop codon also reduces biological
selection when combining precursor portions to produce
expressible oligonucleotides. This is accomplished by
using a non-suppressor (sup O) host strain because nonsuppressor strains will terminate expression after the
oligonucleotide sequences but before the pseudo gVIII
sequences. Therefore, the pseudo gVIII will never be

expressed on the phage surface under these circumstances. Instead, only soluble peptides will be produced. Expression in a non-suppressor strain can be advantageously utilized when one wishes to produce large populations of soluble peptides. Stop codons other than amber, such as opal and ochre, or molecular switches, such as inducible repressor elements, can also be used to unlink peptide expression from surface expression. Additional controls exist as well and are described below.

The vector used for anti-sense strand oligonucleotide portions, M13IX22, (Figure 3A), contains the expression elements for the peptide fusion proteins. Upstream and in frame with the Sac I and Eco RI sites in this vector is a leader sequence for surface expression. A ribosome binding site and Lac Z promoter/operator elements are present for transcription and translation of the peptide fusion proteins.

Both vectors contain a pair of Fok I restriction enzyme sites (Figure 3 A and B) for joining together two 20 precursor oligonucleotide portions and their vector One site is located at the ends of each sequences. precursor oligonucleotide which is to be joined. second Fok I site within the vectors is located at the end of the vector sequences which are to be joined. overhang of this second Fok I site has been altered to encode a sequence which is not found in the overhangs produced at the first Fok I site within the oligonucleotide The two sites allow the cleavage of each circular vector into two portions and subsequent ligation 30 of essential components within each vector into a single circular vector where the two oligonucleotide precursor portions form a contiguous sequence (Figure 3C). compatible overhangs produced at the two Fok I sites allows performing conditions to be selected for optimal 35 concatermization or circularization reactions for joining the two vector portions. Such selection of conditions can be used to govern the reaction order and therefore increase the efficiency of joining.

Fok I is a restriction enzyme whose recognition 5 sequence is distal to the point of cleavage. placement of the recognition sequence in its location to the cleavage point is important since if the two were superimposed within the oligonucleotide portions to be combined, it would lead to an invariant codon sequence at To alleviate the formation of invariant 10 the juncture. codons at the juncture, Fok I recognition sequences can be placed outside of the random codon sequence and still be used to restrict within the random sequence. Subsequent annealing of the single-strand overhangs produced by Fok I and ligation of the two oligonucleotide precursor portions allows the juncture to be formed. A variety of restriction enzymes restrict DNA by this mechanism and can be used instead of Fok I to join precursor oligonucleotides without creating invariant codon sequences. Such enzymes include, 20 for example, Alw I, Bbu I, Bsp MI, Hga I, Hph I, Mbo II, Mnl I, Ple I and Sfa NI. One skilled in the art knows how to substitute Fok I recognition sequences for alternative enzyme recognition sequences such as those above, and use precursor joining for appropriate enzyme the oligonucleotide portions.

precursor the sequences of the Although invariably have oligonucleotides are random and will oligonucleotides within the two precursor populations whose sequences are sufficiently complementary to anneal after 30 cleavage, the efficiency of annealing can be increased by insuring that the single-strand overhangs within one precursor population will have a complementary sequence within the second precursor population. This can be accomplished by synthesizing a non-degenerate series of 35 known sequences at the Fok I cleavage site coding for each

of the twenty amino acids. Since the Fok I cleavage site contains a four base overhang, forty different sequences . are needed to randomly encode all twenty amino acids. example, if two precursor populations of ten codons in 5 length are to be combined, then after the ninth codon position is synthesized, the mixed population of supports are divided into forty reaction vessels for each of the populations and complementary sequences for each of the corresponding reaction vessels between populations are independently synthesized. The sequences are shown in 10 Tables III and VI of Example I where the oligonucleotides on columns 1R through 40R form complementary overhangs with the oligonucleotides on the corresponding columns 1L through 40L once cleaved. The degenerate X positions in 15 Table VI are necessary to maintain the reading frame once the precursor oligonucleotide portions However, use of restriction enzymes which produce a blunt end, such as Mnl I can be alternatively used in place of Fok I to alleviate the degeneracy introduced in maintaining 20 the reading frame.

The last feature exhibited by each of the vectors is an amber stop codon located in an essential coding sequence within the vector portion lost during combining (Figure 3C). The amber stop codon is present to select for viable phage produced from only the proper combination of precursor oligonucleotides and their vector sequences into a single vector species. Other non-sense mutations or selectable markers can work as well.

The combining step randomly brings together different precursor oligonucleotides within the two populations into a single vector (Figure 3C; M13IX). The vector sequences donated from each independent vector, M13IX22 and M13IX42, are necessary for production of viable phage. Also, since the expression elements are contained in M13IX22 and the gVIII sequences are contained in M13IX42, expression of

functional gVIII-peptide fusion proteins cannot be accomplished until the sequences are linked as shown in M13IX.

The combining step is performed by restricting each randomized containing vectors 5 population of oligonucleotides with Fok I, mixing and ligating (Figure Any vectors generated which contain an amber stop codon will not produce viable phage when introduced into a non-suppressor strain (Figure 3D). Therefore, only the 10 sequences which do not contain an amber stop codon will make up the final population of vectors contained in the library. These vector sequences are the sequences required for surface expression of randomized peptides. analogous methodology, more than two vector portions can be combined into a single vector which expresses random 15 peptides.

The invention provides for a method of selecting peptides capable of being bound by a ligand binding protein from a population of random peptides by (a) operationally linking a diverse population of first oligonucleotides having a desirable bias of random codon sequences to a 20 (b) operationally linking first vector; population of second oligonucleotides having a desirable bias of random codon sequences to a second vector; (c) 25 combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors; (d) introducing said population of combined vectors into a compatible host under conditions 30 sufficient for expressing said population of random peptides; and (e) determining the peptides which bind to said binding protein. The invention also provides for determining the encoding nucleic acid sequence of such peptides as well.

ķ

surface expression of the random peptide library is performed in an amber suppressor strain. As described above, the amber stop codon between the random codon sequence and the gVIII sequence unlinks the two components in a non-suppressor strain. Isolating the phage produced from the non-suppressor strain and infecting a suppressor strain will link the random codon sequences to the gVIII sequence during expression (Figure 3E). Culturing the suppressor strain after infection allows the expression of all peptide species within the library as gVIII-peptide fusion proteins. Alternatively, the DNA can be isolated from the non-suppressor strain and then introduced into a suppressor strain to accomplish the same effect.

The level of expression of gVIII-peptide fusion controlled at the additionally be can proteins The gVIII-peptide fusion proteins transcriptional level. Lac the inducible control of the promoter/operator system. Other inducible promoters can work as well and are known by one skilled in the art. 20 high levels of surface expression, the suppressor library is cultured in an inducer of the Lac Z promoter such as isopropylthio-B-galactoside (IPTG). Inducible control is beneficial because biological selection against nonfunctional gVIII-peptide fusion proteins can be minimized 25 by culturing the library under non-expressing conditions. Expression can then be induced only at the time of entire population of screening to ensure that the oligonucleotides within the library are accurately represented on the phage surface. Also this can be used to 30 control the valency of the peptide on the phage surface.

The surface expression library is screened for specific peptides which bind ligand binding proteins by standard affinity isolation procedures. Such methods include, for example, panning, affinity chromatography and solid phase blotting procedures. Panning as described by

FULL CUT . - 17

Ė

parmley and Smith, Gene 73:305-318 (1988), which is incorporated herein by reference, is preferred because high titers of phage can be screened easily, quickly and in small volumes. Furthermore, this procedure can select minor peptide species within the population, which otherwise would have been urdetectable, and amplified to substantially homogenous populations. The selected peptide sequences can be determined by sequencing the nucleic acid encoding such peptides after amplification of the phage population.

The invention provides a plurality of procaryotic cells containing a diverse population of oligonucleotides having a desirable bias of random codon sequences that are operationally linked to expression sequences. The invention provides for methods of constructing such populations of cells as well.

Random oligonucleotides synthesized by any of the methods described previously can also be expressed on the surface of filamentous bacteriophage, such as M13, for example, without the joining together of precursor oligonucleotides. A vector such as that shown in Figure 4, M13IX30, can be used. This vector exhibits all the functional features of the combined vector shown in Figure 3C for surface expression of gVIII-peptide fusion proteins.

The complete nucleotide sequence for M13IX30 (SEQ ID NO: 3) is shown in Figure 7.

M13IX30 contains a wild type gVIII for phage viability and a pseudo gVIII sequence for peptide fusions. The vector also contains in frame restriction sites for cloning random peptides. The cloning sites in this vector are Xho I, Stu I and Spe I. Oligonucleotides should therefore be synthesized with the appropriate complementary ends for annealing and ligation or insertional mutagenesis. Alternatively, the appropriate termini can be generated by

pcR technology. Between the restriction sites and the pseudo gVIII sequence is an in-frame amber stop codon, again, ensuring complete viability of phage in constructing and manipulating the library. Expression and screening is performed as described above for the surface expression library of oligonucleotides generated from precursor portions.

Thus, the invention provides a method of selecting peptides capable of being bound by a ligand binding protein from a population of random peptides by (a) operationally linking a diverse population of oligonucleotides having a desirable bias of random codon sequences to expression elements; (b) introducing said population of vectors into a compatible host under conditions sufficient for expressing said population of random peptides; and (c) determining the peptides which bind to said binding protein. Also provided is a method for determining the encoding nucleic acid sequence of such selected peptides.

The following examples are intended to illustrate, but not limit the invention.

EXAMPLE I

Isolation and Characterization of Peptide Ligands Generated From Right and Left Half Random Oligonucleotides

random synthesis of shows the example 25 oligonucleotides and the construction and expression of surface expression libraries of the encoded randomized peptides. The random peptides of this example derive from joining together of two mixing and the 30 oligonucleotides. Also demonstrated is the isolation and characterization of peptide ligands and their corresponding nucleotide sequence for specific binding proteins.

Synthesis of Random Oligonucleotides

The synthesis of two randomized oligonucleotides which correspond to smaller portions of a larger randomized oligonucleotide is shown below. Each of the two smaller 5 portions make up one-half of the larger oligonucleotide. The population of randomized oligonucleotides constituting each half are designated the right and left half. population of right and left halves are ten codons in length with twenty random codons at each position. 10 right half corresponds to the sense sequence of the randomized oligonucleotides and encode the carboxy terminal half of the expressed peptides. The left half corresponds randomized sequence of the anti-sense oligonucleotides and encode the amino terminal half of the 15 expressed peptides. The right and left halves of the randomized oligonucleotide populations are cloned into separate vector species and then mixed and joined so that the right and left halves come together in random combination to produce a single expression vector species 20 which contains a population of randomized oligonucleotides twenty codons in length. Electroporation of the vector population into an appropriate host produces filamentous phage which express the random peptides on their surface.

The reaction vessels for oligonucleotide synthesis were obtained from the manufacturer of the automated supplier of 25 synthesizer (Millipore, Burlington, MA; MilliGen/Biosearch Cyclone Plus Synthesizer). The vessels were supplied as packages containing empty reaction columns (1 μmole), frits, crimps and plugs (MilliGen/Biosearch Derivatized and underivatized catalog # GEN 860458). control pore glass, phosphoramidite nucleotides, and obtained also were reagents synthesis Crimper and decrimper tools were MilliGen/Biosearch. obtained from Fisher Scientific Co., Pittsburgh, PA (Catalog numbers 06-406-20 and 06-406-25A, respectively). 35

Ten reaction columns were used for right half synthesis of random oligonucleotides ten codons in length. The oligonucleotides have 5 monomers at their 3' end of the sequence 5'GAGCT3' and 8 monomers at their 5' end of the sequence 5'AATTCCAT3'. The synthesizer was fitted with a column derivatized with a thymine nucleotide (T-column, MilliGen/Biosearch # 0615.50) and was programmed to synthesize the sequences shown in Table I for each of ten columns in independent reaction sets. The sequence of the last three monomers (from right to left since synthesis proceeds 3' to 5') encode the indicated amino acids:

Table I

	Column		Sequence (5' to 3')	Amino Acids
15	column	1R	(T/G)TTGAGCT	Phe and Val
10	column	2R	(T/C) CTGAGCT	Ser and Pro
	column	3R	(T/C)ATGAGCT	Tyr and His
	column	4R	(T/C)GTGAGCT	Cys and Arg
	column	5R	(C/A) TGGAGCT	Leu and Met
20	column		(C/G) AGGAGCT	Gln and Glu
20	column		(A/G) CTGAGCT	Thr and Ala
	column		(A/G) ATGAGCT	Asn and Asp
	column		(T/G)GGGAGCT	Trp and Gly
	column		A(T/A)AGAGCT	Ile and Cys

where the two monomers in parentheses denote a single monomer position within the codon and indicate that an equal mixture of each monomer was added to the reaction for coupling. The monomer coupling reactions for each of the 10 columns were performed as recommended by the manufacturer (amidite version S1.06, # 8400-050990, scale 1 μM). After the last coupling reaction, the columns were washed with acetonitrile and lyophilized to dryness.

Following synthesis, the plugs were removed from each

PCT/US91/07141

2

column using a decrimper and the reaction products were poured into a single weigh boat. Initially the bead mass increases, due to the weight of the monomers, however, at later rounds of synthesis material is lost. In either 5 case, the material was equalized with underivatized control pore glass and mixed thoroughly to obtain a random distribution of all twenty codon species. The reaction products were then aliquotted into 10 new reaction columns by removing 25 mg of material at a time and placing it into separate reaction columns. Alternatively, the reaction products can be aliquotted by suspending the beads in a liquid that is dense enough for the beads to remain dispersed, preferably a liquid that is equal in density to the beads, and then aliquoting equal volumes of the suspension into separate reaction columns. The lip on the inside of the columns where the frits rest was cleared of material using vacuum suction with a syringe and 25 G New frits were placed onto the lips, the plugs needle. were fitted into the columns and were crimped into place using a crimper. 20

Synthesis of the second codon position was achieved using the above 10 columns containing the random mixture of reaction products from the first codon synthesis. monomer coupling reactions for the second codon position are shown in Table II. An \underline{A} in the first position means that any monomer can be programmed into the synthesizer. At that position, the first monomer position is not coupled by the synthesizer since the software assumes that the An A also monomer is already attached to the column. 30 denotes that the columns from the previous codon synthesis should be placed on the synthesizer for use in the present Reactions were again sequentially synthesis round. repeated for each column as shown in Table II and the reaction products washed and dried as described above.

Table II

•	Column		Sequence (5' to 3')	Amino Acids
	Column			
	column	1R	(T/G)TT <u>A</u>	Phe and Val
5	column	2R	(T/C)CT <u>A</u>	Ser and Pro
	column	3R	(T/C)AT <u>A</u>	Tyr and His
	column	4R	(T/C)GT <u>A</u>	Cys and Arg
	column	5R	(C/A)TGA	Leu and Met
	column	6R	(C/G)AG <u>A</u>	Gln and Glu
10	column	7R	(A/G) CT <u>A</u>	Thr and Ala
	column 8	8R	(A/G)AT <u>A</u>	Asn and Asp
	column 9	9R	(T/G)GG <u>A</u>	Trp and Gly
	column :	10R	A (T/A) A <u>A</u>	Ile and Cys

Randomization of the second codon position was achieved by removing the reaction products from each of the columns and thoroughly mixing the material. The material was again divided into new reaction columns and prepared for monomer coupling reactions as described above.

Random synthesis of the next seven codons (positions 3 through 9) proceeded identically to the cycle described above for the second codon position and again used the monomer sequences of Table II. Each of the newly repacked columns containing the random mixture of reaction products from synthesis of the previous codon position was used for the synthesis of the subsequent codon position. After synthesis of the codon at position nine and mixing of the reaction products, the material was divided and repacked into 40 different columns and the monomer sequences shown in Table III were coupled to each of the 40 columns in independent reactions. The oligonucleotides from each of the 40 columns were mixed once more and cleaved from the control pore glass as recommended by the manufacturer.

Table III

	Column	Sequence (5' to 3')
	column 1R	AATTCTTTT <u>A</u>
_	column 2R	AATTCTGTT <u>A</u>
5	column 3R	AATTCGTTT <u>A</u>
	column 4R	AATTCGGTT <u>A</u>
	column 5R	AATTCTTCT <u>A</u>
	column 6R	AATTCTCCT <u>A</u>
10	column 7R	AATTCGTCT <u>A</u>
10	column 8R	AATTCGCCT <u>A</u>
	column 9R	AATTCTTAT <u>A</u>
	column 10R	AATTCTCAT <u>A</u>
	column 11R	AATTCGTAT <u>A</u>
. 15	column 12R	AATTCGCAT <u>A</u>
13	column 13R	AATTCTTGT <u>A</u>
•	column 14R	AATTCTCGT <u>A</u>
	column 15R	AATTCGTGT <u>A</u>
	column 16R	AATTCGCGT <u>A</u>
20	column 17R	AATTCTCTG <u>A</u>
	column 18R	AATTCTATG <u>A</u>
	column 19R	AATTCGCTG <u>A</u>
	column 20R	AATTCGATG <u>A</u>
	column 21R	AATTCTCAG <u>A</u>
25	column 22R	AATTCTGAG <u>A</u>
	column 23R	AATTCGCAG <u>A</u>
	column 24R	AATTCGGAG <u>A</u>
	column 25R	AATTCTACT <u>A</u>
•	column 26R	AATTCTGCT <u>A</u>
30	column 27R	AATTCGACT <u>A</u>
	column 28R	AATTCGGCT <u>A</u>
	column 29R	AATTCTAAT <u>A</u>
	column 30R	AATTCTGAT <u>A</u>
	column 31R	AATTCGAAT <u>A</u>
35	column 32R	AATTCGGAT <u>A</u>
	column 33R	AATTCTTGG <u>A</u>

			_
	column	34R	AATTCTGGG <u>A</u>
	column	35R	AATTCGTGGA
	column	36R	AATTCGGGGA
•	column	37R	AATTCTATA <u>A</u>
5	column	38R	AATTCTAAA <u>A</u>
-	column	39R	AATTCGATA <u>A</u>
	column	40R	AATTCGAAA <u>A</u>

Left half synthesis of random oligonucleotides proceeded similarly to the right half synthesis. This half of the oligonucleotide corresponds to the anti-sense sequence of the encoded randomized peptides. Thus, the complementary sequence of the codons in Tables I through III are synthesized. The left half oligonucleotides also have 5 monomers at their 3' end of the sequence 5'GAGCT3' and 8 monomers at their 5' end of the sequence 5'AATTCCAT3'. The rounds of synthesis, washing, drying, mixing, and dividing are as described above.

fitted with a T-column and programmed to synthesize the sequences shown in Table IV for each of ten columns in independent reaction sets. As with right half synthesis, the sequence of the last three monomers (from right to left) encode the indicated amino acids:

<u>Table IV</u>

·	Column		Sequence		Ami	no A	cids
-						and	
	column	TT	AA(A/C)GA				
5	column	2L	AG(A/G)GA	GCT	Ser	and	Pro
	column	3L	AT(A/G)GA	GCT	Tyr	and	His
	column	4 L	AC(A/G)GA	GCT	Cys	and	Arg
	column	5L	CA(G/T)GA	GCT	Leu	and	Met
	column	6L	CT(G/C)GA	GCT	Gln	and	Glu
10	column	7L	AG (T/C) GA	GCT	Thr	and	Ala
	column	8L	AT (T/C) GA	GCT	Asn	and	Asp
	column	9L	CC(A/C)GA	GCT	Trp	and	Gly
	column	10L	T(A/T)TGA	GCT	Ile	and	Cys

Following washing and drying, the plugs for each column were removed, mixed and aliquotted into ten new reaction columns as described above. Synthesis of the second codon position was achieved using these ten columns containing the random mixture of reaction products from the first codon synthesis. The monomer coupling reactions for the second codon position are shown in Table V.

Table V

	Column	(5' to 3')	Amino Acids
	column 1L	$AA(A/C)\underline{A}$	Phe and Val
25	column 2L	$AG(A/G)\underline{A}$	Ser and Pro
	column 3L	$AT(A/G)\underline{A}$	Tyr and His
	column 4L	$AC(A/G)\underline{A}$	Cys and Arg
	column 5L	$CA(G/T)\underline{A}$	Leu and Met
	column 6L	CT(G/C) <u>A</u>	Gln and Glu
30	column 7L	AG(T/C) <u>A</u>	Thr and Ala
	column 8L	AT (T/C) <u>A</u>	Asn and Asp
	column 9L	CC(A/C) <u>A</u>	Trp and Gly
	column 10L	T(A/T)TA	Ile and Cys

Again, randomization of the second codon position was achieved by removing the reaction products from each of the columns and thoroughly mixing the beads. The beads were repacked into ten new reaction columns.

Proceeded identically to the cycle described above for the second codon position and again used the monomer sequences of Table V. After synthesis of the codon at position nine and mixing of the reaction products, the material was divided and repacked into 40 different columns and the monomer sequences shown in Table VI were coupled to each of the 40 columns in independent reactions.

Table VI

15	Column	Sequence (5' to 3')
	column 1L	AATTCCATAAAAXXA
	column 2L	AATTCCATAAACXX <u>A</u>
	column 3L	AATTCCATAACAXX <u>A</u>
	column 4L	AATTCCATAACCXX <u>A</u>
20	column 5L	AATTCCATAGAAXX <u>A</u>
	column 6L	AATTCCATAGACXX <u>A</u>
	column 7L	AATTCCATAGGAXX <u>A</u>
	column 8L	AATTCCATAGGCXX <u>A</u>
	column 9L	AATTCCATATAAXX <u>A</u>
25	column 10L	AATTCCATATACXX <u>A</u>
	column 11L	AATTCCATATGAXX <u>A</u>
	column 12L	AATTCCATATGCXX <u>A</u>
	column 13L	AATTCCATACAAXX <u>A</u>
	column 14L	AATTCCATACACXX <u>A</u>
30	column 15L	AATTCCATACGAXX <u>A</u>
	column 16L	AATTCCATACGCXX <u>A</u>
	column 17L	AATTCCATCAGAXX <u>A</u>
	column 18L	AATTCCATCAGCXX <u>A</u>
	column 19L	AATTCCATCATAXXA
35	column 20L	AATTCCATCATCXXA
30		

•			
	column	21L	AATTCCATCTGAXX <u>A</u>
	column	22L	AATTCCATCTGCXX <u>A</u>
	column	23L	AATTCCATCTCAXX <u>A</u>
•	column	24L	aattccatctccxx <u>a</u>
5	column	25L	AATTCCATAGTAXX <u>A</u>
3	column	26L	AATTCCATAGTCXX <u>A</u>
	column	27L	AATTCCATAGCAXX <u>A</u>
	column	28L	AATTCCATAGCCXX <u>A</u>
	column	29L	AATTCCATATTAXX <u>A</u>
10	column	30L	AATTCCATATTCXX <u>A</u>
10	column	31L	AATTCCATATCAXX <u>A</u>
	column	32L	AATTCCATATCCXX <u>A</u>
	column	33L	AATTCCATCCAAXX <u>A</u>
	column	34L	AATTCCATCCACXXA
15	column	35L	AATTCCATCCCAXX <u>A</u>
	column	36L	AATTCCATCCCCXX <u>A</u>
	column	37L	AATTCCATTATAXX <u>A</u>
	column	38L	AATTCCATTATCXX <u>A</u>
	column	39L	AATTCCATTTTAXX <u>A</u>
20	column	40L	AATTCCATTTTCXX <u>A</u>

The first two monomers denoted by an "X" represent an equal mixture of all four nucleotides at that position. This is necessary to retain a relatively unbiased codon sequence at the junction between right and left half oligonucleotides.

The above right and left half random oligonucleotides were cleaved and purified from the supports and used in constructing the surface expression libraries below.

Vector Construction

Two M13-based vectors, M13IX42 (SEQ ID NO: 1) and M13IX22 (SEQ ID NO: 2), were constructed for the cloning and propagation of right and left half populations of random oligonucleotides, respectively. The vectors were specially constructed to facilitate the random joining and subsequent expression of right and left half

oligonucleotide populations. Each vector within the population contains one right and one left half oligonucleotide from the population joined together to form a single contiguous oligonucleotide with random codons which is twenty-two codons in length. The resultant population of vectors are used to construct a surface expression library.

M13IX42, or the right-half vector, was constructed to randomized half populations of the right 10 oligonucleotides. M13mp18 (Pharmacia, Piscataway, NJ) was the starting vector. This vector was genetically modified to contain, in addition to the encoded wild type M13 gene VIII already present in the vector: (1) a pseudo-wild type M13 gene VIII sequence with a stop codon (amber) placed 15 between it and an Eco RI-Sac I cloning site for randomized oligonucleotides; (2) a pair of Fok I sites to be used for joining with M13IX22, the left-half vector; (3) a second amber stop codon placed on the opposite side of the vector than the portion being combined with the left-half vector; 20 and (4) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

The pseudo-wild type M13 gene VIII was used for surface expression of random peptides. The pseudo-wild type gene encodes the identical amino acid sequence as that 25 of the wild type gene; however, the nucleotide sequence has been altered so that only 63% identity exists between this gene and the encoded wild type gene VIII. Modification of the gene VIII nucleotide sequence used for of possibility the reduces expression 30 recombination with the wild type gene VIII contained on the same vector. Additionally, the wild type M13 gene VIII was retained in the vector system to ensure that at least some functional, non-fusion coat protein would be produced. The inclusion of wild type gene VIII therefore reduces the possibility of non-viable phage production from the random peptide fusion genes.

The pseudo-wild type gene VIII was constructed by chemically synthesizing a series of oligonucleotides which encode both strands of the gene. The oligonucleotides are presented in Table VII (SEQ ID NOS: 7 through 16).

TABLE VII

Pseudo-Wild Type Gene VIII Oligonucleotide Series

	Top Strand Oligonucleotides	Sequence (5' to 3')
10	VIII 03	GATCC TAG GCT GAA GGC GAT GAC CCT GCT AAG GCT GC
	VIII 04	A TTC AAT AGT TTA CAG GCA AGT GCT ACT GAG TAC A
	VIII 05	TT GGC TAC GCT TGG GCT ATG
15	VIII 06	GGT GCT ACC ATA GGG ATT AAA TTA TTC AAA AAG TT
	VIII 07	T ACG AGC AAG GCT TCT TA
20	Bottom Strand Oligonucleotides	
	VIII 08	AGC TTA AGA AGC CTT GCT CGT AAA CTT TTT GAA TAA TTT
	VIII 09	AAT CCC TAT GGT AGC ACC AAC TAT AAC TAC TAC CAT
25	VIII 10	AGC CCA AGC GTA GCC AAT GTA CTC AGT AGC ACT TG
	VIII 11	C CTG TAA ACT ATT GAA TGC . AGC CTT AGC AGG GTC
	VIII 12	ATC GCC TTC AGC CTA G

30 Except for the terminal oligonucleotides VIII 03 (SEQ

ID NO: 7) and VIII 08 (SEQ ID NO: 12), the above oligonucleotides (oligonucleotides VIII 04-VIII 07 and 09-. 12 (SEQ ID NOS: 8 through 11 and 13 through 16)) were mixed at 200 ng each in 10 μ l final volume and phosphorylated 5 with T4 polynucleotide Kinase (Pharmacia, Piscataway, NJ) with 1 mM ATP at 37°C for 1 hour. The reaction was stopped Terminal oligonucleotides were at 65°C for 5 minutes. added to the mixture and annealed into double-stranded form by heating to 65°C for 5 minutes, followed by cooling to 10 room temperature over a period of 30 minutes. The annealed oligonucleotides were ligated together with 1.0 U of T4 DNA ligase (BRL). The annealed and ligated oligonucleotides yield a double-stranded DNA flanked by a Bam HI site at its 5' end and by a Hind III site at its 3' end. 15 translational stop codon (amber) immediately follows the Bam HI site. The gene VIII sequence begins with the codon GAA (Glu) two codons 3' to the stop codon. The doublestranded insert was phosphorylated using T4 DNA Kinase (Pharmacia, Piscataway, NJ) and ATP (10 mM Tris-HCl, pH 20 7.5, 10 mM MgCl₂) and cloned in frame with the Eco RI and Sac I sites within the M13 polylinker. To do so, M13mp18 was digested with Bam HI (New England Biolabs, Beverley, MA) and Hind III (New England Biolabs) and combined at a molar ratio of 1:10 with the double-stranded insert. 25 ligations were performed at 16°C overnight in 1X ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl2, 20 mM DTT, 1 mM ATP, 50 μ g/ml BSA) containing 1.0 U of T4 DNA ligase (New England Biolabs). The ligation mixture was transformed into a host and screened for positive clones using standard 30 procedures in the art.

Several mutations were generated within the right-half vector to yield functional M13IX42. The mutations were generated using the method of Kunkel et al., Meth. Enzymol. 154:367-382 (1987), which is incorporated herein by reference, for site-directed mutagenesis. The reagents, strains and protocols were obtained from a Bio Rad

Mutagenesis kit (Bio Rad, Richmond. CA) and mutagenesis was performed as recommended by the manufacturer.

A Fok I site used for joining the right and left halves was generated 8 nucleotides 5' to the unique Eco RI the oligonucleotide 5'-CTCGAATTCGTACATCCT site using The second Fok I site GGTCATAGC-3' (SEQ ID NO: 17). retained in the vector is naturally encoded at position 3547; however, the sequence within the overhang was changed to encode CTTC. Two Fok I sites were removed from the 10 vector at positions 239 and 7244 of M13mpl8 as well as the Hind III site at the end of the pseudo gene VIII sequence using the mutant oligonucleotides 5'-CATTTTTGCAGATGGCTTAGA -3' (SEQ ID NO: 18) and 5'-TAGCATTAACGTCCAATA-3' (SEQ ID NO: 19), respectively. New Hind III and Mlu I sites were also introduced at position 3919 and 3951 of M13IX42. 15 oligonucleotides used for this mutagenesis had the sequences 5'-ATATATTTTAGTAAGCTTCATCTTCT-3' (SEQ ID NO: 20) 5'-GACAAAGAACGCGTGAAAACTTT-3' (SEQ ID respectively. The amino terminal portion of Lac Z was 20 deleted by oligonucleotide-directed mutagenesis using the oligonucleotide mutant GCGGGCCTCTTCGCTATTGCTTAAGAAGCCTTGCT-3' (SEQ ID NO: 22). This deletion also removed a third M13mp18 derived Fok I The distance between the Eco RI and Sac I sites was increased to ensure complete double digestion by inserting a spacer sequence. The spacer sequence was inserted using oligonucleotide TTCAGCCTAGGATCCGCCGAGCTCTCCTACCTGCGAATTCGTACATCC-3 (SEQID Finally, an amber stop codon was placed at using the mutant oligonucleotide 5'position 4492 TGGATTATACTTCTA AATAATGGA-3' (SEQ ID NO: 24). stop codon is used as a biological selection to ensure the proper recombination of vector sequences to bring together right and left halves of the randomized oligonucleotides. 35 In constructing the above mutations, all changes made in a M13 coding region were performed such that the amino acid sequence remained unaltered. It should be noted that several mutations within M13mp18 were found which differed from the published sequence. Where known, these sequence differences are recorded herein as found and therefore may not correspond exactly to the published sequence of M13mp18.

The sequence of the resultant vector, M13IX42, is shown in Figure 5 (SEQ ID NO: 1). Figure 3A also shows M13IX42 where each of the elements necessary for producing a surface expression library between right and left half randomized oligonucleotides is marked. The sequence between the two Fok I sites shown by the arrow is the portion of M13IX42 which is to be combined with a portion of the left-half vector to produce random oligonucleotides as fusion proteins of gene VIII.

M13IX22, or the left-half vector, was constructed to populations of randomized left half the harbor oligonucleotides. This vector was constructed from M13mp19 (Pharmacia, Piscataway, NJ) and contains: (1) Two Fok I 20 sites for mixing with M13IX42 to bring together the left and right halves of the randomized oligonucleotides; (2) sequences necessary for expression such as a promoter and signal sequence and translation initiation signals; (3) an randomized the for site cloning I RI-Sac Eco 25 oligonucleotides; and (4) an amber stop codon for biological selection in bringing together right and left half oligonucleotides.

Of the two Fok I sites used for mixing M13IX22 with M13IX42, one is naturally encoded in M13mp18 and M13mp19 (at position 3547). As with M13IX42, the overhang within this naturally occurring Fok I site was changed to CTTC. The other Fok I site was introduced after construction of the translation initiation signals by site-directed mutagenesis using the oligonucleotide 5'-

TAACACTCATTCCGGATGGAATTCTGGAGTCTGGGT-3' (SEQ ID NO: 25).

The translation initiation signals were constructed by annealing of overlapping oligonucleotides as described above to produce a double-stranded insert containing a 5'

5 Eco RI site and a 3' Hind III site. The overlapping oligonucleotides are shown in Table VIII (SEQ ID NOS: 26 through 34) and were ligated as a double-stranded insert between the Eco RI and Hind III sites of M13mp18 as described for the pseudo gene VIII insert. The ribosome binding site (AGGAGAC) is located in oligonucleotide 015 (SEQ ID NO: 26) and the translation initiation codon (ATG) is the first three nucleotides of oligonucleotide 016 (SEQ ID NO: 27).

TABLE VIII

Oligonucleotide Series for Construction of Translation Signals in M13IX22

	Oligonucleotide	Sequence (5' to 3')
	015 016	AATT C GCC AAG GAG ACA GTC AT AATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TT
20	017	ATTA CTC GCT GCC CAA CCA GCC ATG
	018	GACC CAG ACT CCA GATATC CAA CAG
2 5	019 020	TCT AGA ACG CGT C ACGT G ACG CGT TCT AGA AT TAA
	021	CACTCA TTC CTG T TG GAT ATC TGG AGT CTG GGT CAT CAC GAG CTC GGC CAT G
30	022	GC TGG TTG GGC AGC GAG TAA TAA
	023	GT AGG CAA TAG GTA TTT CAT TAT GAC TGT CCT TGG CG

Oligonucleotide 017 (SEQ ID NO: 27) contained a Sac I restriction site 67 nucleotides downstream from the ATG codon. The naturally occurring Eco RI site was removed and a new site introduced 25 nucleotides downstream from the Sac I. Oligonucleotides 5'-TGACTGTCTCCTTGGCGTGTGAAATTGTTA-3' (SEQ ID NO: 35) and 5'-TAACACTCATTCCGGATGGAATTCTGGAGTCT GGGT-3' (SEQ ID NO: 36) were used to generate each of the mutations, respectively. An amber stop codon was also introduced at position 3263 of M13mp18 using the oligonucleotide 5'-CAATTTTATCCTAAATCTTACCAAC-3' (SEQ ID NO: 37).

In addition to the above mutations, a variety of other modifications were made to remove certain sequences and redundant restriction sites. The LAC Z ribosome binding site was removed when the original Eco RI site in M13mp18 was mutated. Also, the Fok I sites at positions 239, 6361 and 7244 of M13mp18 were likewise removed with mutant oligonucleotides 5'-CATTTTTGCAGATGGCTTAGA-3' (SEQ ID NO: 38), 5'-CGAAAGGGGGGTGTGCTGCAA-3' (SEQ ID NO: 39) and 5'-TAGCATTAACGTCCAATA-3' (SEQ ID NO: 40), respectively. Again, mutations within the coding region did not alter the amino acid sequence.

The resultant vector, M13IX22, is 7320 base pairs in length, the sequence of which is shown in Figure 6 (SEQ ID NO: 2). The Sac I and Eco RI cloning sites are at positions 6290 and 6314, respectively. Figure 3A also shows M13IX22 where each of the elements necessary for producing a surface expression library between right and left half randomized oligonucleotides is marked.

30 Library Construction

Each population of right and left half randomized oligonucleotides from columns 1R through 40R and columns 1L through 40L are cloned separately into M13IX42 and M13IX22,

ė

10

respectively, to create sublibraries of right and left half randomized oligonucleotides. Therefore, a total of eighty sublibraries are generated. Separately maintaining each population of randomized oligonucleotides until the final 5 screening step is performed to ensure maximum efficiency of annealing of right and left half oligonucleotides. greater efficiency increases the total number of randomized oligonucleotides which can be obtained. Alternatively, one right populations of forty all combine oligonucleotides (columns 1R-40R) into one population and of left half oligonucleotides (columns 1L-40L) into a second population to generate just one sublibrary for each.

For the generation of sublibraries, each of the above populations of randomized oligonucleotides are cloned separately into the appropriate vector. The right half oligonucleotides are cloned into M13IX42 to generate sublibraries M13IX42.1R through M13IX42.40R. The left half oligonucleotides are similarly cloned into M13IX22 to generate sublibraries M13IX22.1L through M13IX22.40L. Each vector contains unique Eco RI and Sac I restriction enzyme sites which produce 5' and 3' single-stranded overhangs, respectively, when digested. The single strand overhangs ligation for the annealing and are complementary single-stranded random oligonucleotides.

The randomized oligonucleotide populations are cloned 25 between the Eco RI and Sac I sites by sequential digestion and ligation steps. Each vector is treated with an excess of Eco RI (New England Biolabs) at 37°C for 2 hours followed by addition of 4-24 units of calf intestinal alkaline phosphatase (Boehringer Mannheim, Indianapolis, IN). Reactions are stopped by phenol/chloroform extraction and ethanol precipitation. The pellets are resuspended in an appropriate amount of distilled or deionized water (dH_2O) . About 10 pmol of vector is mixed with a 5000-fold randomized population cf each of excess molar 35

oligonucleotides in 10 μ l of 1% ligase buffer (50 mM Tris-HCl, pH 7.8, 10 mM MgCl₂, 20 mM DTT, 1 mM ATP, 50 μ g/ml BSA) containing 1.0 U of T4 DNA ligase (BRL, Gaithersburg, MD). The ligation is incubated at 16°C for 16 hours. Reactions 5 are stopped by heating at 75°C for 15 minutes and the DNA is digested with an excess of Sac I (New England Biolabs) for 2 hours. Sac I is inactivated by heating at 75°C for 15 minutes and the volume of the reaction mixture is adjusted to 300 μ l with an appropriate amount of 10X ligase 10 buffer and dH20. One unit of T4 DNA ligase (BRL) is added and the mixture is incubated overnight at 16°C. The DNA is ethanol precipitated and resuspended in TE (10 mM Tris-HCl, DNA from each ligation is pH 8.0, 1 mM EDTA). electroporated into XL1 Blue the cells (Stratagene, La Jolla, 15 CA), as described below, to generate the sublibraries.

E. coli XL1 Blue is electroporated as described by Smith et al., Focus 12:38-40 (1990) which is incorporated herein by reference. The cerls are prepared by inoculating a fresh colony of XLls into 5 mls of SOB without magnesium 20 (20 g bacto-tryptone, 5 g bacto-yeast extract, 0.584 g NaCl, 0.186 g KCl, dH20 to 1,000 mls) and grown with vigorous aeration overnight at 37°C. SOB without magnesium (500 ml) is inoculated at 1:1000 with the overnight culture and grown with vigorous aeration at 37°C until the OD_{550} is 25 0.8 (about 2 to 3 h). The cells are harvested by centrifugation at 5,000 rpm (2,600 x g) in a GS3 rotor (Sorvall, Newtown, CT) at 4°C for 10 minutes, resuspended in 500 ml of ice-cold 10% (v/v) sterile glycerol and centrifuged and resuspended a second time in the same After a third centrifugation, the cells are resuspended in 10% sterile glycerol at a final volume of about 2 ml, such that the OD_{550} of the suspension is 200 to 300. Usually, resuspension is achieved in the 10% glycerol that remains in the bottle after pouring off the supernate. 35 Cells are frozen in 40 μ l aliquots in microcentrifuge tubes using a dry ice-ethanol bath and stored frozen at -70°C.

Frozen cells are electroporated by thawing slowly on ice before use and mixing with about 10 pg to 500 ng of vector per 40 μl of cell suspension. A 40 μl aliquot is placed in an 0.1 cm electroporation chamber (Bio-Rad, Richmond, CA) and pulsed once at 0°C using 200 Ω parallel resistor, 25 μF, 1.88 kV, which gives a pulse length (τ) of 4 ms. A 10 μl aliquot of the pulsed cells are diluted into 1 ml SOC (98 mls SOB plus 1 ml of 2 M MgCl₂ and 1 ml of 2 M glucose) in a 12- x 75-mm culture tube, and the culture is shaken at 37°C for 1 hour prior to culturing in selective media, (see below).

÷

methods known to one skilled in the art. Such methods can be found in Sanbrook et al., Molecular Cloning: A Laboratory Manuel, Cold Spring Harbor Laboratory, Cold Spring Harbor, 1989, and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, New York, 1989, both of which are incorporated herein by reference. Briefly, the above 1 ml sublibrary cultures were grown up by diluting 50-fold into 2XYT media (16 g tryptone, 10 g yeast extract, 5 g NaCl) and culturing at 37°C for 5-8 hours. The bacteria were pelleted by centrifugation at 10,000 xg. The supernatant containing phage was transferred to a sterile tube and stored at 4°C.

Double strand vector DNA containing right and left half randomized oligonucleotide inserts is isolated from the cell pellet of each sublibrary. Briefly, the pellet is washed in TE (10 mM Tris, pH 8.0, 1 mM EDTA) and recollected by centrifugation at 7,000 rpm for 5' in a Sorval centrifuge (Newtown, CT). Pellets are resuspended in 6 mls of 10% Sucrose, 50 mM Tris, pH 8.0. 3.0 ml of 10 mg/μl lysozyne is added and incubated on ice for 20 minutes. 12 mls of 0.2 M NaOH, 1% SDS is added followed by 10 minutes on ice. The suspensions are then incubated on ice for 20 minutes after addition of 7.5 mls of 3 M NaOAC,

pH 4.6. The samples are centrifuged at 15,000 rpm for 15 with and extracted 4°C, RNased at minutes phenol/chloroform, followed by ethanol precipitation. The pellets are resuspended, weighed and an equal weight of 5 CsCl, is dissolved into each tube until a density of 1.60 EtBr is added to 600 μ g/ml and the g/ml is achieved. equilibrium isolated by is DNA double-stranded centrifugation in a TV-1665 rotor (Sorval) at 50,000 rpm for 6 hours. These DNAs from each right and left half 10 sublibrary are used to generate forty libraries in which the left halves of and oligonucleotides have been randomly joined together.

Each of the forty libraries are produced by joining together one right half and one left half sublibrary. The 15 two sublibraries joined together corresponded to the same left half and right for number column sublibrary example, oligonucleotide synthesis. For M13IX42.1R is joined with M13IX22.1L to produce the surface expression library M13IX.1RL. In the alternative situation 20 where only two sublibraries are generated from the combined populations of all right half synthesis and all left half synthesis, only one surface expression library would be produced.

For the random joining of each right and left half into a single populations 25 oligonucleotide expression vector species, the DNAs isolated from each sublibrary are digested an excess of Fok I (New England Biolabs). The reactions are stopped by phenol/chloroform extraction, followed by ethanol precipitation. Pellets are 30 resuspended in dH,O. Each surface expression library is generated by ligating equal molar amounts (5-10 pmol) of Fok I digested DNA isolated from corresponding right and left half sublibraries in 10 μ l of 1X ligase buffer containing 1.0 U of T4 DNA ligase (Bethesda Research Laboratories, Gaithersburg, MD). The ligations proceed 35

overnight at 16°C and are electroporated into the sup 0 strain MK30-3 (Boehringer Mannheim Biochemical, (BMB), Indianapolis, IN) as previously described for XL1 cells. Because MK30-3 is sup 0, only the vector portions encoding the randomized oligonucleotides which come together will produce viable phage.

Screening of Surface Expression Libraries

Purified phage are prepared from 50 ml liquid cultures of XL1 Blue the cells (Stratagene) which are infected at a m.o.i. of 10 from the phage stocks stored at 4°C. cultures are induced with 2 mM IPTG. Supernatants from all cultures are combined and cleared by two centrifugations, and the phage are precipitated by adding 1/7.5 volumes of PEG solution (25% PEG-8000, 2.5 M NaCl), followed by 15 incubation at 4°C overnight. The precipitate is recovered by centrifugation for 90 minutes at 10,000 x g. pellets are resuspended in 25 ml of 0.01 M Tris-HCl, pH 7.6, 1.0 mM EDTA, and 0.1% Sarkosyl and then shaken slowly The solutions are at room temperature for 30 minutes. 20 adjusted to 0.5 M NaCl and to a final concentration of 5% 2 hours at After polyethylene glycol. precipitates containing the phage are recovered by centrifugation for 1 hour at 15,000 X g. The precipitates are resuspended in 10 ml of NET buffer (0.1 M NaCl, 1.0 mM EDTA, and 0.01 M Tris-HCl, pH 7.6), mixed well, and the 25 phage repelleted by centrifugation at 170,000 X g for 3 The phage pellets are subsequently resuspended overnight in 2 ml of NET buffer and subjected to cesium chloride centrifugation for 18 hours at 110,000 X g (3.86 30 g of cesium chloride in 10 ml of buffer). Phage bands are collected, diluted 7-fold with NET buffer, recentrifuged at 170,000 X g for 3 hours, resuspended, and stored at 4°C in 0.3 ml of NET buffer containing 0.1 mM sodium azide.

Ligand binding proteins used for panning on

35

streptavidin coated dishes are first biotinylated and then absorbed against UV-inactivated blocking phage (see below). dissolved biotinylating reagents are dimethylformamide at a ratio of 2.4 mg solid NHS-SS-Biotin 5 (sulfosuccinimidyl 2-(biotinamido)ethyl-1,3'dithiopropionate; Pierce, Rockford, IL) to 1 ml solvent and used as recommended by the manufacturer. Small-scale reactions are accomplished by mixing 1 μ l dissolved reagent with 43 μ l of 1 mg/ml ligand binding protein diluted in 10 sterile bicarbonate buffer (0.1 M NaHCO, pH 8.6). After 2 hours at 25°C, residual biotinylating reagent is reacted with 500 μ l 1 M ethanolamine (pH adjusted to 9 with HCl) for an additional 2 hours. The entire sample is diluted with 1 ml TBS containing 1 mg/ml BSA, concentrated to about 15 50 μ l on a Centricon 30 ultra-filter (Amicon), and washed on the same filter three times with 2 ml TBS and once with 1 ml TBS containing 0.02% NaN3 and 7 x 10^{12} UV-inactivated blocking phage (see below); the final retentate (60-80 μ l) is stored at 4°C. Ligand Dinding proteins biotinylated 20 with the NHS-SS-Biotin reagent are linked to biotin via a disulfide-containing chain.

UV-irradiated M13 phage were used for blocking binding proteins which fortuitously bound filamentous phage in M13mp8 (Messing and Vieira, Gene 19: 262-276 (1982), which is incorporated herein by reference) was chosen because it carries two amber stop codons, which ensure that the few phage surviving irradiation will not grow in the sup O strains used to titer the surface expression libraries. A 5 ml sample containing 5 \times 10¹³ 30 M13mp8 phage, purified as described above, was placed in a small petri plate and irradiated with a germicidal lamp at a distance of two feet for 7 minutes (flux 150 $\mu W/cm^2$). NaN3 was added to 0.02% and phage particles concentrated to particles/ml on a Centricon 30-kDa ultrafilter (Amicon).

For panning, polystyrene petri plates (60 x 15 mm, Falcon; Becton Dickinson, Lincoln Park, NJ) are incubated with 1 ml of 1 mg/ml of streptavidin (BMB) in 0.1 M NaHCO₃ pH 8.6-0.02% NaN₃ in a small, air-tight plastic box overnight in a cold room. The next day streptavidin is removed and replaced with at least 10 ml blocking solution (29 mg/ml of BSA; 3 μg/ml of streptavidin; 0.1 M NaHCO₃ pH 8.6-0.02% NaN₃) and incubated at least 1 hour at room temperature. The blocking solution is removed and plates are washed rapidly three times with Tris buffered saline containing 0.5% Tween 20 (TBS-0.5% Tween 20).

Selection of phage expressing peptides bound by the ligand binding proteins is performed with 5 μ l (2.7 μ g ligand binding protein) of blocked biotinylated ligand 15 binding proteins reacted with a 50 μ l portion of each library. Each mixture is incubated overnight at 4°C, diluted with 1 ml TBS-0.5% Tween 20, and transferred to a streptavidin-coated petri plate prepared as described After rocking 10 minutes at room temperature, 20 unbound phage are removed and plates washed ten times with TBS-0.5% Tween 20 over a period of 30-90 minutes. Bound phage are eluted from plates with 800 μ l sterile elution buffer (1 mg/ml BSA, 0.1 M HCl, pH adjusted to 2.2 with glycerol) for 15 minutes and eluates neutralized with 48 μ l 25 2 M Tris (pH unadjusted). A 20 μ l portion of each eluate is titered on MK30-3 concentrated cells with dilutions of input phage.

A second round of panning is performed by treating 750 μ l of first eluate from each library with 5 mM DTT for 10 minutes to break disulfide bonds linking biotin groups to residual biotinylated binding proteins. The treated eluate is concentrated on a Centricon 30 ultrafilter (Amicon), washed three times with TBS-0.5% Tween 20, and concentrated to a final volume of about 50 μ l. Final retentate is transferred to a tube containing 5.0 μ l (2.7 μ g ligand

•

binding protein) blocked biotinylated ligand binding proteins and incubated overnight. The solution is diluted with 1 ml TBS-0.5% Tween 20, panned, and eluted as described above on fresh streptavidin-coated petri plates. The entire second eluate (800 μ l) is neutralized with 48 μ l 2 M Tris, and 20 μ l is titered simultaneously with the first eluate and dilutions of the input phage.

Individual phage populations are purified through 2 to 3 rounds of plaque purification. Briefly, the second 10 eluate titer plates are lifted with nitrocellulose filters (Schleicher & Schuell, Inc., Keene, NH) and processed by washing for 15 minutes in TBS (10 mM Tris-HCl, pH 7.2, 150 mM NaCl), followed by an incubation with shaking for an additional 1 hour at 37°C with TBS containing 5% nonfat dry milk (TBS-5% NDM) at 0.5 ml/cm2. The wash is discarded and fresh TBS-5% NDM is added (0.1 ml/cm2) containing the ligand binding protein between 1 nM to 100 mM, preferably between 1 to 100 μ M. All incubations are carried out in heatsealable pouches (Sears). Incubation with the ligand binding protein proceeds for 12-16 hours at 4°C with shaking. The filters are removed from the bags and washed 3 times for 30 minutes at room temperature with 150 mls of TBS containing 0.1% NDM and 0.2% NP-40 (Sigma, St. Louis, The filters are then incubated for 2 hours at room temperature in antiserum against the ligand binding protein at an appropriate dilution in TBS-0.5% NDM, washed in 3 changes of TBS containing 0.1% NDM and 0.2% NP-40 as described above and incubated in TBS containing 0.1% NDM and 0.2% NP-40 with 1 \times 10⁶ cpm of 125 I-labeled Protein A 30 (specific activity = 2.1 x 10^7 cpm/ μ g). After a washing with TBS containing 0.1% NDM and 0.2% NP-40 as described above, the filters are wrapped in Saran Wrap and exposed to Kodak X-Omat x-ray film (Kodak, Rochester, NY) for 1-12 Dupont Cronex Lightning at -70°C using 35 Intensifying Screens (Dupont, Willmington, DE).

25

¢

Positive plaques identified are cored with the large end of a pasteur pipet and placed into 1 ml of SM (5.8 g NaCl, 2 g MgSO $_4$ ·7H $_2$ O, 50 ml 1 M Tris-HCl, pH 7.5, 5 mls 2% gelatin, to 1000 mls with dH_20) plus 1-3 drops of CHCl3 and 5 incubated at 37°C 2-3 hours or overnight at 4°C. The phage are diluted 1:500 in SM and 2 μl are added to 300 μl of XL1 cells plus 3 mls of soft agar per 100 mm² plate. cells are prepared for plating by growing a colony overnight in 10 ml LB (10 g bacto-tryptone, 5 g bacto-yeast extract, 10 g NaCl, 1000 ml dH_20) containing 100 μ l of 20% 10 maltose and 100 μ l of 1 M MgSO₄. The bacteria are pelletted by centrifugation at 2000 xg for 10 minutes and the pellet is resuspended gently in 10 mls of 10 mM MgSO4. suspension is diluted 4-fold by adding 30 mls of 10 mM MgS0 $_{4}$ 15 to give an OD_{600} of approximately 0.5. The second and third round screens are identical to that described above except that the plaques are cored with the small end of a pasteur pipet and placed into 0.5 mls SM plus a drop of CHCl3 and 1- $5~\mu l$ of the phage following incubation are used for plating At the end of the third round of without dilution. 20 purification, an individual plaque is picked and the templates prepared for sequencing.

Template Preparation and Sequencing

Templates are prepared for sequencing by inoculating a 1 ml culture of 2XYT containing a 1:100 dilution of an overnight culture of XL1 with an individual plaque. plaques are picked using a sterile toothpick. The culture is incubated at 37°C for 5-6 hours with shaking and then 200 µl of PEG transferred to a 1.5 ml microfuge tube. 30 solution is added, followed by vortexing and placed on ice The phage precipitate is recovered by for 10 minutes. centrifugation in a microfuge at 12,000 x g for 5 minutes. The supernatant is discarded and the pellet is resuspended in 230 μ l of TE (10 mM Tris-HCl, pH 7.5, 1 mM EDTA) by gently pipeting with a yellow pipet tip. Phenol (200 μ l)

WO 92/06176 PCT/US91/07141

53

is added, followed by a brief vortex and microfuged to separate the phases. The aqueous phase is transferred to extracted with 200 tube and a separate phenol/chloroform (1.1) as described above for the phenol 5 extraction. A 0.1 volume of 3 M NaOAc is added, followed by addition of 2.5 volumes of ethanol and precipated at The precipated templates are -20°C for 20 minutes. recovered by centrifugation in a microfuge at 12,000 x g for 8 minutes. The pellet is washed in 70% ethanol, dried 10 and resuspended in 25 μl TE. Sequencing was performed using a Sequenase sequencing kit following the protocol supplied by the manufacturer (U.S. Biochemical, Cleveland, OH).

EXAMPLE II

15 <u>Isolation and Characterization of Peptide Ligands Generated</u> <u>From Oligonucleotides Having Random Codons at Two</u> <u>Predetermined Positions</u>

This example shows the generation of a surface expression library from a population of oligonucleotides having randomized codons. The oligonucleotides are ten codons in length and are cloned into a single vector species for the generation of a M13 gene VIII-based surface expression library. The example also shows the selection of peptides for a ligand binding protein and characterization of their encoded nucleic acid sequences.

Oligonucleotide Synthesis

Oligonucleotides were synthesized as described in Example I. The synthesizer was programmed to synthesize the sequences shown in Table IX. These sequences correspond to the first random codon position synthesized and 3' flanking sequences of the oligonucleotide which hybridizes to the leader sequence in the vector. The

54

complementary sequences are used for insertional mutagenesis of the synthesized population of oligonucleotides.

Table IX

5	Column	Sequence (5' to 3')
	column 1	AA(A/C)GGTTGGTCGGTACCGG
	column 2	AG(A/G)GGTTGGTCGGTACCGG
	column 3	AT(A/G)GGTTGGTCGGTACCGG
	column 4	AC(A/G)GGTTGGTCGGTACCGG
10	column 5	CA(G/T)GGTTGGTCGGTACCGG
	column 6	CT(G/C)GGTTGGTCGGTACCGG
	column 7	AG (T/C) GGTTGGTCGGTACCGG
	column 8	AT(T/C)GGTTGGTCGGTACCGG
	column 9	CC(A/C)GGTTGGTCGGTACCGG
15	column 10	$\mathtt{T}(\mathtt{A}/\mathtt{T})\mathtt{TGGTTGGTCGGTACCGG}$

The next eight random codon positions were synthesized as described for Table V in Example I. Following the ninth position synthesis, the reaction products were once more combined, mixed and redistributed into 10 new reaction columns. Synthesis of the last random codon position and 5' flanking sequences are shown in Table X.

Table X

	Column	Sequence (5' to 3')
	column 1	AGGATCCGCCGAGCTCAA (A/C) \underline{A}
25	column 2	AGGATCCGCCGAGCTCAG(A/G)A
	column 3	AGGATCCGCCGAGCTCAT(A/G) \underline{A}
	column 4	AGGATCCGCCGAGCTCAC(A/G) \underline{A}
	column 5	AGGATCCGCCGAGCTCCA(G/T) \underline{A}
	column 6	AGGATCCGCCGAGCTCCT(G/C) \underline{A}
30	column 7	AGGATCCGCCGAGCTCAG(T/C) A
30	column 8	AGGATCCGCCGAGCTCAT(T/C) \underline{A}
	column 9	AGGATCCGCCGAGCTCCC(A/C)A
	column 10	AGGATCCGCCGAGCTCT(A/T)TA

The reaction products were mixed once more and the oligonucleotides cleaved and purified as recommended by the manufacturer. The purified population of oligonucleotides were used to generate a surface expression library as described below.

Vector Construction

The vector used for generating surface expression libraries from a single oligonucleotide population (i.e., without joining together of right and left half oligonucleotides) is described below. The vector is a M13-based expression vector which directs the synthesis of gene VIII-peptide fusion proteins (Figure 4). This vector exhibits all the functions that the combined right and left half vectors of Example I exhibit.

An M13-based vector was constructed for the cloning 15 populations of surface expression of and oligonucleotides (Figure 4, M13IX30), M13mp19 (Pharmacia) was the starting vector. This vector was modified to contain, in addition to the encoded wild type M13 gene 20 VIII: (1) a pseudo-wild type gene, gene VIII sequence with an amber stop codon placed between it and the restriction sites for cloning oligonucleotides; (2) Stu I, Spe I and Xho I restriction sites in frame with the pseudo-wild type gVIII for cloning oligonucleotides; (3) sequences necessary 25 for expression, such as a promoter, signal sequence and translation initiation signals; (4) various other mutations to remove redundant restriction sites and the amino terminal portion of Lac Z.

Construction of M13IX30 was performed in four steps.

In the first step, a precursor vector containing the pseudo gene VIII and various other mutations was constructed, M13IX01F. The second step involved the construction of a small cloning site in a separate M13mp18 vector to yield

15

In the third step, expression sequences and cloning sites were constructed in M13IX03 to generate the intermediate vector M13IX04B. The fourth step involved the incorporation of the newly constructed sequences from the 5 intermediate vector into M13IX01F to yield M13IX30. Incorporation of these sequences linked them with the pseudo gene VIII.

Construction of the precursor vector M13IX01F was similar to that of M13IX42 described in Example I except 10 for the following features: (1) M13mp19 was used as the starting vector; (2) the Fok I site 5' to the unique Eco RI site was not incorporated and the overhang at the naturally occurring Fok I site at position 3547 was not changed to 5'-CTTC-3'; (3) the spacer sequence was not incorporated between the Eco RI and Sac I sites; and (4) the amber codon at position 4492 was not incorporated.

In the second step, Ml3mp18 was mutated to remove the 5' end of Lac Z up to the Lac i binding site and including Lac Z ribosome binding site and start codon. 20 Additionally, the polylinker was removed and a Mlu I site was introduced in the coding region of Lac Z. A single oligonucleotide was used for these mutagenesis and had the sequence "5'-AAACGACGGCCAGTGCCAAGTGACGCGTGTGAAATTGTTATCC-3'" (SEQ ID NO: 41). Restriction enzyme sites for Hind III and Eco RI were introduced downstream of the MluI site 25 oligonucleotide the using GGCGAAAGGGAATTCTGCAAGGCGATTAAGCTTGGGTAACGCC-3'" (SEQ ID NO: 42). These modifications of M13mpl8 yielded the vector M13IX03.

The expression sequences and cloning sites were 30 introduced into M13IX03 by chemically synthesizing a series of oligonucleotides which encode both strands of the desired sequence. The oligonucleotides are presented in Table XI (SEQ ID NOS: 43 through 50).

TABLE XI
M13IX30 Oligonucleotide Series

	Top Strand Oligonucleotides	Sequence (5' to 3')
5	084	GGCGTTACCCAAGCTTTGTACATGGAGAAAATAAAG
	027	TGAAACAAAGCACTATTGCACTGGCACTCTTACCGT TACCGT
	028	TACTGTTTACCCCTGTGACAAAAGCCGCCCAGGTCC AGCTGC
10	029	TCGAGTCAGGCCTATTGTGCCCAGGGATTGTACTAG TGGATCCG
	Bottom Oligonucleotides	Sequence (5' to 3')
	085	TGGCGAAAGGGAATTCGGATCCACTAGTACAATCCCTG
15	031	GGCACAATAGGCCTGACTCGAGCAGCTGGACCAGGGCG GCTT
	032	TTGTCACAGGGGTAAACAGTAACGGTAACGGTAAGTGT GCCA
20	033	GTGCAATAGTGCTTTGTTTCACTTTATTTTCTCCATGT ACAA

The above oligonucleotides except for the terminal oligonucleotides 084 (SEQ ID NO: 43) and 085 (SEQ ID NO: 47) of Table XI were mixed, phosphorylated, annealed and ligated to form a double stranded insert as described in 25 Example I. However, instead of cloning directly into the intermediate vector the insert was first amplified by PCR using the terminal oligonucleotides 084 (SEQ ID NO: 43) and The terminal (SEQ ID NO: 47) as primers. oligonucleotide 084 (SEQ ID NO: 43) contains a Hind III its nucleotides internal to 30 site Oligonucleotide 085 (SEQ ID NO: 47) has an Eco RI site at Following amplification, the products were its 5' end. restricted with Hind III and Eco RI and ligated as described in Example I into the polylinker of M13mp18

digested with the same two enzymes. The resultant double stranded insert contained a ribosome binding site, a translation initiation codon followed by a leader sequence and three restriction enzyme sites for cloning random oligonucleotides (Xho I, Stu I, Spe I). The vector was named M13IX04.

During cloning of the double-stranded insert, it was found that one of the GCC codons in oligonucleotides 028 and its complement in 031 was deleted. Since this deletion did not affect function, the final construct is missing one of the two GCC codons. Additionally, oligonucleotide 032 contained a GTG codon where a GAG codon was needed. Mutagenesis was performed using the oligonucleotide 5'-TAACGGTAAGAGTGCCAGTGC-3' (SEQ ID NO: 51) to convert the codon to the desired sequence. The resultant intermediate vector was named M13IX04B.

The fourth step in constructing M13IX30 involved inserting the expression and cloning sequences from M13IX04B upstream of the pseudo-wild type gVIII in 20 M13IX01F. This was accomplished by digesting M13IX04B with Dra III and Ban HI and gel isolating the 700 base pair insert containing the sequences of interest. M13IX01F was likewise digested with Dra III and Bam HI. The insert was combined with the double digested vector at a molar ratio of 3:1 and ligated as described in Example I. It should be noted that all modifications in the vectors described herein were confirmed by sequence analysis. The sequence of the final construct, M13IX30, is shown in Figure 7 (SEQ ID NO: 3). Figure 4 also shows M13IX30 where each of the elements necessary for surface expression of randomized oligonucleotides is marked.

Library Construction, Screening and Characterization of Encoded Oligonucleotides

is accomplished identically to that described in Example I for sublibrary construction except the oligonucleotides described above are inserted into M13IX30 by mutagenesis instead of by ligation. The library is constructed and propagated on MK30-3 (BMB) and phage stocks are prepared for infection of XLI cells and screening. The surface expression library is screened and encoding oligonucleotides characterized as described in Example I.

EXAMPLE III

Isolation and Characterization of Peptide Ligands Generated from Right and Left Half Degenerate Oligonucleotides

15

20

This example shows the construction and expression of a surface expression library of degenerate oligonucleotides. The encoded peptides of this example derive from the mixing and joining together of two separate oligonucleotide populations. Also demonstrated is the isolation and characterization of peptide ligands and their corresponding nucleotide sequence for specific binding proteins.

Synthesis of Oligonucleotide Populations

A population of left half degenerate oligonucleotides and a population of right half degenerate oligonucleotides was synthesized using standard automated procedures as described in Example I.

The degenerate codon sequences for each population of oligonucleotides were generated by sequentially

synthesizing the triplet NNG/T where N is an equal mixture of all four nucleotides. The antisense sequence for each population of oligonucleotides was synthesized and each population contained 5' and 3' flanking sequences complementary to the vector sequence. The complementary termini was used to incorporate each population of oligonucleotides into their respective vectors by standard mutagenesis procedures. Such procedures have been described previously in Example I and in the Detailed Description. Synthesis of the antisense sequence of each population was necessary since the single-stranded form of the vectors are obtained only as the sense strand.

The left half oligonucleotide population was

synthesized having the following sequence: 5'
AGCTCCCGGATGCCTCAGAAGATG(A/CNN)₉GGCTTTTGCCACAGGGG-3' (SEQ

ID NO: 52). The right half oligonucleotide population

was synthesized having the following sequence: 5'
CAGCCTCGGATCCGCC(A/CNN)₁₀ATG(A/C)GAAT-3' (SEQ ID NO. 53).

These two oligonucleotide populations when incorporated into their respective vectors and joined together encode a 20 codon oligonucleotide having 19 degenerate positions and an internal predetermined codon sequence.

Vector Construction

Modified forms of the previously described vectors were used for the construction of right and left half sublibraries. The construction of left half sublibraries was performed in an M13-based vector termed M13ED03. This vector is a modified form of the previously described M13IX30 vector and contains all the essential features of both M13IX30 and M13IX22. M13ED03 contains, in addition to a wild type and a pseudo-wild type gene VIII, sequences necessary for expression and two Fok I sites for joining with a right half oligonucleotide

sublibrary. Therefore, this vector combines the advantages of both previous vectors in that it can be used for the generation and expression of surface expression libraries from a single oligonucleotide population or it can be joined with a sublibrary to bring together right and left half oligonucleotide populations into a surface expression library.

M13ED03 was constructed in two steps from M13IX30.

The first step involved the modification of M13IX30 to

remove a redundant sequence and to incorporate a sequence encoding the eight amino-terminal residues of human \$\beta\$
endorphin. The leader sequence was also mutated to increase secretion of the product.

During construction of M13IX04 (an intermediate

vector to M13IX30 which is described in Example II), a

six nucleotide sequence was duplicated in oligonucleotide

027 (SEQ ID NO: 44) and its complement 032 (SEQ ID NO:

49). This sequence, 5'-TTACCG-3', was deleted by

mutagenesis in the construction of M13ED01. The

oligonucleotide used for the mutagenesis was 5'
GGTAAACAGTAACGGTAAGAGTGCCAG-3' (SEQ ID NO: 54). The

mutation in the leader sequence was generated using the

oligonucleotide 5'-GGGCTTTTGCCACAGGGGT-3' (SEQ ID NO:

55). This mutagenesis resulted in the A residue at

position 6353 of M13IX30 being changed to a G residue.

The resultant vector was designated M13IX32.

To generate M13ED01, the nucleotide sequence encoding B-endorphin (8 amino acid residues of B-endorphin plus 3 extra amino acid residues) was incorporated after the leader sequence by mutagenesis. The oligonucleotide used had the following sequence: 5'-AGGGTCATCGCCTTCAGCTCCGGATCCCTCAGAAGTCATAAACCCCCCATAGGC TTTTGCCAC-3' (SEQ ID NO: 56). This mutagenesis also removed some of the downstream sequences through the Spe

I site.

The second step in the construction of M13EDC3
involved vector changes which put the β-endorphin
sequence in frame with the downstream pseudo-gene VIII
sequence and incorporated a Fok I site for joining with a
sublibrary of right half oligonucleotides. This vector
was designed to incorporate oligonucleotide populations
by mutagenesis using sequences complementary to those
flanking or overlapping with the encoded β-endorphin
sequence. The absence of β-endorphin expression after
mutagenesis can therefore be used to measure the
mutagenesis frequency. In addition to the above vector
changes, M13EDO3 was also modified to contain an amber
codon at position 3262 for biological selection during
joining of right and left half sublibraries.

The mutations were incorporated using standard mutagenesis procedures as described in Example I. The frame shift changes and Fok I site were generated using the oligonucleotide 5'-

ID NO: 57). The amber codon was generated using the oligonucleotide 5'-CAATTTTATCCTAAATCTTACCAAC-3' (SEQ ID NO: 58). The full sequence of the resultant vector, M13ED03, is provided in Figure 8 (SEQ ID NO: 4).

The construction of right half oligonucleotide sublibraries was performed in a modified form of the M13IX42 vector. The new vector, M13IX421, is identical to M13IX42 except that the amber codon between the Eco RI-SacI cloning site and the pseudo-gene VIII sequence was removed. This change ensures that all expression off of the Lac Z promoter produces a peptide-gene VIII fusion protein. Removal of the amber codon was performed by mutagenesis using the following oligonucleotide: 5'-GCCTTCAGCCTCGGATCCGCC-3' (SEQ ID NO: 59). The full

sequence of M13IX421 is shown in Figure 9 (SEQ ID NO: 5).

Library Construction, Screening and Characterization of Encoded Oligonucleotides

A sublibrary was constructed for each of the 5 previously described degenerate populations of oligonucleotides. The left half population of oligonucleotides was incorporated into M13ED03 to generate the sublibrary M13ED03.L and the right half population of oligonucleotides was incorporated into 10 M13IX421 to generate the sublibrary M13IX421.R. Each of the oligonucleotide populations were incorporated into their respective vectors using site-directed mutagenesis as described in Example I. Briefly, the nucleotide sequences flanking the degenerate codon sequences were 15 complementary to the vector at the site of incorporation. The populations of nucleotides were hybridized to singlestranded M13ED03 or M13IX421 vectors and extended with T4 DNA polymerase to generate a double-stranded circular vector. Mutant templates were obtained by uridine 20 selection in vivo, as described by Kunkel et al., supra. Each of the vector populations were electroporated into host cells and propagated as described in Example I.

The random joining of right and left half sublibraries into a single surface expression library was accomplished as described in Example I except that prior to digesting each vector population with Fok I they were first digested with an enzyme that cuts in the unwanted portion of each vector. Briefly, M13ED03.L was digested with Bgl II (cuts at 7094) and M13IX421.R was digested with Hind III (cuts at 3919). Each of the digested populations were further treated with alkaline phosphatase to ensure that the ends would not religate and then digested with an excess of Fok I. Ligations, electroporation and propagation of the resultant library

WO 92/06176 PCT/US91/07141

€4

was performed as described in Example I.

The surface expression library was screened for ligand binding proteins using a modified panning 5 procedure. Briefly, 1 ml of the library, about 10¹² phage particles, was added to 1-5 μg of the ligand binding protein. The ligand binding protein was either an antibody or receptor globulin (Rg) molecule, Aruffo et al., Cell 61:1303-1313 (1990), which is incorporated 10 herein by reference. Phage were incubated shaking with affinity ligand at room temperature for 1 to 3 hours followed by the addition of 200 μl of latex beads (Biosite, San Diego, CA) which were coated with goatantimouse IgG. This mixture was incubated shaking for an 15 additional 1-2 hours at room temperature. Beads were pelleted for 2 minutes by centrifugation in a microfuge and washed with TBS which can contain 0.1% Tween 20. Three additional washes were performed where the last wash did not contain any Tween 20. The bound phage were 20 then eluted with 200 μ l 0.1 M Glycine-HC1, pH 2.2 for 15 minutes and the beads were spun down by centrifugation. The supernatant-containing phage (eluate) was removed and phage exhibiting binding to the ligand binding protein were further enriched by one-to-two more cycles of 25 panning. Typical yields after the first eluate were about 1 \times 10⁶ - 5 \times 10⁶ pfu. The second and third eluate generally yielded about 5 x 10^6 - 2 x 10^7 pfu and 5 x $10^7 - 1 \times 10^{10}$ pfu, respectively.

The second or third eluate was plated at a suitable

density for plaque identification screening and
sequencing of positive clones (i.e., plated at confluency
for rare clones and 200-500 plaques/plate if pure plaques
were needed). Briefly, plaques grown for about 6 hours
at 37°C and were overlaid with nitrocellulose filters

that had been soaked in 2 mm IPTG and then briefly dried.
The filters remained on the plaques overnight at room

temperature, removed and placed in blocking solution for 1-2 hours. Following blocking, the filters were incubated in 1 μ g/ml ligand binding protein in blocking solution for 1-2 hours at room temperature. Goat antimouse Ig-coupled alkaline phosphatase (Fisher) was added at a 1:1000 dilution and the filters were rapidly washed with 10 mls of TBS or block solution over a glass vacuum filter. Positive plaques were identified after alkaline phosphatase development for detection.

with several different ligand binding proteins resulted in the identification of peptide sequences which bound to each of the ligands. For example, screening with an antibody to 8-endorphin resulted in the detection of about 30-40 different clones which essentially all had the core amino acid sequence known to interact with the antibody. The sequences flanking the core sequences were different showing that they *ere independently derived and not duplicates of the same clone. Screening with an antibody known as 57 gave similar results (i.e., a core consensus sequence was identified but the flanking sequences among the clones were different).

EXAMPLE IV

Generation of a Left Half Random Oligonucleotide Library

This example shows the synthesis and construction of a left half random oligonucleotide library.

A population of random oligonucleotides nine codons in length was synthesized as described in Example I except that different sequences at their 5' and 3' ends were synthesized so that they could be easily inserted into the vector by mutagenesis. Also, the mixing and dividing steps for generating random distributions of

reaction products was performed by the alternative method of dispensing equal volumes of bead suspensions. The liquid chosen that was dense enough for the beads to remain dispersed was 100% acetonitrile.

Briefly, each column was prepared for the first coupling reaction by suspending 22 mg (1µmole) of 48 µmol/g capacity beads (Genta, San Diego, CA) in 0.5 mls of 100% acetonitrile. These beads are smaller than those described in Example I and are derivatized with a guanine nucleotide. They also do not have a controlled pore size. The bead suspension was then transferred to an empty reaction column. Suspensions were kept relatively dispersed by gently pipetting the suspension during transfer. Columns were plugged and monomer coupling reactions were performed as shown in Table XII.

Table XII

	Column	Sequence (5' to 3')
	column 1L	AA(A/C)GGCTTTTGCCACAGG
20	column 2L	$\mathtt{AG}(\mathtt{A/G})\mathtt{GGCTTTTGCCACAGG}$
	column 3L	AT (A/G) GGCTTTTGCCACAGG
	column 4L	AC(A/G)GGCTTTTGCCACAGG
	column 5L	CA(G/T)GGCTTTTGCCACAGG
	column 6L	CT(G/C)GGCTTTTGCCACAGG
25	column 7L	AG (T/C) GGCTTTTGCCACAGG
	column 8L	AT (T/C) GGCTTTTGCCACAGG
	column 9L	CC(A/C)GGCTTTTGCCACAGG
	column 10L	T(A/T)TGGCTTTTGCCACAGG

After coupling of the last monomer, the columns were unplugged as described previously and their contents were poured into a 1.5 ml microfuge tube. The columns were rinsed with 100% acetonitrile to recover any remaining beads. The volume used for rinsing was determined so

that the final volume of total bead suspension was about 100 \$\mu\$1 for each new reaction column that the beads would be aliquoted into. The mixture was vortexed gently to produce a uniformly dispersed suspension and then divided, with constant pipetting of the mixture, into equal volumes. Each mixture of beads was then transferred to an empty reaction column. The empty tubes were washed with a small volume of 100% acetonitrile and also transferred to their respective columns. Random codon positions 2 through 9 were then synthesized as described in Example I where the mixing and dividing steps were performed using a suspension in 100% acetonitrile. The coupling reactions for codon positions 2 through 9 are shown in Table XIII.

15			Table XIII
	Column		Sequence (5' to 3')
	column	1L	AA(A/C) <u>A</u>
	column	2L	AG (A/G) <u>A</u>
20	column	3L	AT (A/G) <u>A</u>
	column	4L	$AC(A/G)\underline{A}$
	column	5L	CA (G/T) <u>A</u>
	column	6L	CT(G/C) A
	column	7L	$AG(T/C)\underline{A}$
25	column	8L	AT (T/C) <u>A</u>
	column	9L	$CC(A/C)\underline{A}$
	column	10L	$\underline{\mathbf{T}}(\mathbf{T}/\mathbf{A})\mathbf{T}$

After coupling of the last monomer for the ninth codon position, the reaction products were mixed and a portion was transferred to an empty reaction column. Columns were plugged and the following monomer coupling reactions were performed: 5'-CGGATGCCTCAGAAGCCCCXXA-3' (SEQ ID NO: 60). The resulting population of random oligonucleotides was purified and incorporated by

mutagenesis into the left half vector M13ED04.

M13ED04 is a modified version of the M13ED03 vector described in Example III and therefore contains all the features of that vector. The difference between M13ED03 and M13ED04 is that M13ED04 does not contain the five amino acid sequence (Tyr Gly Gly Phe Met) recognized by anti-B-endorphin antibody. This sequence was deleted by mutagenesis using the oligonucleotide 5'-CGGATGCCTCAGAAGGGCTTTTGCCACAGG (SEQ ID NO: 61). The entire nucleotide sequence of this vector is shown in Figure 10 (SEQ ID NO: 6).

Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims.

SEQUENCE LISTING

•	
(1) GENERAL INFORMATION:	
(i) APPLICANT: Huse, William D.	
(ii) TITLE OF INVENTION: SURFACE EXPRESSION LIBRARIES OF RANDOMIZED PEPTIDES	
(iii) NUMBER OF SEQUENCES: 61	
 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark (B) STREET: 444 South Flower Street, Suite 2000 (C) CITY: Los Angeles (D) STATE: California (E) COUNTRY: United States (F) ZIP: 90071 	
 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 	
<pre>(vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION:</pre>	
<pre>(viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Campbell, Cachryn A (B) REGISTRATION NUMBER: 31,815 (C) REFERENCE/DOCKET NUMBER: P31 9072</pre>	
(ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (619) 535-9001 (B) TELEFAX: (619) 535-8949	
(2) INFORMATION FOR SEQ ID NO:1:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7294 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:	
AATGCTACTA CTATTAGTAG AATTGATGCC ACCTTTTCAG CTCGCGCCCC AAATGAAAAT	60
ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG ATATTTGAAG	360

TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA CTATAATAGT

CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC TATCCAGTCT	540
AAACATTTTA CTATTACCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC TCGCTATTTT	600
GGTTTTTATC GTCGTCTGGT AAACGAGGGT TATGATAGTG TTGCTCTTAC TATGCCTCGT	660
AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CGTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AGGTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTG ATGAAGGTCA GCCAGCCTAT GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TTGGTCAGTT CGGTTCCCTT ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CACAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TGTTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1680
TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA	1800
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TITATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCG TITGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GATITIGATI ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460

GAAAACGCGG	C TACAGTCTG	A CGCTAAAGG	C AAACTTGAT	r ctgtcgcta	C TGATTACGGT	252C
GCTGCTATC	G ATGGTTTCA	r tggtgacgt	T TCCGGCCTT	G CTAATGGTA	A TGGTGCTACT	2580
GGTGATTTT	G CTGGCTCTA	A TTCCCAAAT	G GCTCAAGTC	G GTGACGGTG	A TAATTCACCT	2640
TTAATGAATA	A ATTTCCGTCA	ATAITTACC	T TCCCTCCCT	C AATCGGTTGA	ATGTCGCCCT	2700
					AATAAACTTA	2760
					ATTTTCTACG	2820
					GGTATTCCGT	2880
					CTTACTTTTC	2940
				GTTTCTTGCT		3000 -
				CGCTCAATTA		3060
				TCCCTGTTTT		3120
				AAAAATCGTT		3180
				AATTAGGCTC		3240
CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT	3300
CTTGATTTAA	GGCTTCAAAA	CCTCCCGCAA	GTCGGGAGGT	TCGCTAAAAC	GCCTCGCGTT	3360
CTTAGAATAC	CGGATAAGCC	TTCTATATCT	GATTIGCTIG	CTATTGGGCG	CGGTAATGAT	3420
TCCTACGATG	AAAATAAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT	3480
ACCCGTTCTT	GGAATGATAA	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT	ACATGCTCGT	3540
AAATTAGGAT	GGGATATTAT	CTTCCTTCTT	CAGGACTTAT	CTATTGTTGA	TAAACAGGCG	3600
CGTTCTGCAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT	3660
TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA	TGCCTCTGCC	TAAATTACAT	3720
GTTGGCGTTG	TTAAATATGG	CGATTCTCAA	TTAAGCCCTA	CTGTTGAGCG	TIGGCTTTAT	3780
ACTGGTAAGA	ATTTGTATAA	CGCATATGAT	ACTAAACAGG	CTTTTTCTAG	TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATTT	AACGCCTTAT	TTATCACACG	GTCGGTATTT	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
				ATTTTGTTTT		4260
				ATTCGCCTCT		4320
				TTTCTCCCGA		4380
ACTGTTACTG	TATATTCATC	TGACGTTAAA	CCTGAAAATC	TACGCAATTT	CTTTATTTCT	4440
GTTTTACGTG	CTAATAATTT	TGATATGGTT	GGTTCAATTC	CTTCCATTAT	TTAGAAGTAT	4500

TORRATCAT CTGATAATCA GGAATATGAT	÷560
AATCGAAACA ATCAGGATTA TATTGATGAA TTGCCATCAT CTGATAATCA GGAATATGAT	4620
GATAATTCCG CTCCTTCTGG TGGTTTCTTT GTTCCGCAAA ATGATAATGT TACTGAAAGT	4680
TTTAAAATTA ATAACGTTCG GGCAAAGGAT TTAATACGAG TTGTCGAATT GTTTGTAAAG TTTAAAAATTA ATAACGTTCG GGCAAAGGAT TTAATACGAG TTGTCGAATGT ATTAGTTGTT	4740
TTTAAAATTA ATAACGIICG GOODGAATTA TCTATTGACG GCTCTAATCT ATTAGTTGTT TCTAATACTT CTAAATCCTC AAATGTATTA TCTATTGC TTTCTACTGT TGATTTGCCA	4800
AGTGCACCTA AAGATATTTT AGATAACCTT CCTCAATTCC TTTCTACTGT TGATTTGCCA	4860
ACTGACCAGA TATTGATTGA GGGTTTGATA TTTGAGGTTC AGCAAGGTGA TGCTTTAGAT ACTGACCAGA TATTGATTGA GGGTTTGATA TTTGAGGTTC AGCAAGGTGA TACTGACCGC	4920
ACTGACCAGA TATTGATTGA GOODE TOTTGATTGCAG GCGGTGTTAA TACTGACCGC TTTTCATTTG CTGCTGGCTC TCAGCGTGGC ACTGTTGCAG GCGGTGTTAA TACTGACCGC TTTTCATTTG CTGCTAG TTTTTAATGG CGATGTTTTA	4980
CTCACCTCTG TTTTATCTTC TGCTGGTGGT TCGTTCGGTA TTTTTAATGG CGATGTTTTA	5040
GGGCTATCAG TTCGCGCATT AAAGACTAAT AGCCATTCAA AAATATTGTC TGTGCCACGT	5100
ATTCTTACGC TTTCAGGTCA GAAGGGTTCT ATCTCTGTTG GCCAGAATGT CCCTTTTATT	5160
ACTGGTCGTG TGACTGGTGA ATCTGCCAAT GTAAATAATC CATTTCAGAC GATTGAGCGT	5220
CAAAATGTAG GTATTTCCAT GAGCGTTTTT CCTGTTGCAA TGGCTGGCGG TAATATTGTT	5280
CAAAATGTAG GIATITOOAT GIOTOTTAGAGAGAGAG TGATGTTATT CTGGATATTA CCAGCAAGGC CGATAGTTTG AGTTCTTCTA CTCAGGCAAG TGATGTTATT	5340
ACTAATCAAA GAAGTATTGC TACAACGGTT AATTTGCGTG ATGGACAGAC TCTTTTACTC	5400
GGTGGCCTCA CTGATTATAA AAACACTTCT CAAGATTCTG GCGTACCGTT CCTGTCTAAA	5460
ATCCCTTTAA TCGGCCTCCT GTTTAGCTCC CGCTCTGATT CCAACGAGGA AAGCACGTTA	5520
TACGTGCTCG TCAAAGCAAC CATAGTACGC GCCCTGTAGC GGCGCATTAA GCGCGGCGGGG TACGTGCTCG TCAAAGCAAC CATAGTACGC GCCCTGTAGC GGCCTAGCGC CCGCTCCTTT	5580
TACGTGCTCG TCAAAGGAAG GATTGCCAGG GCCCTAGCGG CCGCTCCTTT TGTGGTGGTT ACGCGCCAGCG TGACCGCTAC ACTTGCCAGG GCCCTAGCGG CCGCTCTTT TGTGGTGGTT ACGCGCCAGCG TGACCGCCTTT CCCCGTCAAG CTCTAAATCG	5640
CGCTTCTTC CCTTCCTTTC TCGCCACGTT CGCCGGCTTT CCCCGTCAAG CTCTAAATCG GGGGCTCCCT TTAGGGTTCC GATTTAGTGC TTTACGGCAC CTCGACCCCA AAAAACTTGA	5700
GGGGCTCCCT TTAGGGTTCC GATTTAGTGC TITAGGGCATAG ACGGTTTTTC GCCCTTTGAC TTTGGGTGAT GGTTCACGTA GTGGGCCATC GCCCTGATAG ACGGTTTTTC GCCCTTTGAC	5760
TTTGGGTGAT GGTTCACGTA GTGGGCCATC GGCGTGATTA	5820
GTTGGAGTCC ACGTTCTTTA ATAGTGGACT CTTGTTGCCG ATTTCGGAAC CACCATCAAA TATCTCGGGC TATTCTTTTG ATTTATAAGG GATTTTGCCG ATTTCGGAACT CTCTCAGGGC	5880
TATCTCGGGC TATTCTTTIG ATTIATANGG GATTTTO	5940
CAGGCGTGA AGGGCAATCA GCTGTTGCCC GTCTCGCTGG TGAAAAGAAA AACCACCCTG	6000
CAGGCGGTGA AGGGCAATCA GCTGTTGCCC GCGTTGGCCG ATTCATTAAT GCAGCTGGCA GCGCCCAATA CGCAAACCGC CTCTCCCCCGC GCGTTGGCCG ATTCATTAATC TGAGTTAGCT	6060
GCGCCCAATA CGCAAACCGC CICICCGGG GGCAC GCAATTAATG TGAGTTAGCT CGACAGGTTT CCCGACTGGA AAGCGGGCAG TGAGCGCAAC GCAATTAATG TGAGTTAGCT	6120
CGACAGGTTT CCCGACTGGA AAGCGGGGCAG TEMOCOTTCCG GCTCGTATGT TGTGTGGAAT CACTCATTAG GCACCCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT TGTGTGGAAT	6180
CACTCATTAG GCACCCCAGG CITTACACTI INTO	6240
TGTGAGCGGA TAACAATTTC ACACAGGAAA GACAGGATGACC CTGCTAAGGC TGCATTCAAT GTAGGAGAGC TCGGCGGATC CTAGGCTGAA GGCGATGACC CTGCTAAGGC TGCATTCAAT	6300
GTAGGAGAGC TCGGCGGATC CTAGGCTGAA GGGCTATGGT AGTAGTTATA AGTTTACAGG CAAGTGCTAC TGAGTACATT GGCTACGCTT GGGCTATGGT AGTAGTTATA	6360
AGTTTACAGG CAAGTGCTAC TGAGTACATT GGGTACATTA CGAGCAAGGC TTCTTAACCA GTTGGTGCTA CCATAGGGAT TAAATTATTC AAAAAGTTTA CGAGCAAGGC TTCTTAACCA	6420
GTTGGTGCTA CCATAGGGAI IAAATTATTO LILIAGGGGGTGC CGAACAGTTG CGCAGCCTGA GCTGGCGGTAA TAGCGAAGAG GCCCGCACCCG ATCGCCCTTC CCAACAGTTG CGCAGCCTGA	6480
GCTGGCGTAA TAGCGAAGAG GCCGGAAGGC HAGGAAGC GGTGCCGGAA AGCTGGCTGG ATGGCGAATG GCGCTTTGCC TGGTTTCCGG CACCAGAAGC GGTGCCGGAA AGCTGGCTGG	6540
ATGCCGAATG GCGCTTTGGC TGGTTTGGG ATGCCGAATG	

PCT/US91/07141

AGTGCGATCT TCCTGAGGCC GATACGGTCG TCGTCCCCTC AAACTGGCAG ATGCACGGTT	6600
ACGATGCGCC CATCTACACC AACGTAACCT ATCCCATTAC GGTCAATCCG CCGTTTGTTC	6660
CCACGGAGAA TCCGACGGGT TGTTACTCGC TCACATTTAA TGTTGATGAA AGCTGGCTAC	6720
AGGAAGGCCA GACGCGAATT ATTT TGATG GCGTTCCTAT TGGTTAAAAA ATGAGCTGAT	6780
TTAACAAAA TTTAACGCGA ATTTTAACAA AATATTAACG TTTACAATTT AAATATTTGC	6840
TTATACAATC TTCCTGTTTT TGGGGCTTTT CTGATTATCA ACCGGGGTAC ATATGATTGA	6900
CATGCTAGTT TTACGATTAC CGTTCATCGA TTCTCTTGTT TGCTCCAGAC TCTCAGGCAA	6960
TGACCTGATA GCCTTTGTAG ATCTCTCAAA AATAGCTACC CTCTCCGGCA TTAATTTATC	7020
AGCTAGAACG GTTGAATATC ATATTGATGG TGATTTGACT GTCTCCGGCC TTTCTCACCC	7080
TTTTGAATCT TTACCTACAC ATTACTCAGG CATTGCATTT AAAATATATG AGGGTTCTAA	7140
AAATTTTTAT CCTTGCGTTG AAATAAAGGC TTCTCCCGCA AAAGTATTAC AGGGTCATAA	7200
IGTTTTTGGT ACAACCGATT TAGCTTTATG CTCTGAGGCT TTATTGCTTA ATTTTGCTAA	7260
TTCTTTGCCT TGCCTGTATG ATTTATTGGA CGTT	7294

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7320 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

\	•					
AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG						360
	TTCCTCTTAA					420
					GTTTAAAGCA	480
	ATTCAATGAA					540
					TCGCTATTTT	600
					TATGCCTCGT	660
						720
AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840

CAATGATTAA AGTTGAAATT					900
CTCGTCAGGG CAAGCCTTAT					960
AATATCCGGT TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA TACAAATCTC					1200
CAAAGATGAG TGTTTTAGTG					1260
GTGGCATTAC GTATTTTACC					1320
CAAAGCCTCT GTAGCCGTTG					1380
CGATCCCGCA AAAGCGGCCT					1440
TGCGTGGGCG ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680
TTTACTAACG TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA	1800
TGGGTTCCTA TTGGGCTTGC					1860
TCTGAGGGTG GCGGTTCTGA	GGGTGGCGGT	ACTAAACCTC	CTGAGTACGG	TGATACACCT	1920
ATTCCGGGCT ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA	1980
AACCCCCCTA ATCCTAATCC	TTCTCTTGAG	GAGTCTCAGC	CTCTTAATAC	TTTCATGTTT	2040
CAGAATAATA GGTTCCGAAA					2100
CAAGGCACTG ACCCCGTTAA					2160
TATGACGCTT ACTGGAACGG					2220
GATCCATTCG TTTGTGAATA					2280
GCTGGCGGCG GCTCTGGTGC					2340
GGCGGTTCTG AGGGTGGCGC					2400
GATTTTGATT ATGAAAAGA					2460
GAAAACGCGC TACAGTCTG					2520
GCTGCTATCG ATGGTTTCA					2580
GGTGATTTTG CTGGCTCTA					2640
TTAATGAATA ATTTCCGTC					2700
TTTGTCTTTA GCGCTGGT					2760
TTCCGTGGTG TCTTTGCGT					2820
TTTGCTAACA TACTGCGTA	AA TAAGGAGTO	TAATCATGO	CC AGTTCTTT	G GGTATTCCGT	2880

TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3120
TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3180
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TTAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT	3480
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT CTTCCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	3720
GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGCTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	3840
TCCGGTGTTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA	3900
AATTTAGGTC AGAAGATGAA ATTAACTAAA ATATATTTGA AAAAGTTTTC TCGCGTTCTT	3960
TGTCTTGCGA TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT	4080
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC	4200
ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4260
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT	4320
TGTAACTTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTAAAAGG	4380
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTTATTTC	4440
TGTTTTACGT GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TTCAGAAGTA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	4620
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA	4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTCATTT CCTCCTCCT CTCACCCTCC CACTCTTCCA CCCCCTCTTA ATACTGACCC	4920

, 5	
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTITLATE GGGATGTT	4980
ACCOCTATCA GTTGGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTITAT	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG	5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5340
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCCTGTCTAA	5400
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAAGCACGTT	5460
ATACCTITA ATGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG	5520
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCCGCTCCTT	5580
TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC	5640
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAAACTTG	5700
ATTIGGGIGA IGGTICACGI AGIGGGCCAI CGCCCIGATA GACGGIITTI CGCCCTITGA	5760
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACACTCAACC	5320
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA	5580
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGGAAC TCTCTCAGGG	5940
CCAGGCGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	6000
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	5120
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6180
TGACTCATTA GGONGOOGHO TO TO THE TOTAL GALACTATT CACACGCCAA GGAGACAGTC ATAATGAAAT ACCTATTGCC	6240
TACGGCAGCC GCTGGATTGT TATTACTCGC TGCCCAACCA GCCATGGCCG AGCTCGTGAT	6300
GACCCAGACT CCAGAATTCC ATCCGGAATG AGTGTTAATT CTAGAACGCG TAAGCTTGGC	6360
ACTGGCCGTC GTTTTACAAC GTCGTGACTG GGAAAACCCT GGCGTTACCC AACTTAATCG	6420
ACTIGGCCGTC GTTTTAGAMO GTOGTCATTC CCTTGCAGCA CACCCCCCTT TCGCCAGCTG GCGTAATAGC GAAGAGGCCC GCACCGATCG	6480
CCTTGCAGCA CACCCGGGT TGGGTGAATGG CGAATGGGGG TTTGCCTGGT TTCCGGCACC	6540
AGAAGCGGTG CCGGAAAGCT GGCTGGAGTG CGATCTTCCT GAGGCCGATA CGGTCGTCGT	6600
AGAAGCGGTG CCGGAAAGGT GGGTTACGA TGCGCCCATC TACACCAACG TAACCTATCC	6660
CATTACGGTC AATCCGCCGT TTGTTCCCAC GGAGAATCCG ACGGGTTGTT ACTCGCTCAC	6720
CATTACGGTC AATCCGCCGT TTGTTGGGGT ATTTAATGTT GATGAAAGCT GGCTACAGGA AGGCCAGACG CGAATTATTT TTGATGGCGT	6780
ATTTAATGTT GATGAAAATGA GCTGATTTAA CAAAAATTTA ACGCGAATTT TAACAAAATA TCCTATTGGT TAAAAAATGA GCTGATTTAA CAAAAATTTA ACGCGAATTT TAACAAAAATA	6840
TCCTATTGGT TAAAAAATGA GCTGATTAA GAATCTTCC TGTTTTTGGG GCTTTTCTGA TTAACGTTTA CAATTTAAAT ATTTGCTTAT ACAATCTTCC TGTTTTTTGGG GCTTTTCTGA	6900
TTAACGTTTA CAATTTAAAT ATTIGGTTAT MOMENTUMEN TAACGGTTAACGGTT CATCGATTGT TTATCAACCG GGGTACATAT GATTGACATG CTAGTTTTAC GATTACCGTT CATCGATTGT	6960
TTATCAACCG GGGTAGATAT GATTGAGATG GAMGETTE	

CTTGTTTGC	CCAGACTCTC	AGGCAATGAC	CTGATAGCCT	TTGTAGATCT	CTCAAAAATA	/020
GCTACCCTC	CCGGCATTAA	TTTATCAGCT	AGAACGGTTG	AATATCATAT	TGATGGTGAT	7080
TTGACTGTC	CCGGCCTTTC	TCACCCTTTT	GAATCTTTAC	CTACACATTA	CTCAGGCATT	7140
GCATTTAAAA	TATATGAGGG	TTCTAAAAAT	TTTTATCCTT	GCGTTGAAAT	AAAGGCTTCT	7200
CCCGCAAAAC	TATTACAGGG	TCATAATGTT	TTTGGTACAA	CCGATTTAGC	TTTATGCTCT	7260
GAGGCTTTAT	TGCTTAATTT	TGCTAATTCT	TTGCCTTGCC	TGTATGATTT	ATTGGACGTT	7320

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7445 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

` '	•					
AATGCTACTA	CTATTAGTAG	AATTGATGCC	ACCTTTTCAG	CTCGCGCCCC	AAATGAAAAT	60
ATAGCTAAAC	AGGTTATTGA	CCATTTGCGA	AATGTATCTA	ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA	ATTGGGAATC	AACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT	TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
	GTCGTCTGGT					660
	GGCGTTATGT					720
	CTACCTGTAA					780
	GTCCTGACTG					840
	AGTTGAAATT					900
	CAAGCCTTAT					960
					GCGCCTGGTC	1020
					ATGATTGACC	1080
					CACAATTTAT	1140
					CGCTGGGGGT	1200
					TGCCTTCGTA	1260
OHMONION			*			

TO A	1320
GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CTTTAGTCCT	1380
CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CTGAGGGTGA	
CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC IGTTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT GAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1680
TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA	1300
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
AACCCCCCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTGATGTTT	2040
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2220
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAAGC TCCTGTCAAT	2280
GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2340
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2520
GCTGCTATCG ATGGTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2760
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2820
TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2880
TATTATTGCG TTTCCTCGGT TTCCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TTAAAAAGGG CTTCGGTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3060
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3120
TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3180
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3240
CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAT AGCAACTAAT	3300
CIGATINGO IIO MILITARIA	

. 5	
CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3360
CTTAGAATAC CGGATAAGCC TTCTATATCT GATTTGCTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT	3480
ACCCGTTCTT GGAATGATAA GCAA/GACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3540
AAATTAGGAT GGGATATTAT TTTTCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3600
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3660
TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	3720
GTTGGCGTTG TTAAATATGG CGATTCTCAA TTAAGCCCTA CTGTTGAGCG TTGGCTTTAT	3780
ACTGGTAAGA ATTTGTATAA CGCATATGAT ACTAAACAGG CTTTTTCTAG TAATTATGAT	3840
TCCGGTGTTT ATTCTTATTT AACGCCTTAT TTATCACACG GTCGGTATTT CAAACCATTA	3900
AATTTAGGTC AGAAGATGAA GCTTACTAAA ATATATTTGA AAAAGTTTTC ACGCGTTCTT	3960
TGTCTTGCGA TTGGATTTGC ATCAGCATTT ACATATAGTT ATATAACCCA ACCTAAGCCG	4020
GAGGTTAAAA AGGTAGTCTC TCAGACCTAT GATTTTGATA AATTCACTAT TGACTCTTCT	4080
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	4140
AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TACTGTTTCC	4200
ATTAAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TCTTGATGTT	4260
TGTTTCATCA TGTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TGCGCGATTT	4320
TGTAACTTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GTTTCTCCCG ATGTAAAAGG	4380
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TCTTTATTTC	4440
TGTTTTACGT GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TTCAGAAGTA	4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AGGAATATGA	4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TTACTCAAAC	4620
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TGTTTGTAAA	4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TATTAGTTGT	4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTGATTTGCC	4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATGCTTTAGA	4860
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATACTGACCG	4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCGATGTTTT	4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTGTGCCACG	5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCCCTTTTAT	5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGATTGAGCG	5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTAATATTGT	5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTGATGTTAT	5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTCTTTTACT	5340

GGTGGCCTC ACTGATTATA	AAAACACTTG	TCAAGATTCT	GGCGTACCGT	TCCTGTCTAA	5400
ATCCCTTTA ATCGCCTCC	TGTTTAGCTC	CCGCTCTGAT	TCCAACGAGG	AAAGCACGTT	5460
TACGTGCTC GTCAAAGCAA	CCATAGTACG	CGCCCTGTAG	CGGCGCATTA	AGCGCGGCGG	5520
TGTGGTGGT TACGCGCAGC	GTGACCGCTA	CACTTGCCAG	CGCCCTAGCG	CCCGCTCCTT	5580
CCCTTTCTT CCCTTCCTTT	CTCGCCACGT	TCGCCGGCTT	TCCCCGTCAA	GCTCTAAATC	5640
REGERETECE TITAGESTIC	CGATTTAGTG	CTTTACGGCA	CCTCGACCCC	AAAAAACTTG	5700
ATTTGGGTGA TGGTTCACGT	AGTGGGCCAT	CGCCCTGATA	GACGGTTTTT	CGCCCTTTGA	5760
CTTGGAGTC CACGTICTTT	AATAGTGGAC	TCTTGTTCCA	AACTGGAACA	ACACTCAACC	5820
CTATCTCGGG CTATTCTTT	GATTTATAAG	GGATTTTGCC	GATTTCGGAA	CCACCATCAA	5880
					5940
CAGGGGGTG AAGGGCAATC	AGCTGTTGCC	CGTCTCGCTG	GTGAAAAGAA	AAACCACCCT	6000
					6060
					5120
					6180
					6240
					6300
					6360
					6420
					6480
					6540
					6600
					6660
					6720
GTCGTCCCCT CAAACTGGC	A GATGCACGGT	TACGATGCGC	CCATCTACAC	CAACGTAACC	6780
TATCCCATTA CGGTCAATC	C GCCGTTTGT	I CCCACGGAGA	A ATCCGACGG	TTGTTACTCG	6840
CTCACATTTA ATGTTGATG	A AAGCTGGCT	A CAGGAAGGC	C AGACGCGAA'	TATTTTTGAT	6900
GGCGTTCCTA TTGGTTAAA	A AATGAGCTG	A TTTAACAAA	A ATTTAACGC	G AATTTTAACA	6960
AAATATTAAC GTTTACAA	TTTATAATT TT	G CTTATACAA	T CTTCCTGTT	T TTGGGGCTTT	7020
TCTGATTATC AACCGGGG	TA CATATGATI	G ACATGCTAG	TTTACGATT	A CCGTTCATCG	7080
ATTCTCTTGT TTGCTCCA	GA CTCTCAGG	DA ATGACCTGA	AT AGCCTTIGT	A GATCTCTCAA	7140
AAATAGCTAC CCTCTCCG	GC ATTAATTT	AT CAGCTAGA	AC GGTTGAATA	AT CATATTGATG	7200
GTGATTTGAC TGTCTCCG	GC CTTTCTCA	CC CTTTTGAA	IC TITACCIA	CA CATTACTCAG	7260
GCATTGCATT TAAAATAT	AT GAGGGTTC	TA AAAATTTT	TA TCCTTGCG	TT GAAATAAAGG	7320
CTTCTCCCGC AAAAGTAT	TTA CAGGGTCA	TA ATGTTTT	GG TACAACCG	AT TTAGCTTTAT	7380
	ATCCCTTA ATCGCCTCC ATACGTGCTC GTCAAAGCAA GTGTGGTGGT TACGCGCAGC GCGCTTCTT GCCTTCCTTT GGGGGCTCCC TTTAGGGTTC ATTTGGGTGA TGGTTGACGT CGTTGGAGTC CACGTTCTTT ACAGGATTT CGCCTGCTGG CCAGGCGGTG AAGGGCAATC GCGCCCAAT ACGCAAACCG ACGACAGGTT TCCCGACTGG TCACTCATTA GGCACCCCAG TTGTGAGCGG ATAACAATTT GGGCGCAGGTC CAGCTGCTCG CAGGCTGAA GGCACCCCAG TTGTGAGCGG ATAACAATTT GGACTGGAA GGCGATGACC CTAGGCTGAA GGCGATGACC CTCACATTA CAAAAGTTTA GATCGCCCTT CCCAACAGTT GCACCAGAAC CTCACATTA ATGTTGATC CTCACATTA ATGTTGATC CTCACATTTA TTGGTTCAAA AAATATTAAC GTTTACAAT TCTGATTATC AACCGGGGC ATTCTCTTGT TTGCTCCA AAATAGCTAC CCTCTCCG GCATTGCATT TAAAATAT	ATCCCTTTA ATCGGCCTCC TGTTTAGGTC ATACGTGCTC GTCAAAGCAA CCATAGTACG CTGTGGTGGT TACGCGCAGC GTGACCGCTA CGCTTTCTT CCCTTCCTTT CTCGCCACGT CGGGGGCTCCC TTTAGGGTTC CGATTTAGTC ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGTTGGAGTC CACGTTCTTT AATAGTGGAC CTATCTCGGG CTATTCTTTT GATTTATAAG ACAGGATTTT CGCCTGCTGG GGCAAACCAG CCAGGCGGTG AAGGCCAATC AGCTGTTGCC ACGACAGGTT TCCCGACTGG AAAGCCGGCA ACGACAGGTT TCCCGACTGG ACCACGCGTC CTGCTCGCAAAACCATT CACACGCGTC CTAGGCTGAA GGCGATGACC TCTTACCGTT CGCCCAGGTC CAGCTGCTCG AGTCAGGCCT CTAGGCTGAA GGCGATGACC CTGCTAAGGC TGAATTATTC AAAAAATTTA CGAGCAAGGC CTCCCCCT CAAACTGGCA GATGCACGGT CGCCCAGGAA CGGTGCCGGA AAGCTGGCTC CTCACATTA ATGTTGATGA AAGCTGGCT CTCACATTA ATGTTGATGA AAGCTGGCT CTCACATTA ATGTTGATGA AAGCTGGCT AAATTATAC GTTTACAATT TAAATATTT TCTGATTATC AACCGGGGTA CATATGATT ATTCTCTTGT TTGCTCCAGG CTTCTCAA CGATTGCATT CACCTCCGGC ATTAATTT CTGATTATC CACCGGGCTA CATATGATT AATTCTCTTGT TTGCTCCAGG CTTCTCAA CGATTGCATT TAAAATATAT GAGGGTTC CCAATTGCATT TAAAATATAT GAGGGTTC	ATACCTTTA ATCGGCCTCC TGTTTAGGTC CCGCTGTAGATAGGTGCTC GTCAAAAGCAA CCATAGTACG CGCCCTGTAGGTGTGGTGGTTAGGTGCTGTTT CTCGCCACCT TCGCCGGCTTGGGGGTTTCTT CTCGCCACCT TCGCCGGCTTGGGGGGTTTTTAGGGTTC CGATTTAGTG CTTTACGGCAAATTTGGGTGA TGGTTGAGGT AGTGGGCCAT CGCCCTGATAATTTGGGTGATTTTT GATTTATAAAG GGATTTTGCAAAGAAAAAGAATTTAGGAAAAAAAAAA	ATACCTTTA ATCGCCCCC TGTTTACCTC CCCCTCGAT TCCAACGAGG ATACCTGCCC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCCCATTA CTGTGGGTGT TACGCGCAGC GTGACCGCTA CACTTCCCAG CGCCCTAGCG CGCCTTCTT CCCCCACGT TCCCCGGCTT TCCCCGTCAA CGGGGCTCCC TTTAGGGTTC CGATTTAGTC CTTTACGGCA CCTCGACCCC ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTT CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA CTATCTCGGG CTATTCTTT GATTTATAAG GGATTTTGC GATTTCGGAA CAGAGGATTTT CGCCTGCTGG GGCAAACCAG CGTCGACCGC TTGCTGAACA CAGAGGATTT CCCCGCTGCG GGCAAACCAG CGTCGACCGC TTGCTGAAC CCAGGGGGTG AAGGCCAAT AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA CAGAGGATTT CCCCGACTGG AAAGCGGGCA CGCGTTGGCC GATTCATTAA CAGACAGGTT TCCCGACTGG AAAGCGGGCA CTGACCGCAA CGCAATAAT CCACTCATTA GGCACCCAG GCTTTACACT TTATGCTTCC GGCCTGATG CTGACTGGGA AAACCCTGGC GTTACCCAAC CTTTGTACAT GGCAGAAAATA CAGACAGTTT GCACTGCCA GTTACCCAAC CTTTGTACAT GGCAGAAAATA CAGACAGTTT GCACTGCCA CTTTACCGTT ACCGTTACCT TTACCCCTG CGCCCAAGTC CAGCTGCCAC CTCTACCGT ACTTGCACT GGCGTTGTC CTGACTGGGA AAACCCTGGC GTTACCCAAC CTTTGTACAT TTACCCCTG CTGACTGGGA AAACCCTGCC GTTACCCAAC CTTTGTACAT TTACCCCTG CTGACTGGAA GGCGATGACC CTCTACAGCT TACCGTTACAT AGTTTACAGG TGAGTACATT GCCTACGCTT GGGCTATGGT ACCGTTACAT AGTTTACAGG TGAGTACATT GCCTACGCTT GGGCTATGGT AGCGTTACAT AGTTTACAGG TGAGTACATT GCCTACGCTT GCGCAACGCT TTCTTAAAATATTC AAAAAAGTTTA CGAGCACAGC TTCTTAAAATATTC AAAAAAGTTTA CGAGCACAAGC CTCACACAAAC CGGTGCCGA AAGCTGGCTG AATGGCGAAT GCGCGTTTGC CTCACATTA ATGTTGATGA AAGCTGGCTA CAGGAAGGCC AATGGCGAAC CTCACACATTA ATGTTGATAAA AATGACCTGA TTCACAAT TTACACAAT TTACCACTG CCCACCATTA AGCTTAAAAA AATGACCTGA TTAAAATATTC CACACGGGTA CTCCCAGGAAA ATCCACCGTT CTCACATTA ATGTTGAAAA AATGACCTGA TTAAAAAAAAAA	ATTOCOCTO ACTGATTATA AAAAGACTTC TCAAGATTCT GGGGTAGGGT TCCTGTAAAAGACTTTA ATGGGCCTCC TGTTTAGGTC CGCCTCGAT TCGAACGAGG AAAGCAGGTT AGACGAGC GTGAAAGCAA CCATAGTAGG CGCCCTGTAG CGCGGGATTA AGCGCGGGGG GTGTGCGGGGGT TAGCGCGGAGG GTGAACGAGG GTGACCGCTAGG CGCCCTTTTCTC CGCTTCCTTT CTCGCGACGT TCGCGGGGTT TCCCGGGGTT TCGCGGGGTT TCGCGGGGGTT TCGCGGGGGTT TCGCGGGGGTT TCGCGGGGGTT TCGCGGGGGTT TCGCGGGGGTT TCGCGGGGGTT TCGGGGGGGTT TCGGGGGGGG

PCT/US91/07141

81

GCTCTGAGGC	TTTATTGCTT	AATTTTGCTA	ATTCTTTGCC	TTGCCTGTAT	GATTTATTGG	7440
• CCTT						7445
ACGTT						,)

(2) INFORMATION FOR SEO ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:

 (A) LENGTH: 7409 base pairs

 (B) TYPE: nucleic acid

 (C) STRANDEDNESS: both

 (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATGCTACTA CTATTAGTA	G AATTGATGC	C ACCTTTTCAC	G CTCGCGCCCC	C AAATGAAAAT	60
ATAGCTAAAC AGGTTATTG	A CCATTTGCGA	A AATGTATCTA	ATGGTCAAA	TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC	CAACTGTTACA	TGGAATGAAA	CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT TAAAACATGT	TGAGCTACAG	CACCAGATTC	AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA	TCAAAAGGAG	CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT	GGTTCGCTTT	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA CTATTACCCC	CTCTGGCAAA	ACTTCTTTTG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
ATGAATCTTT CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTIT	780
TCTTCCCAAC GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
•		•			

82.	
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GGAGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TGTTCCTTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AGAAAATTCA	1680
TITTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TJAGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAAGTCAGTG TTACGGTACA	1800
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT	1920
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	1980
ATTCCGGGCT ATACTTATAT CARGOSTOTS AACCCCGGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT	2040 .
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2100
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
CAAGGCACTG ACCCCGITAA AACTTTITTO TO TO TO TO THE TOTAL ACCT TO THE	2220
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2280
GATCCATTCG TITGTGARTA TORROSOGNAT TOTAL	2340
GCTGGCGGCG GCTCTGGTGG TGCTTGTGGTGGCTC GTGGTTGCGGT GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2400
GGCGCTTCTG AGGGTGGCGG CTGTGACCGAT AATAAGGGGG CTATGACCGA AAATGCCGAT	2460
GATTTTGATT ATGAAAAGAT GGGTTAGGT TOTTGATT CTGTCGCTAC TGATTACGGT GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2520
GAAAACGCGC TACAGTCTGA CGCTTALTOO TECCGGCCTTG CTAATGGTAA TGGTGCTACT GCTGCTATCG ATGGTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2580
GCTGCTATCG ATGGTTTCAT TECTOMOTE GCTCAAGTCG GTGACGGTGA TAATTCACCT	2640
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2700
TTAATGAATA ATTIGGGTGA ATTITTATTG ATTGTGACAA AATAAACTTA	2760
TTTGTGTTTA GGGGTGGTAA AGGTATTTATAT GTTGGCACGT TTATGTATGT ATTTTGTACG	2820
TTCCGTGGTG TCTTTGCGTT TOTTTTTTTTTTTTTTTT	2880
TATTATTGCG TITCCTCGGT TICCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	2940
TATTATTGCG ITTCCTCGGT ITCCTTGTT ITCTTGCT CTTATTATTG	3000
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTGAATTA CCCTCTGACT	3060
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCGCTGTTTT TATGTTATTC	3120
TTGTTCAGGG TGTTCAGTTA ATTGTGGGGT COUNTY AAAAATCGTT TCTTATTTGG TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3180
TCTCTGTAAA GGCTGCTATT TTCATTTTT MOOTHERS ATTAGGCTC TGGAAAGACG	3240
ATTGGGATAA ATAATATGGC TGTTTATTT GTTTTTTTTTT	3300
CTCGTTAGCG TTGGTAAGAI ICAGGATAAA MITOTTOOTOO CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT	3360
CTTGATTTAA GGCTTCAAAA CCTCGGGGAA GTGGGGTTG CTATTGGGCG CGGTAATGAT	3420
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT	r 3480
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTGTGCTTCT ACATGCTCGC ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGC	T 3540
ACCCGTTCTT GGAATGATAA GGAAAGAGAG GGGTTTTTT	

			T CACCACTTA	ም ርጥል ጥ ተርጥጥር	A TAAACAGGGG	3600
•					A TAAACAGGCG	3660
					T TACTTTACCT	3720
					C TAAATTACAT	• . • .
					G TIGGCTTTAT	3780
					G TAATTATGAT	3840
TCCGGTGTTT	ATTCTTATT	AACGCCTTA1	TTATCACAC	GTCGGTATT1	CAAACCATTA	3900
AATTTAGGTC	AGAAGATGAA	GCTTACTAAA	ATATATTTGA	AAAAGTTTTC	ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTGC	ATCAGCATTT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAAG	GTAATTCAAA	TGAAATTGTT	AAATGTAATT	AATTTTGTTT	TCTTGATGTT	4260
TGTTTCATCA	TCTTCTTTTG	CTCAGGTAAT	TGAAATGAAT	AATTCGCCTC	TGCGCGATTT	4320
TGTAACTTGG	TATTCAAAGC	AATCAGGCGA	ATCCGTTATT	GTTTCTCCCG	ATGTAAAAGG	4380
TACTGTTACT	GTATATTCAT	CTGACGTTAA	ACCTGAAAAT	CTACGCAATT	TCTTTATTTC	4440
TGTTTTACGT	GCTAATAATT	TTGATATGGT	TGGTTCAATT	CCTTCCATAA	TTCAGAAGTA	4500
TAATCCAAAC	AATCAGGATT	ATATTGATGA	A.TTGCCATCA	TCTGATAATC	AGGAATATGA	4560
TGATAATTCC	GCTCCTTCTG	GTGGTTTCTT	TGTTCCGCAA	AATGATAATG	TTACTCAAAC	4620
TTTTAAAATT	AATAACGTTC	GGGCAAAGGA	TTTAATACGA	GTTGTCGAAT	TGTTTGTAAA	4680
GTCTAATACT	TCTAAATCCT	CAAATGTATT	ATCTATTGAC	GGCTCTAATC	TATTAGTTGT	4740
TAGTGCACCT	AAAGATATTT	TAGATAACCT	TCCTCAATTC	CTTTCTACTG	TTGATTTGCC	4800
AACTGACCAG	ATATTGATTG	AGGGTTTGAT	ATTTGAGGTT	CAGCAAGGTG	ATGCTTTAGA	4860
TTTTTCATTT	GCTGCTGGCT	CTCAGCGTGG	CACTGTTGCA	GGCGGTGTTA	ATACTGACCG	4920
CCTCACCTCT						4980
AGGGCTATCA	GTTCGCGCAT	TAAAGACTAA	TAGCCATTCA	AAAATATTGT	CTGTGCCACG	5040
TATTCTTACG	CTTTCAGGTC	AGAAGGGTTC	TATCTCTGTT	GGCCAGAATG	TCCCTTTTAT	5100
TACTGGTCGT	GTGACTGGTG	AATCTGCCAA	TGTAAATAAT	CCATTTCAGA	CGATTGAGCG	5160
TCAAAATGTA	GGTATTTCCA	TGAGCGTTTT	TCCTGTTGCA	ATGGCTGGCG	GTAATATTGT	5220
				ACTCAGGCAA		5280
				GATGGACAGA		5340
					TCCTGTCTAA	5400
				TCCAACGAGG		5460
				CGGCGCATTA		5520
					CCCGCTCGTT	5580

TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCTCTAAATC	5640
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAAAAACTTG	570 0
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGCCCTTTGA	5760
ATTTGGGTGA TGGTTCACGI AGTGGGGCCAI CGGGGTCATAT ATTTGGGTGA TGGTTGGAGCA ACACTCAACC CGTTGGAGCA CACGGGACA ACACTCAACC	5820
CGTTGGAGTC GACGTTCTTT AATAGTGGAC TOTTGTTGGC GATTTCGGGAA CCACCATCAA	5880
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CCACCATCAA	5940
ACAGGATTTT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TCTCTCAGGG	6000
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AAACCACCCT	6060
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TGCAGCTGGC	6120
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GTGAGTTAGC	6180
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TTGTGTGGAA	6240
TTGTGAGCGG ATAACAATTT CACACGCGTC ACTTGGCACT GGCCGTCGTT TTACAACGTC	6300
GTGACTGGGA AAACCCTGGC GTTACCCAAG CTTTGTACAT GGAGAAAATA AAGTGAAACA	
AAGCACTATT GCACTGGCAC TCTTACCGTT ACTGTTTACC CCTGTGGCAA AAGCCTATGG	6360
GGGGTTTATG ACTTCTGAGG GATCCGGAGC TGAAGGCGAT GACCCTGCTA AGGCTGCATT	6420
CAATAGTTTA CAGGCAAGTG CTACTGAGTA CATTGGCTAC GCTTGGGCTA TGGTAGTAGT	6480
TATAGTTGGT GCTACCATAG GGATTAAATT ATTCAAAAAG TTTACGAGCA AGGCTTCTTA	6540
AGCAATAGCG AAGAGGCCCG CACCGATCGC CCTTCCCAAC AGTTGCGCAG CCTGAATGGC	6600
GAATGGCGCT TTGCCTGGTT TCCGGCACCA GAAGCGGTGC CGGAAAGCTG GCTGGAGTGC	6660
GATCTTCCTG AGGCCGATAC GGTCGTCGTC CCCTCAAACT GGCAGATGCA CGGTTACGAT	6720
GCGCCCATCT ACACCAACGT AACCTATCCC ATTACGGTCA ATCCGCCGTT TGTTCCCACG	6780
GAGAATCCGA CGGGTTGTTA CTCGCTCACA TTTAATGTTG ATGAAAGCTG GCTACAGGAA	6840
GGCGAGACGC GAATTATTTT TGATGGCGTT CCTATTGGTT AAAAAATGAG CTGATTTAAC	6900
AAAAATTTAA CGCGAATTTT AACAAAATAT TAACGTTTAC AATTTAAATA TTTGCTTATA	6960
CAATCTICCT GTTTTIGGGG CTTTTCTGAT TATCAACCGG GGTACATATG ATTGACATGC	7020
TAGTITTACG ATTACCGTIC ATCGATTCTC TIGTITGCTC CAGACTCTCA GGCAATGACC	7080
TGATAGCCTT TGTAGATCTC TCAAAAATAG CTACCCTCTC CGGCATTAAT TTATCAGCTA	7140
GAACGGTTGA ATATCATATT GATGGTGATT TGACTGTCTC CGGCCTTTCT CACCCTTTTG	7200
AATCTTTACC TACACATTAC TCAGGCATTG CATTTAAAAT ATATGAGGGT TCTAAAAATT	7260
TTTATCCTTG CGTTGAAATA AAGGCTTCTC CCGCAAAAGT ATTACAGGGT CATAATGTTT	7320
TTTATCCTTG CGITGAAATA AAGGGTTGTG GCTAATTTT GCTAATTCTT TTGGTACAAC CGATTTAGCT TTATGCTCTG AGGCTTTATT GCTAATTTT GCTAATTCTT	7380
	7409
TGCCTTGCCT GTATGATTTA TTGGACGTT	

(2) INFORMATION FOR SEQ ID NO:5:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7294 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

(33-)			·			
AATGCTACT	A CTATTAGTA	G AATTGATGC	C ACCTTTTCA	G CTCGCGCCC	C AAATGAAAAT	60
ATAGCTAAA	C AGGTTATTG	A CCATTTGCG.	A AATGTATCT	A ATGGTCAAA	C TAAATCTACT	120
CGTTCGCAGA	A ATTGGGAAT	AACTGTTAC	A TGGAATGAAA	A CTTCCAGACA	A CCGTACTTTA	180
GTTGCATAT	TAAAACATG1	TGAGCTACAC	GACCAGATTO	AGCAATTAAC	CTCTAAGCCA	240
TCTGCAAAAA	TGACCTCTTA	TCAAAAGGAG	G CAATTAAAGG	TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG	CTTCCGGTCT	GGTTCGCTTI	GAAGCTCGAA	TTAAAACGCG	ATATTTGAAG	360
TCTTTCGGGC	TTCCTCTTAA	TCTTTTTGAT	GCAATCCGCT	TTGCTTCTGA	CTATAATAGT	420
CAGGGTAAAG	ACCTGATTTT	TGATTTATGG	TCATTCTCGT	TTTCTGAACT	GTTTAAAGCA	480
TTTGAGGGGG	ATTCAATGAA	TATTTATGAC	GATTCCGCAG	TATTGGACGC	TATCCAGTCT	540
AAACATTTTA	CTATTACCCC	CTCTGGCAAA	ACTICTITIG	CAAAAGCCTC	TCGCTATTTT	600
GGTTTTTATC	GTCGTCTGGT	AAACGAGGGT	TATGATAGTG	TTGCTCTTAC	TATGCCTCGT	660
AATTCCTTTT	GGCGTTATGT	ATCTGCATTA	GTTGAATGTG	GTATTCCTAA	ATCTCAACTG	720
ATGAATCTTT	CTACCTGTAA	TAATGTTGTT	CCGTTAGTTC	GTTTTATTAA	CGTAGATTTT	780
TCTTCCCAAC	GTCCTGACTG	GTATAATGAG	CCAGTTCTTA	AAATCGCATA	AGGTAATTCA	840
CAATGATTAA	AGTTGAAATT	AAACCATCTC	AAGCCCAATT	TACTACTCGT	TCTGGTGTTT.	900
CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG	960
AATATCCGGT	TCTTGTCAAG	ATTACTCTTG	ATGAAGGTCA	GCCAGCCTAT	GCGCCTGGTC	1020
TGTACACCGT	TCATCTGTCC	TCTTTCAAAG	TTGGTCAGTT	CGGTTCCCTT	ATGATTGACC	1080
GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT	1140
CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT	1200
CAAAGATGAG	TGTTTTAGTG	TATTCTTTCG	CCTCTTTCGT	TTTAGGTTGG	TGCCTTCGTA	1260
GTGGCATTAC	GTATTTTACC	CGTTTAATGG	AAACTTCCTC	ATGAAAAAGT	CTTTAGTCCT	1320
CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	CTGAGGGTGA	1380
CGATCCCGCA	AAAGCGGCCT	TTAACTCCCT	GCAAGCCTCA	GCGACCGAAT	ATATCGGTTA	1440
TGCGTGGGCG	ATGGTTGTTG	TCATTGTCGG	CGCAACTATC	GGTATCAAGC	TGTTTAAGAA	1500
ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT	1560
TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC	1620
TATTCTCACT	CCGCTGAAAC	TGTTGAAAGT	TGTTTAGCAA	AACCCCATAC	AGAAAATTCA	1680

TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TGAGGGTTGT	1740
TTTACTAACG TCTGGAAAGA CGACAAAACT TTACMTTOTACTCACGT TTACGGTACA CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TTACGGTACA CTGTGGGGGT	1800
CTGTGGAATG CTACAGGGGT TGTAGTTIGT ACTGAGGGTG GTGGCTCTGA GGGTGGCGGT	1860
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GGGTGGCGGT	1920
TGGGTTCCTA TTGGGGTTGG GGGTGGCGGT ACTAAACCTC CTGAGTACGG TGATACACCT TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TACTGAGCAA	1980
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TACTGAGCAA	2040
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TTTCATGTTT AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTATACGGG GACTGTTACT	2100
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CACTGTTACT	2160
CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2220
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA	2280
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTGTCAAT	2340
GATCCATTCG TTTGTGTGT GGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT	2400
GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2460
GGCGGTTCTG AGGGTGGGT AATAAGGGGG CTATGACCGA AAATGCCGAT GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2520
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2580
GAAAACGCGC TACHCTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOTOT	2640
GGTGGTATUG ATGGTTONT GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA ATGTCGCCCT	2700
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2760
TTAATGAATA ATTTOOGTON ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATGT ATTTTCTACG	2820
TTCCGTGGTG TCTTTGCGTT TCTTTTATAT GTTGCCACCT TTATGTATGT ATTTTCTACG	2880
TTCCGTGGTG TGTTTGGGTA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT TTTGCTAACA TACTGCGTAA TAAGGAGTCT TAATCATGCC AGTTCTTTTG GGTATTCCGT	2940
TATTATTGCG TITCCTCGGT TICCTTCTGG TAACTTTGTT CGGCTATCTG CTTACTTTTC	3000
TATTATIGCG IIIGGIGGGI TITGGIGGGIGGGIGGGIGGGIGGGIG	3060
GGCTTAACTC AATTCTTGTG GGTTATCTCT CTGATATTAG CGCTCAATTA CCCTCTGACT	3120
TTGTTCAGGG TGTTCAGTTA ATTCTCCCGT CTAATGCGCT TCCCTGTTTT TATGTTATTC	3180
TTGTTCAGGG TGTTCAGTTT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG TCTCTGTAAA GGCTGCTATT TTCATTTTTG ACGTTAAACA AAAAATCGTT TCTTATTTGG	3240
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3300
ATTGGGATAA ATAATATGGG TOTTOOM TOTTOOM ATTGTAGCTG GGTGCAAAAT AGCAACTAAT CTCGTTAGCG TTGGTAAGAT TCAGGATAAA ATTGTAGCTG GGTGCAAAAC GCCTCGCGTT	3360
CTCGTTAGCG TIGGTAAGAT TONOCCOCCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT CTTGATTTAA GGCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT CATTTGCTTC CTATTGGGCG CGGTAATGAT	3420
CTTGATITAA GGCIICAAAI OOTOO	3480
TCCTACGATG AAAATAAAAA CGGCTTGCTT GTTCTCGATG AGTGCGGTAC TTGGTTTAAT	3540
ACCCGTTCTT GGAATGATAA GGAAAGACAG CCGATTATTG ATTGGTTTCT ACATGCTCGT	3600
ACCCGTTGTT GGAATGATAT CONTINUE CAGGACTTAT CTATTGTTGA TAAACAGGCG AAATTAGGAT GGGATATTAT CTTCCTTGTT CAGGACTTAT CTATTGTTGA TAAACAGGCG	3660
CGTTCTGCAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGACAGAAT TACTTTACCT	3720
TTTGTCGGTA CTTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCTGCC TAAATTACAT	

GTTGGCGTT	TTAAATATG	G CGATTCTCA	A TTAAGCCCT	A CTGTTGAGC	G TIGGCTITAT	3780
ACTGGTAAGA	A ATTTGTATA	A CGCATATGA	r actaaacag	G CTTTTTCTA	G TAATTATGAT	3840
TCCGGTGTT	r ATTCTTATT	r aacgcctta:	TTATCACAC	G GTCGGTATT	CAAACCATTA	3900
AATTTAGGTO	AGAAGATGAA	A GCTTACTAA	A ATATATTIGA	AAAAGTTTT(ACGCGTTCTT	3960
TGTCTTGCGA	TTGGATTTG	ATCAGCATT	ACATATAGTT	ATATAACCCA	ACCTAAGCCG	4020
GAGGTTAAAA	AGGTAGTCTC	TCAGACCTAT	GATTTTGATA	AATTCACTAT	TGACTCTTCT	4080
CAGCGTCTTA	ATCTAAGCTA	TCGCTATGTT	TTCAAGGATT	CTAAGGGAAA	ATTAATTAAT	4140
AGCGACGATT	TACAGAAGCA	AGGTTATTCA	CTCACATATA	TTGATTTATG	TACTGTTTCC	4200
ATTAAAAAGG	TAATTCAAAT	GAAATTGTTA	AATGTAATTA	ATTTTGTTTT	CTTGATGTTT	4260
GTTTCATCAT	CTTCTTTTGC	TCAGGTAATT	GAAATGAATA	ATTCGCCTCT	GCGCGATTTT	4320
GTAACTTGGT	ATTCAAAGCA	ATCAGGCGAA	TCCGTTATTG	TTTCTCCCGA	TGTAAAAGGT	4380
ACTGTTACTG	TATATTCATC	TGACGTTAAA	CCTGAAAATC	TACGCAATTT	CTTTATTTCT	4440
GTTTTACGTG	CTAATAATTT	TGATATGGTT	GGTTCAATTC	CTTCCATTAT	TTAGAAGTAT	4500
AATCCAAACA	ATCAGGATTA	TATTGATGAA	TTGCCATCAT	CTGATAATCA	GGAATATGAT	4560
GATAATTCCG	CTCCTTCTGG	TGGTTTCTTT	GTTCCGCAAA	ATGATAATGT	TACTCAAACT	4620
TTTAAAATTA	ATAACGTTCG	GGCAAAGGAT	TTAATACGAG	TTGTCGAATT	GTTTGTAAAG	4680
TCTAATACTT	CTAAATCCTC	AAATGTATTA	TCTATTGACG	GCTCTAATCT	ATTAGTTGTT	4740
AGTGCACCTA	AAGATATTTT	AGATAACCTT	CCTCAATTCC	TTTCTACTGT	TGATTTGCCA	4800
ACTGACCAGA	TATTGATTGA	GGGTTTGATA	TTTGAGGTTC	AGCAAGGTGA	TGCTTTAGAT	4860
TTTTCATTTG	CTGCTGGCTC	TCAGCGTGGC	ACTGTTGCAG	GCGGTGTTAA	TACTGACCGC	4920
CTCACCTCTG	TTTTATCTTC	TGCTGGTGGT	TCGTTCGGTA	TTTTTAATGG	CGATGTTTTA	4980
GGGCTATCAG	TTCGCGCATT	AAAGACTAAT	AGCCATTCAA	AAATATTGTC	TGTGCCACGT	5040
ATTCTTACGC	TTTCAGGTCA	GAAGGGTTCT	ATCTCTGTTG	GCCAGAATGT	CCCTTTTATT	5100
ACTGGTCGTG	TGACTGGTGA	ATCTGCCAAT	GTAAATAATC	CATTTCAGAC	GATTGAGCGT	5160
CAAAATGTAG	GTATTTCCAT	GAGCGTTTTT	CCTGTTGCAA	TCGCTGGCGG	TAATATTGTT	5220
CTGGATATTA	CCAGCAAGGC	CGATAGTTTG	AGTTCTTCTA	CTCAGGCAAG	TGATGTTATT	5280
ACTAATCAAA	GAAGTATTGC	TACAACGGTT	AATTTGCGTG	ATGGACAGAC	TCTTTTACTC	5340
					CCTGTCTAAA	5400
			CGCTCTGATT			5460
			GCCCTGTAGC			5520
-					CCGCTCCTTT	5580
					CTCTAAATCG	5640
GGGGCTCCCT	TTAGGGTTCC	GATTTAGTGC	TTTACGGCAC	CTCGACCCCA	AAAAACTTGA	5700
TTTGGGTGAT	GGTTCACGTA	GTGGGCCATC	GCCCTGATAG	ACGGTTTTTC	GCCCTTTGAC	5760

		amaa. am	OFFICTTCC A A	ACTGGAAGAA	CACTCAACCC	5820
GTTGGAGTCC	ACGTTCTTTA	ATAGTGGACT	CITCLICONY	ATTTCCCAAC	CACCATCAAA	5880
TATCTCGGGC	TATTCTTTTG	ATTTATAAGG	GATTTTGGGG	ATTICGGAAC	CHOCKLONER!	5940
CAGGATTTTC	GCCTGCTGGG	GCAAACCAGC	GTGGACCGCT	TGCTGCAACT	CTCTCAGGGC	
CAGGCGGTGA	AGGGCAATCA	GCTGTTGCCC	GTCTCGCTGG	TGAAAAGAAA	AACCACCCTG	6000
GCGCCCAATA	CGCAAACCGC	CTCTCCCCGC	GCGTTGGCCG	ATTCATTAAT	GCAGCTGGCA	6060
CGACAGGTTT	CCCGACTGGA	AAGCGGGCAG	TGAGCGCAAC	GCAATTAATG	TGAGTTAGCT	6120
CACTCATTAG	GCACCCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	TGTGTGGAAT	6180
		ACACAGGAAA				6240
		CGAGGCTGAA				6300
AGTTTACAGG	CAAGTGCTAC	TGAGTACATT	GGCTACGCTT	GGGCTATGGT	AGTAGTTATA	6360
GTTGGTGCTA	CCATAGGGAT	TAAATTATTC	AAAAAGTTTA	CGAGCAAGGC	TTCTTAACCA	6420
GCTGGCGTAA	TAGCGAAGAG	GCCCGCACCG	ATCGCCCTTC	CCAACAGTTG	CGCAGCCTGA	6480
ATGGCGAATG	GCGCTTTGCC	TGGTTTCCGG	CACCAGAAGC	GGTGCCGGAA	AGCTGGCTGG	6540
AGTGCGATCT	TCCTGAGGCC	GATACGGTCG	TCGTCCCCTC	AAACTGGCAG	ATGCACGGTT	6600
		AACGTAACCT				6660
CCACGGAGAA	TCCGACGGGT	TGTTACTCGC	TCACATTTAA	TGTTGATGAA	AGCTGGCTAC	6720
AGGAAGGCGA	GACGCGAATT	ATTTTTGATG	GCGTTCCTAT	TGGTTAAAAA	ATGAGCTGAT	6780
TTAACAAAAA	TTTAACGCGA	ATTTTAACAA	AATATTAACG	TTTACAATTT	AAATATTTGC	6840
TTATACAATC	TTCCTGTTTT	TGGGGCTTTT	CTGATTATCA	ACCGGGGTAC	ATATGATTGA	6900
CATCCTACTT	TTACGATTAC	CGTTCATCGA	TTCTCTTGTT	TGCTCCAGAC	TCTCAGGCAA	6960
TCACCTCATA	CCCTTTGTAG	ATCTCTCAAA	AATAGCTACC	CTCTCCGGCA	TTAATTTATC	7020
ACCTACAACC	GTTGAATATC	ATATTGATGG	TGATTTGACT	GTCTCCGGCC	TTTCTCACCC	7080
AGGIAGAACG	TTACCTACAC	ATTACTCAGG	CATTGCATTT	AAAATATATG	AGGGTTCTAA	7140
TTTTGAATGI	י ררדידררומידיומ	AAATAAAGGO	TTCTCCCGCA	AAAGTATTAC	AGGGTCATAA	7200
AAATTTTAT	. 0011000110	TACCTTATO	CTCTGAGGCT	TTATTGCTTA	ATTTTGCTAA	7260
						7294
TTCTTTGCC	r TGCCTGTATC	ATTTATTGG	7 0011			

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7394 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ATAGCTAAAC AGGTTATTGA CCATTTGCGA AATGTATCTA ATGGTCAAAC	TAAATCTACT	120
CGTTCGCAGA ATTGGGAATC AACTGTTACA TGGAATGAAA CTTCCAGACA	CCGTACTTTA	180
GTTGCATATT TAAAACATGT TGAGCTACAG CACCAGATTC AGCAATTAAG	CTCTAAGCCA	240
TCTGCAAAAA TGACCTCTTA TCAAAAGGAG CAATTAAAGG TACTCTCTAA	TCCTGACCTG	300
TTGGAGTTTG CTTCCGGTCT GGTTCGCTTT GAAGCTCGAA TTAAAACGCG A	ATATTTGAAG	360
TCTTTCGGGC TTCCTCTTAA TCTTTTTGAT GCAATCCGCT TTGCTTCTGA C	CTATAATAGT	420
CAGGGTAAAG ACCTGATTTT TGATTTATGG TCATTCTCGT TTTCTGAACT G	STTTAAAGCA	480
TTTGAGGGGG ATTCAATGAA TATTTATGAC GATTCCGCAG TATTGGACGC T	ATCCAGTCT	540
AAACATTTTA CTATTAGCCC CTCTGGCAAA ACTTCTTTTG CAAAAGCCTC T	CGCTATTTT	600
COTTTTTATC CTCCTCTCCT AAACGAGGGT TATGATAGTG TTGCTCTTAC TA	ATGCCTCGT	660 .
AATTCCTTTT GGCGTTATGT ATCTGCATTA GTTGAATGTG GTATTCCTAA AT	TCTCAACTG	720
ATGAATCTTT CTACCTGTAA TAATGTTGTT CCGTTAGTTC GTTTTATTAA CC	GTAGATTTT	780
TCTTCCCAAC GTCCTGACTG GTATAATGAG CCAGTTCTTA AAATCGCATA AG	GTAATTCA	840
CAATGATTAA AGTTGAAATT AAACCATCTC AAGCCCAATT TACTACTCGT TO	TGGTGTTT	900
CTCGTCAGGG CAAGCCTTAT TCACTGAATG AGCAGCTTTG TTACGTTGAT TT	GGGTAATG	960
AATATCCGGT TCTTGTCAAG ATTACTCTTC ATGAAGGTCA GCCAGCCTAT GC	CGCCTGGTC	1020
TGTACACCGT TCATCTGTCC TCTTTCAAAG TGGTCAGTT CGGTTCCCTT AT	GATTGACC	1080
GTCTGCGCCT CGTTCCGGCT AAGTAACATG GAGCAGGTCG CGGATTTCGA CA	CAATTTAT	1140
CAGGCGATGA TACAAATCTC CGTTGTACTT TGTTTCGCGC TTGGTATAAT CG	CTGGGGGT	1200
CAAAGATGAG TGTTTTAGTG TATTCTTTCG CCTCTTTCGT TTTAGGTTGG TG	CCTTCGTA	1260
GTGGCATTAC GTATTTTACC CGTTTAATGG AAACTTCCTC ATGAAAAAGT CT	TTAGTCCT	1320
CAAAGCCTCT GTAGCCGTTG CTACCCTCGT TCCGATGCTG TCTTTCGCTG CT	GAGGGTGA	1380
CGATCCCGCA AAAGCGGCCT TTAACTCCCT GCAAGCCTCA GCGACCGAAT AT	ATCGGTTA	1440
TGCGTGGGCG ATGGTTGTTG TCATTGTCGG CGCAACTATC GGTATCAAGC TG	TTTAAGAA	1500
ATTCACCTCG AAAGCAAGCT GATAAACCGA TACAATTAAA GGCTCCTTTT GG	AGCCTTTT	1560
TTTTTGGAGA TTTTCAACGT GAAAAAATTA TTATTCGCAA TTCCTTTAGT TG	TTCCTTTC	1620
TATTCTCACT CCGCTGAAAC TGTTGAAAGT TGTTTAGCAA AACCCCATAC AG	GAAAATTCA	1680
TTTACTAACG TCTGGAAAGA CGACAAAACT TTAGATCGTT ACGCTAACTA TG	AGGGTTGT	1740
CTGTGGAATG CTACAGGCGT TGTAGTTTGT ACTGGTGACG AAACTCAGTG TT	TACGGTACA	1800
TGGGTTCCTA TTGGGCTTGC TATCCCTGAA AATGAGGGTG GTGGCTCTGA GC	GGTGGCGGT	1860
TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT ACTAAACCTC CTGAGTACGG TC	GATACACCT	1920
ATTCCGGGCT ATACTTATAT CAACCCTCTC GACGGCACTT ATCCGCCTGG TA	ACTGAGCAA	1980
AACCCCGCTA ATCCTAATCC TTCTCTTGAG GAGTCTCAGC CTCTTAATAC TT	ITCATGTTT	2040
CAGAATAATA GGTTCCGAAA TAGGCAGGGG GCATTAACTG TTTATACGGG CA	ACTGTTACT	2100

CAAGGCACTG ACCCCGTTAA AACTTATTAC CAGTACACTC CTGTATCATC AAAAGCCATG	2160
CAAGGCACTG ACCCCGTTAA AACTTATTAC GAGTAGAGT TCCATTCTGG CTTTAATGAA	2220
TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTT TCCATTCTGG CTTTAATGAA TATGACGCTT ACTGGAACGG TAAATTCAGA GACTGCGCTTCACC TCCTCTCAAT	2280
GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCAACC TCCTCTCAAT GATCCATTCG TTTGTGAATA TCAAGGCCAA TCGTCTGACC TGCCTCGTGG CTCTGAGGGT	2340
GATCCATICG TITGTCATATA CONTROL OF	2400
GCTGGCGGGG GCTGTGGGGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT	2460
GGCGGTTCTG AGGGTEGGT GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT GATTTTGATT ATGAAAAGAT GGCAAACGCT AATAAGGGGG CTATGACCGA AAATGCCGAT	2520
GAAAACGCGC TACAGTCTGA CGCTAAAGGC AAACTTGATT CTGTCGCTAC TGATTACGGT	2580
GAAAACGCGC TACAGTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT GCTGCTATCG ATGGTTTCAT TGGTGACGTT TCCGGCCTTG CTAATGGTAA TGGTGCTACT	2640
GCTGCTATCG ATGGTTTATA GGTGATTTTG CTGGCTCTAA TTCCCAAATG GCTCAAGTCG GTGACGGTGA TAATTCACCT	2700
TTAATGAATA ATTTCCGTCA ATATTTACCT TCCCTCCCTC AATCGGTTGA ATGTCGCCCT	2760
TTTGTCTTTA GCGCTGGTAA ACCATATGAA TTTTCTATTG ATTGTGACAA AATAAACTTA	2820
TICCGIGGIG TCTTIGCGIT TCTTITATAT GTIGCCACCI TTATGTATGT ATTITCTACG	2880
TACTICITARICA TACTICICITAR TRAGGAGTOT TRATCATGOO ACTTOTTITIC GGIRTIOOGT	2940
THE TRACE TELECTORIC TROCTORIC TARCTITISTE COGCULATORIC CLIRCITIES	3000
TIMAACCC CTTCGCTAAG ATAGCTATTG CTATTTCATT GTTTCTTGCT CTTATTATTG	3060
THE ACTO ANTICITETE GETTATCTCT CIGATATTAG CGCTCAATTA CCCTOTOMOT	3120
TOTAL GOO TOTTCAGTTA ATTOTCCCGT CTAATGCGCT TCCCTG1111 TATGTATT	3180
TOTAL A COCTACTATE TICATITITE ACCITAAACA AAAAATUGII IGIIAIII	3240
ATTGGGATAA ATAATATGGC TGTTTATTTT GTAACTGGCA AATTAGGCTC TGGAAAGACG	3300
ANGENTAGES TEGETAAGAT TEAGGATAAA ATTGTAGCTG GGTGUAAAAT AGOAAGITTE	3360
CCCTTCAAAA CCTCCCGCAA GTCGGGAGGT TCGCTAAAAC GCCTCGGGT	3420
THE COCATA AGCC TICTATATCT GATTIGCTTG CTAILGGGGG GGGTATE	3480
CGCTTGCTT GTTCTCGATG AGTGCGGTAC TIGGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT	3540
CCAATGATAA GGAAAGACAG CCGATTATTG ATIGGITICT ACATTGATAG	3600
CCCATATTAT TITTCTTGTT CAGGACTTAT CTATIGTICA TAMESTO	3660
TAGCTGAGAT TAGCTGAACA TGTTGTTTAT TGTCGTCGTC TGGAGAGAA1 1AG11111001	3720
CTTATATTC TCTTATTACT GGCTCGAAAA TGCCTCIGCC TAAATITC	3780
TAAATATGG CGATTCTCAA TTAAGCCCTA CTG11GAGCG 11GG012	3840
ATTECTATA CGGATATGAT ACTAAACAGG CTTTTTCTAG TAATIMTOTT	3900
ATTECTATT AACGCCTTAT TTATCACACG GTCGGIAIII GAALGCTTAT	3960
ACACATGAA GCTTACTAAA ATATATTTGA AAAAGIIIIG AGGGCL	4020
TECCATTEC ATCAGCATT ACATATAGTT ATATAAGGG AGGINIO	4080
ACCTACTCTC TCAGACCTAT GATTTTGATA AATICACIAI TCAGACCTAT	4140
CAGCGTCTTA ATCTAAGCTA TCGCTATGTT TTCAAGGATT CTAAGGGAAA ATTAATTAAT	,

AGCGACGATT TACAGAAGCA AGGTTATTCA CTCACATATA TTGATTTATG TA	
ATTAAAAAG GTAATTCAAA TGAAATTGTT AAATGTAATT AATTTTGTTT TO	CTTGATGTT 4260
TGTTTCATCA TCTTCTTTTG CTCAGGTAAT TGAAATGAAT AATTCGCCTC TC	GCGCGATTT 4320
TGTAACTTGG TATTCAAAGC AATCAGGCGA ATCCGTTATT GT1TCTCCCG AT	IGTAAAAGG 4380
TACTGTTACT GTATATTCAT CTGACGTTAA ACCTGAAAAT CTACGCAATT TO	CTTTATTTC 4440
TGTTTTACGT GCTAATAATT TTGATATGGT TGGTTCAATT CCTTCCATAA TT	CAGAAGTA 4500
TAATCCAAAC AATCAGGATT ATATTGATGA ATTGCCATCA TCTGATAATC AG	GAATATGA 4560
TGATAATTCC GCTCCTTCTG GTGGTTTCTT TGTTCCGCAA AATGATAATG TT	ACTCAAAC 4620
TTTTAAAATT AATAACGTTC GGGCAAAGGA TTTAATACGA GTTGTCGAAT TG	TTTGTAAA 4680
GTCTAATACT TCTAAATCCT CAAATGTATT ATCTATTGAC GGCTCTAATC TA	TTAGTTGT 4740
TAGTGCACCT AAAGATATTT TAGATAACCT TCCTCAATTC CTTTCTACTG TTC	GATTTGCC 4800
AACTGACCAG ATATTGATTG AGGGTTTGAT ATTTGAGGTT CAGCAAGGTG ATG	GCTTTAGA 4860
TTTTTCATTT GCTGCTGGCT CTCAGCGTGG CACTGTTGCA GGCGGTGTTA ATA	ACTGACCG 4920
CCTCACCTCT GTTTTATCTT CTGCTGGTGG TTCGTTCGGT ATTTTTAATG GCC	GATGTTTT 4980
AGGGCTATCA GTTCGCGCAT TAAAGACTAA TAGCCATTCA AAAATATTGT CTC	STGCCACG 5040
TATTCTTACG CTTTCAGGTC AGAAGGGTTC TATCTCTGTT GGCCAGAATG TCC	CCTTTTAT 5100
TACTGGTCGT GTGACTGGTG AATCTGCCAA TGTAAATAAT CCATTTCAGA CGA	ATTGAGCG 5160
TCAAAATGTA GGTATTTCCA TGAGCGTTTT TCCTGTTGCA ATGGCTGGCG GTA	AATATTGT 5220
TCTGGATATT ACCAGCAAGG CCGATAGTTT GAGTTCTTCT ACTCAGGCAA GTG	SATGTTAT 5280
TACTAATCAA AGAAGTATTG CTACAACGGT TAATTTGCGT GATGGACAGA CTC	CTTTTACT 5340
CGGTGGCCTC ACTGATTATA AAAACACTTC TCAAGATTCT GGCGTACCGT TCC	TGTCTAA 5400
AATCCCTTTA ATCGGCCTCC TGTTTAGCTC CCGCTCTGAT TCCAACGAGG AAA	AGCACGTT 5460
ATACGTGCTC GTCAAAGCAA CCATAGTACG CGCCCTGTAG CGGCGCATTA AGC	GCGGCGG 5520
GTGTGGTGGT TACGCGCAGC GTGACCGCTA CACTTGCCAG CGCCCTAGCG CCC	CGCTCCTT 5580
TCGCTTTCTT CCCTTCCTTT CTCGCCACGT TCGCCGGCTT TCCCCGTCAA GCT	CTAAATC 5640
GGGGGCTCCC TTTAGGGTTC CGATTTAGTG CTTTACGGCA CCTCGACCCC AAA	
ATTTGGGTGA TGGTTCACGT AGTGGGCCAT CGCCCTGATA GACGGTTTTT CGC	CCCTTTGA 5760
CGTTGGAGTC CACGTTCTTT AATAGTGGAC TCTTGTTCCA AACTGGAACA ACA	ACTCAACC 5820
CTATCTCGGG CTATTCTTTT GATTTATAAG GGATTTTGCC GATTTCGGAA CC	ACCATCAA 5880
ACAGGATITT CGCCTGCTGG GGCAAACCAG CGTGGACCGC TTGCTGCAAC TC	TCTCAGGG 5940
CCAGGCGGTG AAGGGCAATC AGCTGTTGCC CGTCTCGCTG GTGAAAAGAA AA	ACCACCCT 6000
GGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC GATTCATTAA TG	CAGCTGGC 6060
ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA CGCAATTAAT GT	GAGTTAGC 6120
TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC GGCTCGTATG TT	GTGTGGAA 6180

ŕ

Ì

37

			· CTTCCC · CT	GGCCGTCGTT	TTACAACGTC	5240
TTGTGAGCGG A	TAACAATTI	CACACGCGTC	ACTIGGORGA	CCACAAAATA	AAGTGAAACA	6300
TTGTGAGCGG A	AACCCTGGC	GTTACCCAAG	CTTTGTACAI	o omorece ch h	AAGCCCTTCT	6360
		TOTTACCGTT	ACTGTTTACC	(010100121		6420
_		CCGATGACCC	TGCTAAGGCT	COMITORNIA		6480
		CCTACGCTTG	GGCTATGGTA	GIMGLIALIO		
	A COMPANY COL	AAAAGTTTAC	GAGCAAGGCI	ICITAMOCIA		6540
GCCGGCACCG A	MATIMITOR	CONNCACTTO	CGCAGCCTGA	ATGGCGAATG	GCGCTTTGCC	6600
GCCCGCACCG A	ATCGCCCTTC	CCAACAGIIG	ACCTGGGTGG	AGTGCGATCT	TCCTGAGGCC	6660
TGGTTTCCGG (CACCAGAAGC	GGTGCCGGAA	AGGIGGETT	ACGATGCGCC	CATCTACACC	6720
TGGTTTCCGG C	rcgtcccctc	AAACTGGCAG	AIGCAGGGII	CCACGGAGAA	TCCGACGGGT	6780
GATACGTTCG T	ATCCCATTAC	GGTCAATCCG	CCGTTTGTTC	. ACCAACCCCA	GACGCGAATT	6840
TGTTACTCGC	TCACATTTAA	TGTTGATGAA	AGCTGGCTAC	AGGAAGGGGA	TTTAACGCGA	6900
	OCCUPATO COTAT	TCCTTAAAAA	ATGACCTGAT	TIMMUMME	• • • • •	6960
		TTTACAATTI	AAATATTTGC	TIAIRUARIC	22000	7020
	OTT STCA	A CCGGGGGTAC	ATATGATIGA	CAIGUINGIA		
	ما	TOCTCCAGAG	TCTCAGGCA	i ICACCIONII	. 000	7080
CGTTCATCGA	1 I C I C I C C	· crcrccggc	A TTAATTTAT	C AGCTAGAAC	G GTTGAATATC	7140
ATCTCTCAAA	AATAGCIAC	, 010100000.	C TTTCTCACC	C TTTTGAATC	T TTACCTACAC	7200
ATATTGATGG	TGATTTGAC.	L GICICOGGC	o recentera	A AAATTTTTA	T CCTTGCGTTG	7260
ATTACTCAGG	CATTGCATT	T AAAATATAT	- ACCTCATA	A TGTTTTTGG	T CCTTGCGTTG T ACAACCGATT	7320
AAATAAAGGC	TTCTCCCGC	A AAAGTATTA	C AGGGIGATA	.x	T ACAACCGATT TGCCTGTATG	7380
TAGCTTTATG	CTCTGAGGC	T TTATTGCTT	A ATTTTGGTA	W IIOIIIO	T TGCCTGTATG	7394
ATTTATTGGA						

(2) INFORMATION FOR SEQ ID NO:7:

- (1) SEQUENCE CHARACTERISTICS:

 (A) LENGTH: 37 base pairs

 - (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: GATCCTAGGC TGAAGGCGAT GACCCTGCTA AGGCTGC

(2) INFORMATION FOR SEQ ID NO:8:

- (1) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(x1) SEQUENCE DESCRIPTION: SEQ ID NO.0.	
ATTCAATAGT TTACAGGCAA GTGCTACTGA GTACA	35
(2) INFORMATION FOR SEQ ID NO:9:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	
TTGGCTACGC TTGGGCTATG GTAGTAGTTA TAGTT	35
(2) INFORMATION FOR SEQ ID NO:10:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:	
GGTGCTACCA TAGGGATTAA ATTATTCAAA AACTT	35
(2) INFORMATION FOR SEQ ID NO:11:	
(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:	
TACGAGCAAG GCTTCTTA	18
(2) INFORMATION FOR SEQ ID NO:12:	
(1) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:	
AGCTTAAGAA GCCTTGCTCG TAAACTTTTT GAATAATTT	39

(2) INFORMATION FOR SEQ ID NO:13:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:	36
AATCCCTATG GTAGCACCAA CTATAACTAC TACCAT	
(2) INFORMATION FOR SEQ ID NO:14:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:	
AGCCCAAGCG TAGCGAATGT ACTCAGTAGC ACTTG	35
(2) INFORMATION FOR SEQ ID NO:15:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:	
CCTGTAAACT ATTGAATGCA GCCTTAGCAG GGTC	34
(2) INFORMATION FOR SEQ ID NO:16:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:	16
ATCGCCTTCA GCCTAG	LO
(2) INFORMATION FOR SEQ ID NO:17:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:	
CTCGAATTCG TACATCCTGG TCATAGC	27
(2) INFORMATION FOR SEQ ID NO:18:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:	
CATTTTTGCA GATGGCTTAG A	21
(2) INFORMATION FOR SEQ ID NO:19:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:	
TAGCATTAAC GTCCAATA	18
(2) INFORMATION FOR SEQ ID NO:20:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
ATATATTTTA GTAAGCTTCA TCTTCT	26
(2) INFORMATION FOR SEQ ID NO:21:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
GACAAAGAAC GCGTGAAAAC TTT	23

(2) INFORMATION FOR SEQ ID NO:22:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	•
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:	35
GCGGGCCTCT TCGCTATTGC TTAAGAAGCC TTGCT	33
(2) INFORMATION FOR SEQ ID NO:23:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	•
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	4.2
TTCAGCCTAG GATCCGCCGA GCTCTCCTAC CTGCGAATTC GTACATCC	48
(2) INFORMATION FOR SEQ ID NO:24:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:	24
TGGATTATAC TTCTAAATAA TGGA	24
(2) INFORMATION FOR SEQ ID NO:25:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:	36
TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT	20
(2) INFORMATION FOR SEQ ID NO:26:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single	

TCTAGAACGC GTC

(x1) SEQUENCE DESCRIPTION: SEQ ID NO:26:	
AATTCGCCAA GGAGACAGTC AT	2
(2) INFORMATION FOR SEQ ID NO:27:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:	
AATGAAATAC CTATTGCCTA CGGCAGCCGC TGGATTGTT	39
(2) INFORMATION FOR SEQ ID NO:28:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:	
ATTACTCGCT GCCCAACCAG CCATGGCCGA GCTCGTGAT	39
(2) INFORMATION FOR SEQ ID NO:29:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:	
GACCCAGACT CCAGATATCC AACAGGAATG AGTGTTAAT	3 9
(2) INFORMATION FOR SEQ ID NO:30:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:	

(2) INFORMATION FOR SEQ ID NO:31:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:	2.5
ACGTGACGCG TTCTAGAATT AACACTCATT CCTGT	35
(2) INFORMATION FOR SEQ ID NO:32:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:	
TGGATATCTG GAGTCTGGGT CATCACGAGC TCGGCCATG	39
(2) INFORMATION FOR SEQ ID NO:33:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:	
GCTGGTTGGG CAGCGAGTAA TAACAATCCA GCGGCTGCC	39
(2) INFORMATION FOR SEQ ID NO:34:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:	27
GTAGGCAATA GGTATTTCAT TATGACTGTC CTTGGCG	3 7
(2) INFORMATION FOR SEQ ID NO:35:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:	
TGACTGTCTC CTTGGCGTGT GAAATTGTTA	30
(2) INFORMATION FOR SEQ ID NO:36:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:	
TAACACTCAT TCCGGATGGA ATTCTGGAGT CTGGGT	36
(2) INFORMATION FOR SEQ ID NO:37:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:	
CAATTTTATC CTAAATCTTA CCAAC	25
(2) INFORMATION FOR SEQ ID NO:38:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:	
CATTTTTGCA GATGGCTTAG A	21
(2) INFORMATION FOR SEQ ID NO:39:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:	
CGAAAGGGGG GTGTGCTGCA A	21

(2) INFORMATION FOR SEQ ID NO:40:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:	18
TAGCATTAAC GTCCAATA	16
(2) INFORMATION FOR SEQ ID NO:41:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:	
AAACGACGGC CAGTGCCAAG TGACGCGTGT GAAATTGTTA TGC	43
(2) INFORMATION FOR SEQ ID NO:42:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 43 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:	
GGCGAAAGGG AATTCTGCAA GGCGATTAAG CTTGGGTAAC GCC	43
(2) INFORMATION FOR SEQ ID NO:43:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:	
GGCGTTACCC AAGCTTTGTA CATGGAGAAA ATAAAG	36

(2) INFORMATION FOR SEQ ID NO:44:

	•	
	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:	
TGAAA	CAAAG CACTATTGCA CTGGCACTCT TACCGTTACC GT	4
(2) II	NFORMATION FOR SEQ ID NO:45:	
((i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x	(i) SEQUENCE DESCRIPTION: SEQ ID NO:45:	
TACTGT	TTTAC CCCTGTGACA AAAGCCGCCC AGGTCCAGCT GC	42
(2) IN	FORMATION FOR SEQ ID NO:46:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x	i) SEQUENCE DESCRIPTION: SEQ ID NO:46:	
TCGAGT	CAGG CCTATTGTGC CCAGGGATTG TACTAGTGGA TCCG	44
(2) IN	FORMATION FOR SEQ ID NO:47:	
(.	i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x	i) SEQUENCE DESCRIPTION: SEQ ID NO:47:	
TGGCGA	AAGG GAATTCGGAT CCACTAGTAC AATCCCTG	38
(2) IN	FORMATION FOR SEQ ID NO:48:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:	
GGCACAATAG GCCTGACTCG AGCAGCTGGA CCAGGGCGGC TT	42
(2) INFORMATION FOR SEQ ID NO:49:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:	
TTGTCACAGG GGTAAACAGT AACGGTAACG GTAAGTGTGC CA	42
(2) INFORMATION FOR SEQ ID NO:50:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:	
GTGCAATAGT GCTTTGTTTC ACTTTATTTT CTCCATGTAC AA	42
(2) INFORMATION FOR SEQ ID NO:51:	
 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:	
TAACGGTAAG AGTGCCAGTG C	21
(52) INFORMATION FOR SEQ ID NO:52:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 68 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(25, "") (D) OTHER INFORMATION: /note= "M REPRESENTS AN EQUAL MIXTURE OF A AND C AT THIS LOCATION AND AT LOCATIONS 28, 31, 34, 37, 40, 43, 46 & 49"	

(xi) SEQUENCE DESCRIPTION: SEQ 1D NO:52.	
AGCTCCCGGA TGCCTCAGAA GATGMNNMNN MNNMNNMNNM NNMNNMNNMN NGGCTTTTGC	60
CACAGGGG	68
(2) INFORMATION FOR SEQ ID NO:53:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ix) FEATURE: (A) NAME/KEY: misc_difference (B) LOCATION: replace(17, "") (D) OTHER INFORMATION: /note= "M REPRESENTS AN EQUAL MIXTURE OF A AND C AT THIS LOCATION AND AT LOCATIONS 20, 23, 26, 29, 32, 35, 38, 41, 44 & 50"	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:	
CAGCCTCGGA TCCGCCMNNM NNMNNMNNMN NMNNMNNMNN MNNMNNATGM GAAT	54
(2) INFORMATION FOR SEQ ID NO:54:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:	
GGTAAACAGT AACGGTAAGA GTGCCAG	27
(2) INFORMATION FOR SEQ ID NO:55:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:	
GGGCTTTTGC CACAGGGGT	19
(2) INFORMATION FOR SEQ ID NO:56:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 63 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:	
AGGGTCATCG CCTTCAGCTC CGGATCCCTC AGAAGTCATA AACCGCCCAT AGGCTTTTGC	60
	63
CAC	
(2) INFORMATION FOR SEQ ID NO:57:	•
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	3
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:	47
TCGCCTTCAG CTCCCGGATG CCTCAGAAGC ATGAACCCCC CATAGGC	·+ /
(2) INFORMATION FOR SEQ ID NO:58:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(x1) SEQUENCE DESCRIPTION: SEQ ID NO:58: CAATTTATC CTAAATCTTA CCAAC	25
(2) INFORMATION FOR SEQ ID NO:59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:	21
GCCTTCAGCC TCGGATCCGC C	
(2) INFORMATION FOR SEQ ID NO:60:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:	21
CGGATGCCTC AGAAGCCCCN N	21

105

- (2) INFORMATION FOR SEQ ID NO:61:
 - (i) SEQUENCE CHARACTERISTICS:

 (A) LENGTH: 30 base pairs

 (B) TYPE: nucleic acid

 (C) STRANDEDNESS: single

 (D) TOPOLOGY: linear
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

CGGATGCCTC AGAAGGGCTT TTGCCACAGG

I CLAIM:

- A composition of matter comprising a
 plurality of cells containing a diverse population of
 expressible oligonucleotides operationally linked to
 expression elements, said expressible oligonucleotides
 having a desirable bias of random codon sequences
 produced from random combinations of first and second
 oligonucleotide precursor populations having a desirable
 bias of random codon sequences.
 - 2. The composition of claim 1, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is unbiased.
 - 3. The composition of claim 1, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is biased toward a predetermined sequence.
 - 4. The composition of claim 1, wherein said first and second oligonucleotides having random codon sequences have at least one specified codon at a predetermined position.
 - 5. The composition of claim 1, wherein said cells are procaryotes.
 - 6. The composition of claim 1, wherein said cells are $\underline{\text{E. coli}}$.

- for the expression of a diverse population of random peptides from combined first and second oligonucleotides having a desirable bias of random codon sequences, comprising: two vectors: a first vector having a cloning site for said first oligonucleotides and a pair of restriction sites for operationally combining first oligonucleotides with second oligonucleotides; and a second vector having a cloning site for said second oligonucleotides and a pair of restriction sites complementary to those on said first vector, one or both vectors containing expression elements capable of being operationally linked to said combined first and second oligonucleotides.
 - 8. The kit of claim 7, wherein said vectors are in a filamentous bacteriophage.
 - 9. The kit of claim 8, wherein said filamentous bacteriophage are M13.
 - 10. The kit of claim 7, wherein said vectors are plasmids.
 - 11. The kit of claim 7, wherein said vectors are phagemids.
 - 12. The kit of claim 7, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is unbiased.
 - 13. The kit of claim 7, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is diverse but biased toward a predetermined sequence.

- 14. The kit of claim 7, wherein said first and second oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 15. The kit of claim 7, wherein said pair of restriction sites are Fok I.
- peptides from diverse populations of combined first and second oligonucleotides having a desirable bias of random codon sequences, comprising: a set of first vectors

 having a diverse population of first oligonucleotides having a desirable bias of random codon sequences and a set of second vectors having a diverse population of second oligonucleotides having a desirable bias of random codon sequences, said first and second vectors each having a pair of restriction sites so as to allow the operational combination of first and second oligonucleotides into a contiguous oligonucleotide having a desirable bias of random codon sequences.
 - 17. The cloning system of claim 16, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is unbiased.
 - 18. The cloning system of claim 16, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is diverse but biased toward a predetermined sequence.
 - 19. The cloning system of claim 16, wherein said first and second oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.

- 20. The cloning system of claim 16, wherein said combined first and second vectors is through a pair of restriction sites.
- 21. The cloning system of claim 16, wherein said pair of restriction sites are Fok I.
- 22. A composition of matter comprising a plurality of cells containing a diverse population of expressible oligonucleotides operationally linked to expression elements, said expressible oligonucleotides having a desirable bias of random codon sequences.
 - 23. The composition of claim 22, wherein said cells are procaryotes.
 - 24. The composition of claim 22, wherein said expressible oligonucleotides are expressed as peptide fusion proteins on the surface of a filamentous bacteriophage.
 - 25. The composition of claim 22, wherein said filamentous bacteriophage is M13.
 - 26. The composition of claim 22, wherein said fusion protein contains the product of gene VIII.
 - 27. The composition of claim 22, wherein said diverse population of oligonucleotides having a desirable bias of random codon sequences are produced from the combination of diverse populations of first and second oligonucleotides having a desirable bias of random codon sequences.

?

- The composition of claim 22, wherein the desirable bias of random codon sequences of said oligonucleotides is unbiased.
- 29. The composition of claim 22, wherein the desirable bias of random codon sequences of said oligonucleotides is diverse but biased toward a predetermined sequence.
- The composition of claim 22, wherein said oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- A plurality of vectors containing a diverse population of expressible oligonucleotides having a desirable bias of random codon sequences.
- 32. The vectors of claim 31, wherein said oligonucleotides are expressible as fusion proteins on the surface of filamentous bacteriophage.
- The vectors of claim 31, wherein said filamentous bacteriophage is M13.
- 34. The vectors of claim 31, wherein said fusion protein contains the product of gene VIII.
- The vectors of claim 31, wherein the desirable bias of random codon sequences of said oligonucleotides is unbiased.
- 36. The vectors of claim 31, wherein the desirable bias of random codon sequences of said oligonucleotides is diverse but biased toward a predetermined sequence.

111

- 37. The vectors of claim 31, wherein said oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 38. A composition of matter, comprising a diverse population of oligonucleotides having a desirable bias of random codon sequences produced from random combinations of two or more oligonucleotide precursor populations having a desirable bias of random codon sequences.
- 39. A method of constructing a diverse population of vectors having combined first and second oligonucleotides having a desirable bias of random codon sequences capable of expressing said combined oligonucleotides as random peptides, comprising the steps of:

10

15

- (a) operationally linking sequences from a diverse population of first oligonucleotides having a desirable bias of random codon sequences to a first vector;
- (b) operationally linking sequences from a diverse population of second oligonucleotides having a desirable bias of random codon sequences to a second vector; and
- (c) combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors capable of being expressed.

- 40. The method of claim 39, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is unbiased.
- 41. The method of claim 39, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is diverse but biased toward a predetermined sequence.

ž,

- 42. The method of claim 39, wherein said first and second oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 43. The method of claim 38, wherein steps (a) through (c) are repeated two or more times.

5

10

15

- 44. A method of selecting a peptide capable of being bound by a ligand binding protein from a population of random peptides, comprising:
 - (a) operationally linking a diverse population of first oligonucleotides having a desirable bias of random codon sequences to a first vector;
 - (b) operationally linking a diverse population of second oligonucleotides having a desirable bias of random codon sequences to a second vector;
 - (c) combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors;
 - (d) introducing said population of combined vectors into a compatible host under conditions sufficient for expressing said population of random peptides; and
 - (e) determining the peptide which binds to said ligand binding protein.
- 45. The method of claim 44, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is unbiased.
- 46. The method of claim 44, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is diverse but biased toward a predetermined sequence.

- 47. The method of claim 44, wherein said first and second oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 48. The method of claim 44, wherein steps (a) through (c) are repeated two or more times.

49. A method for determining the nucleic acid sequence encoding a peptide capable of being bound by a ligand binding protein which is selected from a population of random peptides, comprising:

5

operationally linking a diverse population (a) of first oligonucleotides having a desirable bias of random codon sequences to a first vector;

10

operationally linking a diverse population (b) of second oligonucleotides having a desirable bias of random codon sequences to a second vector;

15

(c) combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors;

20

introducing said population of combined (d) vectors into a compatible host under conditions sufficient for expressing said population of random peptides;

(e) determining the peptide which binds to said ligand binding protein;

25

isolating the nucleic acid encoding said (f) peptide; and

sequencing said nucleic acid. (g)

- 50. The method of claim 49, wherein the 'desirable bias of random codon sequences of said first and second oligonucleotides is unbiased.
- 51. The method of claim 49, wherein the desirable bias of random codon sequences of said first and second oligonucleotides is diverse but biased toward a predetermined sequence.
- 52. The method of claim 49, wherein said first and second oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 53. The method of claim 49, wherein steps (a) through (c) are repeated two or more times.
- 54. A method of constructing a diverse population of vectors containing expressible oligonucleotides having a desirable bias of random codon sequences, comprising operationally linking a diverse population of oligonucleotides having a desirable bias of random codon sequences to expression elements.
 - 55. The method of claim 54, wherein said oligonucleotides are expressible as fusion proteins on the surface of filamentous bacteriophage.
 - 56. The method of claim 54, wherein said filamentous bacteriophage are M13.
 - 57. The method of claim 54, wherein said fusion protein contains the product of gene VIII.

- 58. The method of claim 54, wherein the desirable bias of random codon sequences of said oligonucleotides is unbiased.
- 59. The method of claim 54, wherein the desirable bias of random codon sequences of said oligonucleotides is diverse but biased toward a predetermined sequence.
- 60. The method of claim 54, wherein said oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 61. The method of claim 54, wherein said operationally linking further comprising the steps of:

5

10

- (a) operationally linking a diverse population of first oligonucleotides having a desirable bias of random codon sequences to a first vector;
- (b) operationally linking a diverse population of second oligonucleotides having a desirable bias of random codon sequences to a second vector; and
- (c) combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors.
- 62. The method of claim 61, wherein steps (a) through (c) are repeated two or more times.

5

10

- 63. A method of selecting a peptide capable of being bound by a binding protein from a population of random peptides, comprising:
 - (a) operationally linking a diverse population of oligonucleotides having a desirable bias of random codon sequences to expression elements;
 - (b) introducing said population of vectors into a compatible host under conditions sufficient for expressing said population of random peptides; and
 - (c) determining the peptide which binds to said ligand binding protein.
- 64. The method of claim 63, wherein said population of random peptides are expressed as fusion proteins on the surface of filamentous bacteriophage.
- 65. The method of claim 63, wherein said filamentous bacteriophage are M13.
- 66. The method of claim 63, wherein said fusion protein contains the product of gene VIII.
- 67. The method of claim 63, wherein the desirable bias of random codon sequences of said oligonucleotides is unbiased.
- 68. The method of claim 63, wherein the desirable bias of random codon sequences of said oligonucleotides is diverse but biased toward a predetermined sequence.

5

10

- 69. The method of claim 63, wherein said oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 70. The method of claim 63, wherein step (a) further comprises:
 - (a1) operationally linking a diverse population of first oligonucleotides having a desirable bias of random codon sequences to a first vector;
 - (a2) operationally linking a diverse population of second oligonucleotides having a desirable bias of random codon sequences to a second vector; and
 - (a3) combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors.
- 71. The method of claim 70, wherein steps (al) through (a3) are repeated two or more times.

15

÷

- 72. A method of determining the nucleic acid sequence encoding a peptide capable of being bound by a ligand binding protein which is selected from a population of random peptides, comprising:
- operationally linking a diverse population of oligonucleotides having a desirable bias of random codon sequences to expression elements.
- (b) introducing said population of vectors into a compatible host under conditions sufficient for expressing said population of random peptides;
 - (c) determining the peptide which binds to said ligand binding protein;
 - (d) isolating the nucleic acid encoding said peptide; and
 - (e) sequencing said nucleic acid.
 - 73. The method of claim 72, wherein said population of random peptides are expressed as fusion proteins on the surface of filamentous bacteriophage.
 - 74. The method of claim 72, wherein said filamentous bacteriophage are M13.
 - 75. The method of claim 72, wherein said fusion protein contains the product of gene VIII.
 - 76. The method of claim 72, wherein the desirable bias of random codon sequences of said oligonucleotides is unbiased.

WO 92/06176

5

10

- 77. The method of claim 72, wherein the desirable bias of random codon sequences of said oligonucleotides is diverse but biased toward a predetermined sequence.
- 78. The method of claim 72, wherein said oligonucleotides having a desirable bias of random codon sequences have at least one specified codon at a predetermined position.
- 79. The method of claim 72, wherein step (a) further comprises:
 - (a1) operationally linking a diverse population of first oligonucleotides having a desirable bias of random codon sequences to a first vector;
 - (a2) operationally linking a diverse population of second oligonucleotides having a desirable bias of random codon sequences to a second vector; and
 - (a3) combining the vector products of steps (a) and (b) under conditions where said populations of first and second oligonucleotides are joined together into a population of combined vectors.
- 80. The method of claim 78, wherein steps (al) through (a3) are repeated two or more times.
- 81. A vector comprising two copies of a gene encoding a filamentous bacteriophage coat protein, both copies encoding substantially the same amino acid sequence but having different nucleotide sequences.

122

- 82. The vector of claim 81, wherein said filamentous bacteriophage is M13.
- 83. The vector of claim 81, wherein said gene is gene VIII.
- 84. The vector of claim 81, wherein said vector has substantially the sequence shown in Figure 5 (SEQ ID NO: 1).
- encoding a filamentous bacteriophage coat protein, one copy of said gene capable of being operationally linked to an oligonucleotide wherein said oligonucleotide can be expressed as a fusion protein on the surface of said filamentous bacteriophage or as a soluble peptide.
 - 86. The vector of claim 84, wherein said one copy of said gene is expressed on the surface of said filamentous bacteriophage.

₹

87. The vector of claim 84, wherein said bacteriophage coat protein is M13 gene VIII.




FIG. 1

SUBSTITUTE SHEET





FIG. 2






FIG. 4

10 20	30 40 50 50
1 AATGCTACTA CTATTAGTAG AATTGATG	CC ACCTITICAG CICGOGCOCO AAATGAAAAT 60
121 CGTTCGCAGA ATTGGGAATC AACTGTTA	CA TGGAATGAAA CTTCCAGACA CCGTACTTTA 180
181 GTTGCATATT TAAAACATGT TGAGCTAC 241 TCTGCAAAAA TGACCTCTTA TCAAAAGG	AG CACCAGATTC AGCAATTAAG CTCTAAGCCA 240
301 TTGGAGTTTG CTTCCGGTCT GGTTCGCT	AG CAATTAAAGG LACICTCTAA TCCTGACCTG 300 TI GAAGCTCGAA TTAAAACGCG ATATTTGAAG 360
361 TCTTTCGGGC TTCCTCTTAA TCTTTTTG/ 421 CAGGGTAAAG ACCTGATTTT TGATTTATO	AT GCAATCCGCT TTGCTTCTGA CTATAATAGT 420
481 TTTGAGGGG ATTCAATGAA TATTTATGA	AC GATTCCGCAG TATTGGACGC TATCCAGTCT 540
541 AAACATTTTA CTATTACCCC CTCTGGCAA 601 GGTTTTTATC GTCGTCTGGT AAACGAGGG	NA ACTICITITG CAAAAGCCIC TCGCTATTIT 600
661 AATTCCTTTT GGCGTTATGT ATCTGCATT	A GTTGAATGTG GTATTCCTAA ATCTCAACTG 720
721 ATGAATCTTT CTACCTGTAA TAATGTTGT 781 TCTTCCCAAC GTCCTGACTG GTATAATGA	T CCGTTAGTTC GTTTTATTAA CGTAGATTTT 780 G CCAGTTCTTA AAATCGCATA AGGTAATTCA 840
841 CAATGATTAA AGTTGAAATT AAACCATCT	C AAGCCCAATT TACTACTCGT TCTGGTGTTT 900
901 CTCGTCAGGG CAAGCCTTAT TCACTGAAT 961 AATATCCGGT TCTTGTCAAG ATTACTCTTG	G AGCAGCTTTG TTACGTTGAT TTGGGTÄÄTE 960 G <u>ATGAAGGTCA GCCAGCCTAT</u> GCGCCTGGTC 1020
1021 TGTACACCGT TCATCTGTCC TCTTTCAAAC	S TTGGTCAGTT CGGTTCCCTT ATGATTGACC IORN
1141 CAGGCGATGA TACAAATCTC CGTTGTACTT	r TGTTTCGCGC TTGGTATAAT CGCTGGGGGT 1200
1201 CAAAGATGAG TGTTTTAGTG TATTCTTTCG 1261 GTGGCATTAC GTATTTTACC CGTTTAATGG	
1321 CAAAGCCTCT GTAGCCGTTG CTACCCTCGT	TCCGATGCTG TCTTTCGCTG CTGAGGGTGA 1380
1381 CGATCCCGCA AAAGCGGCCT TTAACTCCCT 1441 TGCGTGGGCG ATGGTTGTTG TCATTGTCGG	
1501 ATTCACCTCG AAAGCAAGCT GATAAACCGA 1561 TTTTTGGAGA TTTTCAACGT GAAAAAATTA	TACAATTAAA GGCTCCTTTT GGAGCCTTTT 1560
1621 TATTCTCACT CCGCTGAAAC TGTTGAAAGT	TGTTTAGCAA AACCCCATAC AGAAAATTCA 1680
1681 TTTACTAACG TCTGGAAAGA CGACAAAACT 1741 CTGTGGAATG CTACAGGCGT TGTAGTTTGT	TTAGATCGTT ACGCTAACTA TGAGGGTTGT 1740 ACTGGTGACG AAACTCAGTG TTACGGTACA 1800
1801 TGGGTTCCTA TTGGGCTTGC TATCCCTGAA 1861 TCTGAGGGTG GCGGTTCTGA GGGTGGCGGT	AATGAGGGTG GTGGCTCTGA GGGTGGCGGT 1860 ACTAAACCTC CTGAGTACGG TGATACACCT 1920
1921 ATTCCGGGCT ATACTTATAT CAACCCTCTC	GACGGCACTT ATCCGCCTGG TACTGAGCAA 1980
1981 AACCCCGCTA ATCCTAATCC TTCTCTTGAG 2041 CAGAATAATA GGTTCCGAAA TAGGCAGGGG	GAGTCTCAGC CTCTTAATAC TTTCATGTTT 2040 GCATTAACTG TTTATACGGG CACTGTTACT 2100
2101 CAAGGCACTG ACCCCGTTAA AACTTATTAC 2161 TATGACGCTT ACTGGAACGG TAAATTCAGA	CAGTACACTC CTGTATCATC AAAAGCCATG 2160
2221 GATCCATTCG TTTGTGAATA TCAAGGCCAA	TCGTCTGACC TCGGTCAACC TCCTGTCAAT 2280
2281 GCTGGCGGCG GCTCTGGTGG TGGTTCTGGT 2341 GGCGGTTCTG AGGGTGGCGG CTCTGAGGGA	GGCGGCTCTG AGGGTGGTGG CTCTGAGGGT 2340 GGCGGTTCCG GTGGTGGCTC TGGTTCCGGT 2400
2401 GATTTTGATT ATGAAAAGAT GGCAAACGCT	AATAAGGGGG CTATGACCGA AAATGCCGAT 2460
2521 GCTGCTATCG ATGGTTTCAT TGGTGACGTT	TCCGGCCTTG CTAATGGTAA TGGTGCTACT 2580
2641 TTAATGAATA ATTTCCGTCA ATATTTACCT	GCTCAAGTCG GTGACGGTGA TAATTCACCT 2640 TCCCTCCCTC AATCGGTTGA ATGTCGCCCT 2700
2701 TTTGTCTTTA GCGCTGGTAA ACCATATGAA	TTTTCTATTG ATTGTGACAA AATAAACTTA 2760 GTTGCCACCT TTATGTATGT ATTTTCTACG 2820
2821 TTTGCTAACA TACTGCGTAA TAAGGAGTCT	TAATCATGCC AGTTCTTTTG GGTATTCCGT 2880
2941 ITAAAAAGGG CTTCGGTAAG ATAGCTATTG	TAACTTTGTT GCCGTATCTG CTTACTTTTC 2940 CTATTTCATT GTTTCTTGCT CTTATTATTG 3000
3001 GGCTTAACTC AATTCTTGTG GGTTATCTCT	CTGATATTAG CGCTCAATTA CCCTCTGACT 3060 CTAATGCGCT TCCCTGTTTT TATGTTATTC 3120
3121 TCTCTGTAAA GGCTGCTATT TTCATTTTTG	ACGTTAAACA AAAAATCGTT TCTTATTTGG 3180
3181 ATTGGGATAA ATAATATGGC TGTTTATTTT 3241 CTCGTTAGCG TTGGTAAGAT TCAGGATAAA	GTAACTGGCA AATTAGGCTC TGGAAAGACG 3240 ATTGTAGCTG GGTGCAAAAT AGCAACTAAT 3300
3301 CCTGATTTAA GGCTTCAAAA CCTCCCGCAA	GTCGGGAGGT TCGCTAAAAC GCCTCGCGTT 3360 GATTTGCTTG CTATTGGGCG CGGTAATGAT 3420
3421 TCCTACGATG AAAATAAAAA CGGCTTGCTT	GTTCTCGATG AGTGCGGTAC TTGGTTTAAT 3480
3541 AAATTAGGAT GGGATATTAT CTTCCTTGTT	CCGATTATTG ATTGGTTTCT ACATGCTCGT 3540 CAGGACTTAT CTATTGTTGA TAAACAGGCG 3600
3601 CGTTCTGCAT TAGCTGAACA TCTTGTTTAT	TGTCGTCGTC TGGACAGAAT TACTTTACCT 3660 GGCTCGAAAA TGCCTCTGCC TAAATTACAT 3720
3721 GTTGGCGTTG TTAAATATGG CGATTCTCAA	TTAAGCCCTA CIGITGAGCG TTGGCTTTAT 3780
3781 ACTĞĞTAAĞA ATTTĞTATAA CĞCATATĞAT	ACTAAACAGG CTTTTTCTAG TAATTATGAT 3840

FIG. 5-1

```
AGAAGATGAA
TTGGATTTGC
AGGTAGTCTA
TACAGAAGCTA
TAATTCAAAACT
CTTCAAAAGCA
TATTCAAAAGCA
TATTCAAAACAT
ATTCAAAAATAATTA
                                                                                                                                                                                                                 TGACTCTTCT
ATTAATTAAT
TACTGTTTCC
CTTGATGTTT
GCGCGATTTT
TGTAAAAGGT
                                                                                                                                      GATTITGATA AATTCACTAT
TICAAGGATT CTAAGGGAAA
                                                                                               TCAGACCTAT
TCGCTATGTT
                                                                                                                                                                          CTAAGGGAAA
TTGATTTATG
ATTTTGTTTT
ATTCGCCTCT
TTTCTCCCGA
TACGCAATTT
CTTCATAATCA
                  GAGGTTAAAA
 4021
                                                                                                                                                                                                                                                          4200
                  CAGCGACGATT
AGCGACGATT
                                                                                                                                      CTCACATATA
AATGTAATTA
                                                                                               AĞĞTTATTCA
GAAATTGTTA
 4081
 4141
                                                                                                                                     GAAATGAATA
TCCGTTATIG
                  ATTAAAAAAGG
                                                                                               TCAGGTAATT
ATCAGGCGAA
TGACGTTAAA
TGATATGGTT
 4201
                                                                                                                                                                                                                                                         4380
                 GTTTCATCAT
GTAACTTGGT
ACTGTTACTG
GTTTTACGTG
AATCCAAACA
GATAATACTA
                                                                                                                                                                                                                  CTTTATTTCT 4440
TTAGAAGTAT 4500
GGAATATGAT 4560
TACTCAAACT 4620
                                                                                            CCTGAAAATC
GGTTCAATTC
TTGCCATCAT
GTTCCGCAAA
 4381
 4441
                                                         ATCAGGATTA
CTCCTTCTGG
ATAACGTTCG
CTAAATCCTC
                                                                                                                                                                                                                  GTTTGTAAAG 4680
ATTAGTTGTT 4740
TGATTTGCCA 4800
TGCTTTAGAT 4860
TACTGACCGC 4920
CGATGTTTTA 4980
 4501
 4561
                 TTTAAAATTA
TCTAATACTT
AGTGCACCTA
ACTGACCAGA
 4621
 4681
                                                         AAGATATTTT
                                                        AAGATATIII
TATTGATTGA
CTGCTGGCTC
TTCGCGCATT
TTCCAGGTCA
TGACTGGTGA
GTATTTCCAT
CCAGCAAGGC
GAAGTATTGC
CTGATTATAA
 4741
 4801
                                                                                                                                                                                                                  CGATGTTTTA 4980
TGTGCCACGT 50400
TGTGCCACGT 51600
TGATGTTATT 51220
TGATGTTATT 52280
TGATGTTATT 52280
TGATGTTATT 55400
TGATGTTATTATT 55400
CCTCTAAATA 555800
CTCTAAATCG 557600
CTCTAAATCG 557600
CACCTCAAACCC 5820
CACCATCAAA 5880
                  TTTTCATTTG
CTCACCTCTG
GGGCTATCAG
ATTCTTACGC
ACTGGTCGTG
 4861
4921
  4981
  5041
  5101
                   CĂĂĂĂŤĞŤĂĞ
 5161
5221
5281
5341
                  CAAAATGTAG
CTGGATATTA
ACTAATCAAA
GGTGGCCTCA
ATCCCTTTAA
TACGTGCTCGCT
CGCTTCTCCCT
CGCGCTCCCT
                                                          CTGATTATAA
TCGGCCTCCT
TCAAAGCAAC
  5401
   5461
                                                        5581
   5641
5701
                    GGGGCTCCCT
TTTGGGTGAT
GTTGGAGTCC
TATCTCGGGC
CAGGATTTTC
CAGGCCGCAATA
CGACCCCAATA
CGACTCATTAG
CGACTCATTAG
                                                                                                                                                                                                                    CACCATCAAA
                                                                                                                                                                                                                                                          5880
                                                                                                                                                                                                                    CTCTCAGGGC 5940
AACCACCTG 6000
GCAGCTGGCA 6060
TGAGTTAGCT 6120
TGTGTGGGAAT 6240
    5761
    5821
    5881
    5941
    6001
                                                                                                                                                                                                                    TGTGTGGAAT 6180
GAATTCGCAG 6240
TGCATTCAAT 6300
AGTAGTTATA 6360
TTCTTAACCA 6420
CGCAGCCTGA 6480
AGCTGGCTGG 6540
ATGCACGGTT 6600
CCGTTTGTTC 6660
AGCTGGCTAC 6720
ATGAGCTGAT 6780
AAATATTTGC 6840
     6061
    6121
6181
                    CACTCATTAG
TGTGAGCGGA
GTAGGAGAGC
AGTTTACAGG
GTTGGTGCTA
ACTGGCGAATG
AGTGCGATCT
ACGATGCGCC
AGGAAGGCCA
TTAACAAAA
      6301
      6361
      6421
                                                                                                                                         TCACATTTAA TGTTGATGAA AGCTGGCTAC
GCGTTCCTAT TGGTTAAAAA ATGAGCTGAT
AATATTAACG TTTACAATTT AAATATTTGC
CTGATTATCA ACCGGGGTAC ATATGATTGA
TTCTCTTGTT TGCTCCAGAC TCTCAGGCAA
AATAGCTACC CTCTCCGGCA TTAATTTATC
TGATTTGACT GTCTCCGGCC TTTCTCACCCC
CATTGCATTT AAAATATATG AGGGTCATAA
TTCTCCCGCA AAAGTATTAC AGGGTCATAA
CTCTGAGGCT TTATTGCTTA ATTTTGCTAA
CTCTGAGGCT TTATTGCTTA ATTTTGCTAA
CTCTGAGGCT TTATTGCTTA ATTTTGCTAA
       6481
       6541
       6601
       6661
6721
6781
                                                                                                                                                                                                                                                               6840
                                                                                                                                                                                                                                                               6900
                        TTAACAAAA
                                                                                                                                                                                                                                                               6960
        6841
                        CATGCTAGTT
TGACCTGATA
AGCTAGAACG
TTTTGAATCT
                                                               GCCTTTGTAG
GCTTGAATATC
TTACCTACAC
CCTTGCGTTG
ACAACCGATT
TGCCTGTATG
                                                                                                                                                                                                                                                                 7080
        6901
                                                                                                                                                                                                                                                                 7140
         6961
                                                                                                                                                                                                                                                                7200
7260
7294
          702Ī
                                                                                                      AAATAAAGGC
TAGCTTTATG
ATTTATTGGA
1 30
          7081
                         AAATTTTTÄT
TGTTTTTGGT
TTCTTTGCCT
         7141
7201
7261
                                                                                                                                                                           40
```

FIG. 5-2

SUBSTITUTE SHEET

FIG. 6-1

```
3841 TCCGGTGTTT ATTCTTATTT AACGCCTTAT
                                                                 3960
                                                                 4080
                                                                 4140
                                                                 4200
                                                                 4260
4081
4141
4201
                                                                 4500
                                                                 4560
4620
4381
                                                                 4680
                                                                 4800
                                                                 4860
4681
                                                                 4920
                                                                 4980
4801
                                                                 5040
5100
4861
                                                      5160
5220
5041
 5101
 5161
 5221
5281
 5401
 5641
 6001
 6061
6121
6181
 6241
6301
 6361
  6421
  6481
                                                                   6840
                                                                   6900
                                                                   6960
                                                                   7020
                                                                   7080
                                                                   7140
                                                                   7200
                                                                    7260
```

FIG. 6-2

	! 1) 2	0 3	Λ · μ	0 1 5	0 1 60
	1 AATGCTACT	A CTATTAGTA	G AATTGATGC	C ACCTTTTCA	G CTCGCGCCC	C AAATGAAAAT 60
6.	1 ATAGCTAAA	C AGGTTATTG	A CCATTTGCG	A AATGTATCT		
12. 18.		A ATTGGGAAT F TAAAACATG		A TGGAATGAA G CACCAGATT	C AGCAATTAA	
10. 24.				G CAATTAAAG	G TACTCTCTA	A TCCTGACCTG 300
30:	TTGGAGTTT(G CTTCCGGTC			A TTAAAACGC T TTGCTTCTG	G ATATTTGAAG 360 A CTATAATAGT 420
361 421		TTCCTCTTA ACCTGATTT				
481		S ATTCAATGA/	A TATTTATGA(GATTCCGCA	G TATTGGACG	C TATCCAGTCT 540
541		CTATTACCC				
601 661	GGTTTTTATC				G GTATTCCTA <i>A</i>	ATCTCAACT6 720
721	ATGAATCTTT	CTACCTGTAA	\ TAATGTTGTT	CCGTTAGTT	GTTTTATTAA	CGTAGATTTT 780 AGGTAATTCA 840
781 841	TCTTCCCAAC CAATGATTAA	GTCCTGACTG AGTTGAAATT	GTATAATGAG AAACCATCTC	CCAGTTCTTA AAGCCCAATT	AAATCGCATA TACTACTCGT	
901	CTCGTCAGGG	CAAGCCTTAT	TCACTGAATG	AGCAGCTTTG	TTACGTTGAT	TTGGGTAATG 960
961	AATATCCGGT	TCTTGTCAAG TCATCTGTCC	ATTACTCTTG TCTTTCAAAG	ATGAAGGTCA TTGGTCAGTT	GCCAGCCTAT	GCGCCTGGTC 1020 ATGATTGACC 1080
1021 1081	TGTACACCGT GTCTGCGCCT	CGTTCCGGCT	AAGTAACATG	GAGCAGGTCG	CGGATTTCGA	CACAATTTAT 1140
1141	CAGGCGATGA	TACAAATCTC	CGTTGTACTT	TGTTTCGCGC	TTGGTATAAT	CGCTGGGGGT 1200 TGCCTTCGTA 1260
1201 1261	CAAAGATGAG GTGGCATTAC	TGTTTTAGTG	TATTCTTTCG CGTTTAATGG	CCTCTTTCGT	TTTAGGTTGG ATGAAAAAGT	TGCCTTCGTA 1260 CTTTAGTCCT 1320
1321	CAAAGCCTCT	GTAGCCGTTG	CTACCCTCGT	TCCGATGCTG	TCTTTCGCTG	ČTGAGGGTGA 1380
1381 1441	CGATCCCGCA TGCGTGGGCG	AAAGCGGCCT ATGGTTGTTG	TTAACTCCCT TCATTGTCGG	GCAAGCCTCA CGCAACTATC	GCGACCGAAT GGTATCAAGC	ATATCGGTTA 1440 TGTTTAAGAA 1500
1501	ATTCACCTCG	AAAGCAAGCT	GATAAACCGA	TACAATTAAA	GGCTCCTTTT	GGAGCCTTTT 1560
1561	TTTTTGGAGA	TTTTCAACGT	GAAAAAATTA TGTTGAAAGT	TTATTCGCAA	TTCCTTTAGT	TGTTCCTTTC 1620 AGAAAATTCA 1680
1621 1681	TATTCTCACT	TCTGGAAAGA	CGACAAAACT	TTAGATCGTT	ACGCTAACTA	TGAGGGTTGT 1740
1741	CTGTGGAATG	CTACAGGCGT	TGTAGTTTGT	ACTGGTGACG	AAACTCAGTG	TTACGGTACA 1800 GGGTGGCGGT 1860
1801 1861	TGGGTTCCTA TCTGAGGGTG	TTGGGCTTGC GCGGTTCTGA	TATCCCTGAA GGGTGGCGGT	AATGAGGGTG	CTGAGTACGG	TGATACACCT 1920
1921	ATTCCGGGCT	ATACTTATAT	CAACCCTCTC	GACGGCACTT	ATCCGCCTGG	TACTGAGCAA 1980 TTTCATGTTT 2040
1981 2041	AACCCCGCTA CAGAATAATA	ATCCTAATCC GGTTCCGAAA	TTCTCTTGAG	GAGTCTCAGC GCATTAACTG	CTCTTAATAC	CACTGTTACT 2100
2101	CAAGGCACTG	ACCCCGTTAA	AACTTATTAC	CAGTACACTC	CTGTATCATC	AAAAGCCATG 2160
	TATGACGCTT GATCCATTCG		TAAATTCAGA TCAAGGCCAA	GACTGCGCTT TCGTCTGACC	TCCATTCTGG TGCCTCAACC	TCCTGTCAAT 2280
2281	GCTGGCGGCG	GCTCTGGTGG	TGGTTCTGGT	GGCGGCTCTG	AGGGTGGTGG	CTCTGAGGGT 2340
	GGCGGTTCTG	AGGGTGGCGG ATGAAAAGAT	CTCTGAGGGA GGCAAACGCT	GGCGGTTCCG AATAAGGGGG	GTGGTGGCTC CTATGACCGA	TGGTTCCGGT 2400 AAATGCCGAT 2450
	GATTTTGATT GAAAACGCGC	TACAGTCTGA	CGCTAAAGGC	AAACTTGATT	CTGTCGCTAC	TGATTACGGT 2520
2521	GCTGCTATCG	ATGGTTTCAT CTGGCTCTAA	TGGTGACGTT		CTAATGGTAA GTGACGGTGA	TAATTCACCT 2580
2581 2641		ATTTCCGTCA	ATATTTACCT	TCCCTCCCTC	AATCGGTTGA	ATGTCGCCCT 2700
2701	TTTGTCTTTA	GCGCTGGTAA	ACCATATGAA TCTTTTATAT	GTTGCCACCT	ATTGTGACAA TTATGTATGT	AATAAACTTA 2760 ATTTTCTACG 2820
	TTCCGTGGTG TTTGCTAACA	TCTTTGCGTT	TAAGGAGTCT	TAATCATGCC	AGTTCTTTTG	GGTATTCCGT 2880
2881	TATTATTGCG	TTTCCTCGGT	TTCCTTCTGG	TAACTTTGTT	CGGCTATCTG	CTTACTTTTC 2940 CTTATTATTG 3000
2941 3001	TTAAAAAGGG GGCTTAACTC	CTTCGGTAAG	ATAGCTATTG	CTATTTCATT	CGCTCAATTA	CCCTCTGACT 3060
3061	TTGTTCAGGG	TGTTCAGTTA	ATTCTCCCGT	CTAATGCGCT	TCCCTGTTTT	TATGTTATTC 3120 TCTTATTTGG 3180
3121 3181	TCTCTGTAAA ATTGGGATAA	GGCTGCTATT ATAATATGGC	TTCATTTTTG	ACGTTAAACA GTAACTGGCA	AAAAATCGTT	TGGAAAGACG 3240
3241	CTCGTTAGCG	TTGGTAAGAT	TCAGGATAAA	ATTGTAGCTG	GGTGCAAAAT	AGCAACTAAT 3300
3301	CTTGATTTAA	GGCTTCAAAA CGGATAAGCC	CCTCCCGCAA	GTCGGGAGGT GATTTGCTTG	TCGCTAAAAC CTATTGGGCG	GCCTCGCGTT 3360 CGGTAATGAT 3420
3421	CTTAGAATAC	AAAATAAAA	CGGCTTGCTT	GTTCTCGATG	AGTGCGGTAC	TTGGTTTAAT 3480
3481	ACCCGTTCTT	GGAATGATAA GGGATATTAT	GGAAAGACAG	CCGATTATTG	ATTGGTTTCT CTATTGTTGA	ACATGCTCGT 3540 TAAACAGGCG 3600
3541 3601	AAATTAGGAT	TAGCTGAACA	TGTTGTTTAT	TGTCGTCGTC	TGGACAGAAT	TACTTTACCT 3660
3661	TTTGTCGGTA	CTTTATATTC	TCTTATTACT	GGCTCGAAAA TTAAGCCCTA	TGCCTCTGCC	TAAATTACAT 3720 TTGGCTTTAT 3780
3721	GTTGGCGTTG	TTAAATATGG	COMITCICAN	TIANUCUCIA	CIGIIONGCO	1,000111/11 2700

FIG. 7-1

7441 ACGTT 10 20 30 40 50 30
--

FIG. 7-2

FIG. 8-2

1 AATGETACTA CTATTAGEA AATTGATGC ACCTITTCAG CICCCCCC AAATGAAAAT 60 of ATAGCTAACA AGGITATIGA CATTTGAGA AATTGATGC ACCTITTCAGA CICCCCCCC AAATGAAAAT 60 of ATAGCTAACA AGGITATIGA CATTTGAGA AATGATAAT ATGGTAAATTGATCA CATTTGAGA AATGATAAT ATGGTAACATTTA 180 181 GTHCATATT TAAAACATGT TGACCTAGAA CACAGATTAA GAGAAGAAA CTACAGACACATTAA CACAGATTAA CACAAGAGATA TAATTAACACA CACAGATTAA CACAGATT

FIG. 9-1 SUBSTITUTE SHEET

FIG. 9-2

1

15/16

FIG. 10-1

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/07141

I. CLASSIFI	ICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)	6
	I Day Charles (IRC) acts poin National Classification and IPC	
IPC(5): U.S. CL	C12N 1/24, 15/00; C07H 21/00 435/252.33, 320.1, 172.3; 536/27	
II FIELDS S	BEARCHED	
	Minimum Documentation Searched 7	
Classification 5	System Classification Symbols	
Ľ.S.	435/252.33, 320.1, 172.3, 69.1; 536/27	
	Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Soarched (
APS, CAS	S: search terms: Codon bins, codon preference	
III. DOCUMBR	MAR COURIDENIO AO RE USFIAVUA :	
Calegory °	Citation of Document, 11 with indication, where appropriate, of the relevant passaged 2	Relevant to Claim No. 13
	EP. A. 0.383.620 (Cook) 22 August 1990. See entire document.	1-87
	28. A. 4.458.066 (Caruthers et al.) 03 July 1984. see entire document.	1-87
Y U	US. A. 4.771.000 (Verrips et al.) 3 September 1988. see entire document.	8.9.24-26 32-34. 55-57. 64-66. 73-75. 81-87
Vo et of po	PPLIED MICROBIOLOGY AND BIOTECHNOLOGY. olume 21. issued 1985. J.M. Jaynes t al., "Construction and expression f synthetic DNA fragments coding for olypeptides with elevated levels of sential amino acids". pages 200-205. ee entire document.	1-87
"A" documor consider of filing da "L" documor which is criation "O" documo other m" "P" documo later the IV. CERTIPIC	ont which may three doubts on priority claim(s) or is cited to establish the publication date of another is crited to establish the publication date of another is crited to establish the priority date claimed of the priority date claimed CATION CENTION CECEMBER 1991	note the claimed invention or cannot be canadered to connect to canadered to concert the claimed invention was an invention to a mention to an invention to a mention or mere other such decuring obvious to a person skilled and potent family
International S	Sparching Authority Signature of Authorited Officer Jennes Ketter	ebw

··· DOCUM	DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SEC ND SHEET)				
ategory *	Citation of Document, with indication, where appropriate, of the relevant passages				
alego/Y 1	GENE, Volume 44, issued 1986. A.R. Oliphant, "Cloning of randon-sequence oligodeoxynucleotides", pages 177-183, see entire document.	1-87			
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE. Volume 87, issued August 1990, Cwirla et al., "Peptides on phage: A vast library of peptides for identifying ligands". pages 6378-6382. see entire document.	1-87			
۲	SCIENCE. Volume 249. issued 27 July 1990, J.J. Devlin, "Random Peptide Libraries: A Source of Specific Protein Binding Molecules", pages 404-406, see entire document.	1-87			
Y	SCIENCE. Volume 249. issued 27 July 1990. J.K. Scott. "Searching for Peptide Ligands with an Epitope Library". pages 386-390. see entire document.	1-87			
`}*	EL. WINNACKER. "From Genes to Clones: Introduction to Gene Technology". published 1987 by VCH VmbH (Weinheim. Germany), See pages 276-279. especially Table 7-4.	1-87			
Y	SCIENCE. Volume 228. issued 14 June 1985. G.P. Smith. "Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface". pages 1315-1317. see entire document.	8.9.24-26 32-34, 55-57. 64-66. 73-75. 81-87			